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1. Abstract 
1.1. Zusammenfassung 
Die humane Serinprotease HTRA1 spielt eine wichtige Rolle bei vielen verschiedenen physiologischen 
Prozessen. Sie ist dabei an der Erkennung und Prozessierung einer Vielzahl verschiedener Substrate 
beteiligt. Eine wachsende Zahl an Studien deutet darauf hin, dass HTRA1 bei der Entstehung oder 
Progression unterschiedlicher Krankheiten wie beispielsweise Arthrose, Krebs, altersbedingter 
Makulardegeneration oder Alzheimer eine Rolle spielt. 
Ziel dieser Arbeit war die Entwicklung von Modulatoren, welche die Aktivität von HTRA1 beeinflussen, 
um dadurch Werkzeuge zur Validierung von HTRA1 als mögliches Zielmolekül für neue 
Therapieansätze zu generieren. 
Der ursprüngliche Ansatz war die Herstellung von Monomeren der multimeren Protease HTRA1, 
welche sich sowohl als Trimer, oder als höheres Oligomer von unbekannter Zusammensetzung, 
assembliert. Der erste Schritt zur Monomerisierung des Zielmoleküls sollte zu einem leicht 
handhabbaren und beherrschbaren Zielmolekül für das evolutive Proteindesign führen. Daher wurden 
Strukturdaten des Trimers genutzt um Aminosäureaustausche vorzunehmen, die als hauptursächlich 
für die Trimerisierung beschrieben wurden. Diese führten zu stabilen, monomeren Fraktionen der 
katalytischen Domäne von HTRA1. 
Proteinbibliotheken drei verschiedener Grundgerüste wurden für die Durchmusterung nach Bindern 
für monomeres HTRA1 eingesetzt. Die auf dem Miniprotein McoTI-II basierende Bibliothek, welches 
ein Trypsin Inhibitor aus Kürbisgewächsen ist, lieferte ein einzelnes Molekül, welches zwar mit 
nanomolarer Affinität monomeres HTRA1, aber nicht natives trimeres, erkannte. Ähnlich verhielten 
sich die beiden Moleküle, die aus einer immunisierten cameliden VHH Bibliothek, wobei es sich um die 
variable Domäne eines Einzelketten-Immunglobulins eines Lamas handelt, isoliert wurden. Hier 
erkannten ebenfalls beide Moleküle zwar das monomere HTRA1 mit nanomolaren Affinitäten, aber 
nicht das native, trimere. 
Bei der dritten Bibliothek handelte es sich um ein vNAR Grundgerüst, welches die variable Domäne 
eines Einzelketten-Immunglobulins von Haien darstellt, bei der CDR3 synthetisch randomisiert wurde. 
Bei der Durchmusterung wurden sechs Moleküle isoliert, die mikromolare Affinitäten gegenüber 
monomerem HTRA1 aufwiesen und von denen fünf auch natives, trimeres HTRA1 erkannten. Durch 
schrittweise Affinitätsmaturierung von CDR1 und HV2 konnten Affinitäten im zweistellig nanomolaren 
Bereich erzielt werden. 
Zuletzt wurden die erfolgversprechenden vNAR Varianten löslich exprimiert und in Aktivitätstests 
wurde überprüft, ob sie einen Einfluss auf die Aktivität von HTRA1 haben. Drei Moleküle erhöhten die 
Aktivität in einem Bereich von 150 % bis 400 %. Diese Modulatoren können für in vitro und in vivo 
Analysen eingesetzt werden und dazu beitragen die Frage zu beantworten, ob HTRA1 ein sinnvolles 
therapeutisches Ziel darstellt. 
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1.2. Abstract 
Human serine protease HTRA1 plays an important role in a plethora of physiological processes by 
recognition and conversion of numerous different substrates. Various studies suggested that HTRA1 is 
involved in several diseases, such as osteoarthritis, cancer, age-related macular degeneration or 
Alzheimer disease. The aim of this work was the generation of molecules that modulate HTRA1 
activity, which could act as tools for validation of HTRA1 as a potential therapeutic target. 
An initial approach was the monomerization of multimeric HTRA1 that is composed of trimers as well 
as higher oligomers of unknown composition to get an easier to handle and more controllable target 
for evolutionary design of interacting molecules. Accordingly, structural data of the trimer was applied 
for the design of amino acid replacements that are supposedly important for trimerization, resulting in 
stable monomeric fractions of HTRA1 catalytic domain. 
Three different scaffold libraries were screened by yeast surface display towards binding of monomeric 
HTRA1. The miniprotein McoTI-II-based library, which is a trypsin inhibitor from squash plant, 
delivered a single molecule that bound monomeric HTRA1 with nanomolar affinity, but not native 
trimeric HTRA1. Similarly, the two molecules isolated from an immunized VHH library, which is the 
variable domain of a single domain camelid immunoglobulin, also bind only monomeric HTRA1 with 
nanomolar affinities, but not native trimeric HTRA1. 
The third library was a vNAR library, which is the variable domain of a single domain shark 
immunoglobulin that was synthetically randomized in CDR3. Six independent molecules were isolated 
against monomeric HTRA1 and five of them were shown to bind native trimeric HTRA1 with 
micromolar affinities. By stepwise affinity maturation of CDR1 and HV2, affinities were improved to 
double digit nanomolar affinities. 
Finally, promising vNAR molecules were soluble expressed and evaluated for modulation of HTRA1 
activity by activity assays, resulting in three molecules that enhance HTRA1 activity in a range from 
150 % to 400 %. Therefore, we successfully generated activators that enhance HTRA1 activity with 
different strengths that can be used in in vitro and in vivo assays for validation of human HTRA1 as 
novel therapeutic target. 
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2. Introduction 
Degradation of molecules is an extremely important feature found in all living organisms with respect 
to nutrition uptake, tissue remodeling, recycling of biomolecules or degradation of toxic substances. 
Moreover, it is also an important tool for regulation of homeostasis to keep control of a plethora of 
effector functions. Many degradative proteins are themselves regulated by degradative processes, since 
they exist in an inactive pre-form that has to be partially degraded to become an active compound1, 2. 
In the last decade, systems biology tried to quantify these events occurring on many different pathways 
in multi-cellular organisms for a better understanding of these events3. Nevertheless, many degradative 
events as well as their interplay with regulation of cellular and organismic processes are not fully 
understood. 
One of the most prominent building blocks of life are amino acids, which are assembled during the 
process of translation to proteins. During protein biosynthesis, information stored in the nucleotide 
sequence of DNA is translated into proteins via formation of peptide bonds between amino acids in an 
ordered and defined manner4. 
Under physiological conditions the peptide bond is quite stable5 but tools for cleaving it have evolved 
during evolution. Protein cleaving enzymes that are capable of catalyzing the hydrolysis of peptide 
bonds are called protease and thousands are currently known6-9. Proteases have been classified into 
seven different groups by the intrinsic mechanism for catalytic support of peptide bond cleavage6, 10. 
One of the most prominent mechanisms is based on the nucleophilic attack of the peptide bond 
carbonyl by an activated serine residue which gives these enzymes the name serine proteases11. Two 
further amino acids are involved in this type of catalysis, a histidine and an aspartate. Together they 
form the so-called catalytic triad. The specific distances between these residues caused by the tertiary 
structure of the enzyme causes a proton shuttle, where the aspartate with its negatively charged 
carboxyl side chain stabilizes a positive charge of the imidazole ring of the histidine side chain during 
the reaction. The basic reaction mechanism is shown in figure 1. 
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Figure 1 Basic reaction mechanism catalyzed by serine protease chymotrypsin. Amino acid residues of chymotrypsin involved in 
catalysis are shown in red. Asp102, His57 and Ser195 build up the catalytic triad. The phenylalanine is in P1 position of the 
-terminus) a -terminus). 
The reaction center of an enzyme is called active-site and is surrounded by amino acid side chains 
giving each protease its special substrate specificity. This area is called substrate-specificity pocket and 
selects whether a substrate will be cleaved or not, which is mediated by hydrogen bonds, electrostatic 
interactions and hydrophobic interactions of the specificity pocket and the substrates amino acid 
sequence. As a consequence, many proteases cleave adjacent to a specific amino acid or amino acid 
sequence. 
Regulation of serine protease activity is based on various modes of action. One strategy is protease 
inhibition with molecules binding covalently or non-covalently to the active-site12, 13. Most organisms 
use this strategy to prevent unwanted proteolysis by synthesizing inhibitors to control their own or to 
escape host proteases. Another strategy relies on the fact that a substrate cleavage site is buried inside 
a folded substrate or covered by an interacting molecule such that it only undergoes proteolysis if the 
substrate becomes unfolded or the interacting molecule is dissociated. Furthermore, it is conceivable to 
modulate the tertiary structure of a protease by ligands, thereby disordering the important distances 
between the residues of the catalytic triad. But also changes in the environment like pH, temperature 
or salt shifts could reduce or enlarge the activity14, 15. Thus, modulation of proteolytic activity is an 
essential physiological regulation mechanism, which can also be used for controlling diseases by 
external intervention strategies. 
2.1. Protease HTRA1 
HTRA1 is the abbreviation for high temperature requirement protein A1. The first representative of 
this class of enzymes was discovered in E. coli and was designated as DegP or protease Do23. Null 
mutants of DegP showed reduced growth at an elevated temperature, respectively the expression is 
controlled by the stress signaling pathway σE and the Cpx pathway 24, 25. One task of a heat shock 
protein, namely degradation of misfolded proteins, could be predicted by the homology to serine 
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proteases. Moreover it was demonstrated that DegP combines proteolytic function with chaperone 
activity26, 27. Thus, it was shown that DegP plays an important role to overcome the harmful effect of 
misfolded proteins during heat stress in E. coli26, 27. Moreover, expression of human HTRA1 is induced 
by oxidative stress and it promotes premature cell senescence through p38 MAPK in a protease 
activity-dependent manner28. 
According to the MEROPS database, a classification system which groups all known proteases based on 
the alignment of their amino acid sequences7-9,DegP and human HTRA1 belong to the clan PA, family 
S1 and subfamily S1C. The MEROPS identifier is S01.277. 
Further bioinformatics analysis revealed strong homology of E. coli DegP to proteins found in all 
empires of life. So it is highly conserved in vertebrates fulfilling a totally different task compared to 
HTRA1 in microorganisms. In vertebrates HTRA1 is mainly localized in the extracellular matrix and 
found in all tissues. There it was found to have a broad substrate spectrum focusing on signaling 
molecules and extracellular matrix components. This task and its altered expression patterns found in 
patients lead to the idea that HTRA1 plays an important role in disease. The following chapters 
describe  
2.1.1. Structure of HTRA1 
HTRA1 is a multi-domain protein consisting of a trypsin-like protease domain and at least one 
carboxyl-terminal so-called PDZ domain29. Further domains which are not found in all species are for 
example a second PDZ domain in E. coli, S. cerevisiae and A. thaliana or an amino-terminal insulin-like 
growth factor binding protein (IGFBP) and a Kazal-like inhibitor domain (KI) in vertebrates. The 
carboxyl-terminal PDZ domain shows no influence on proteolytic activity of human HTRA130, 31, in 
contrast to DegP in E. coli27. Organization of domains of different species is shown in figure 2. 
Interestingly, the PDZ domain has an influence on length of product peptides after cleavage27, 31. The 
vertebrate-specific amino-terminal domains are also not well characterized. They most likely do not 
influence HTRA1 activity30. Recent findings suggest that IGFP and the Kazal-like domain can act as a 
redox sensing probe. Reduction of its several disulfides results in an autolytic degradation of the 
N-terminal domain of HTRA1 while not affecting proteolytic activity of HTRA132. Additionally, there 
are membrane-bound HTRAs with an amino-terminal transmembrane anchor or signal sequences as 
localization signals found in several species29. 
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Figure 2 HTRA domain organization of different organisms (modified from Clausen et al.29). Transmembrane domain (TM) in 
dark blue; insulin-like growth factor binding protein (IGFBP) in green; Kazal-like inhibitor domain (KI) in light blue; catalytic 
domain (protease) in blue and post synaptic density, discs large, zonula occludentes-1 domain (PDZ) in red. 
Most classical serine proteases, especially of the SA clan, are synthesized as inactive zymogenes which 
are converted into an active form by proteolytic cleavage of an amino-terminal pro-peptide, as found in 
trypsin for example33. In contrast to this irreversible activation mechanism, it was found that there are 
also proteases like HTRA1 which have a reversible activation mechanism. This activation is thought to 
be substrate induced but latest crystal structures revealed that there is a substrate independent 
equilibrium between the active and the inactive state30, 31. It is suggested that the switch from 
competent to incompetent active-site conformers is only separated by a low-energy barrier, causing a 
conformational selection by substrate30, 34. Whether there are further allosteric activation signals 
involved remains to be investigated. 
Crystal structures of DegP, as well as of HTRA1, revealed a homo-trimeric structure mediated by 
hydrophobic interactions of aromatic amino acids at the amino terminus of the protease domain 
(figure 4b). The protease domains have a flat disk shape where the active-site is localized at the 
-terminus (figure 3b). A single protease domain 
consists of two perpendicular β-barrel lobes (β1-β6 and β7-β12) with the catalytic triad residues 
histidine220, aspartate250 and serine328 located in the cleft between them. The amino and carboxyl-
terminus of the protease domain are enclosed by an -helix each. A low resolution structure of the 
molecular envelop of trimeric full-length human HTRA1 revealed that the PDZ domains protrude from 
the protease core and the amino-terminal domains are lying flat on the opposite side of the active-site. 
Several structures of DegP showed various oligomeric states of trimers, hexamers, 12-mers and 24-
mers (figure 3a)27, 35, 36. In human HTRA1 only crystal structures of trimers were observed (figure 3b)31. 
However, size-exclusion chromatography revealed complexes about MW 600,000, thereby indicating 
the formation of higher oligomers in solution. Interestingly, these higher oligomers were formed in 
presence of an artificial substrate leading also to a 2.8-fold higher activity31. However, it is unclear 
whether these higher oligomers of human HTRA1 resemble the cage-like structure of DegP or if they 
assemble in a completely different manner. Interestingly, a higher oligomerization state of human 
HTRA1 was observed in variants lacking all domains except the protease domain, while for DegP 
crystal structures reveal an involvement of PDZ domains in higher oligomer formation35. 
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Figure 3 a) X-ray crystal ribbon structure (PDB entry 3CS0) of DegP monomer protease domain (green) with its two carboxyl 
terminal PDZ domains (blue, purple) is shown at the top. Side chains of catalytic triad are shown in grey. DegP 24-mer is 
shown at the bottom. b) X-ray crystal ribbon structure (PDB entry 3NUM) of trimeric human HTRA1 protease domains (each in 
green, blue, and red) in side view at the top and in top view at the bottom. 
In the active state the loops L1, L2, L3 and LD rearrange from a disordered to an ordered conformation 
resulting in catalytic active distances of the active-site residues (figure 4a). The oxyanion hole, which 
stabilizes negatively charged oxygen of serine328 during catalysis, is formed by the residues 325-327 
of loop L1. Loops are described using the chymotrypsin nomenclature. The specificity pocket selecting 
for P1 residue, 
cleavage occurs, is built of the side chains of the residues lysine346 and isoleucine323 suggesting a 
preference for aliphatic residues such as leucine or valine. Studies about the preferable attacked P1 
threonine30, 31. Cleavage was also observed after methionine, serine, isoleucine and glutamine30. A 
mixture-
ly arginine and aspartate, are dominant. Nonpolar residues, namely 
proline and phenylalanine were preferred at 37. 
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Figure 4 a) X-ray crystal ribbon structures of human HTRA1 protease domain in active (dim grey) and inactive state (grey) 
superimposed. The loops LD, L1, L2 and L3 involved in reversible activation mechanism are indicated in green, red, gold and 
blue. Active side residues are shown in detail at the bottom. b) X-ray ribbon structure of human HTRA1 trimer. Aromatic 
residues mediating trimerization by hydrophobic interactions are shown in detail at the bottom. 
2.1.2. Function of HTRA1 
Recent studies revealed that mammalian HTRA1 is involved in many physiological processes of cells 
such as migration, growth, invasion and neoplasticity38-43. These multiple tasks are correlated to its 
broad substrate spectrum. It was shown that HTRA1 is a mediator in signaling pathways. It degrades 
insulin growth factor binding protein (IGFBP5) which results in the release of insulin growth factor 1 
(IGF1) that stimulates cell proliferation44. Another target of HTRA1 is transforming growth factor beta 
(TGFβ). Its inactivation is a control mechanism in neuronal maturation as well as developmental 
survival45. Additionally, further members of the TGFβ family are processed by HTRA1 such as bone 
morphogenic protein 4 (BMP4), growth differentiation factor 5 (GDF5) and activin which was shown 
to be associated with defects in chick eye development46. Tuberin, a tumor suppressor protein is 
activated by cleavage of its pre-form. This activates the downstream elements eIFE4E-binding protein 
(4E-BP1) and S6 kinase (S6K) leading to initiation of translation47. Besides cell signaling molecules, 
numerous proteins of the extracellular matrix have at least one HTRA1 cleavage site, such as 
fibronectin, decorin, aggrecan, type-II collagen, vitronectin, fibromodulin, biglycan, clusterin, a 
disintergrin and metalloproteinase domain-containing 9 (ADAM9) and the amyloid precursor protein 
fragment Aβ 18, 46, 48-50. DegP as well as HTRA1 were shown to degrade the unstructured protein 
β-casein into several polypeptide fragments. DegP, as well as human HTRA1 are endoproteases31, 51, 52. 
Although structural studies reveal preference of HTRA1 for cleavage after large aliphatic amino acid 
side chains31 there are substrates being cleaved after other residues30. Alignment of known substrate 
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sequence residues before P1 residue does not indicate a clear consensus sequence to be preferred in 
cleavage by HTRA1, raising questions of the mechanism of substrate recognition and specificity30, 31, 53. 
Besides the natural substrates mentioned above, some artificial chromogenic substrates of HTRA1 
especially for DegP were developed such as peptides labeled with para-nitroaniline derived from E. coli 
citrate synthase sequence (DPMFKLV-pNA) and anti-RNA polymerase sigma factor E sequence 
(VFNTLPMMGKASPV-pNA)31. Another fluorescence-quenched peptide substrate 
(Mca-IRRVSYSF(Dnp)KK) named H2opt derived from a substrate library screened on HTRA2 was also 
reported30, 53. This substrate allowed more sensitive measurements of HTRA1 activity compared to 
chromogenic substrates. The poor affinity to all known artificial substrates reveals that HTRA1 activity 
is low in vitro possibly due to a lack of physiological allosteric activators30. Furthermore, it remains 
unclear whether HTRA1 recognizes structural motifs or sequence motifs distant from the P1 position30. 
For DegP it was shown that activity raises at temperatures above 30 °C in a non-linear manner, 
whereas it was almost inactive at temperatures below 20 °C15, 54. A similar temperature-dependent gain 
of activity was observed for human HTRA131. 
Only few inhibitors of human HTRA1 are known. It is inhibited by diisopropyl fluorophosphate (DFP) 
like DegP30. Interestingly, for DegP it was demonstrated that it was only inhibited by DFP but not by 
phenylmethylsulfonyl fluoride (PMSF)51. Both irreversible small molecule inhibitors are unspecific and 
highly reactive with the serine protease catalytic active serine. Another boronic acid-based HTRA1 
inhibitor NVP-LBG976 was developed by Novartis55. Further inhibitors for DegP were developed by 
introducing chloromethyl ketone or boronic acid functionalities at the carboxyl-terminus of artificial 
peptide substrates. It was shown that human HTRA1 was inhibited by DPMFKLboroV which also acts 
on E. coli DegP31, 47. Additionally, it was shown that HTRA1 activity is inhibited by the serum protease 
inhibitor alpha-1 anti-trypsin, a finding that points in the direction of alpha-1 antitrypsin being a 
potential physiologic inhibitor56. 
DegP was found to be attached to cellular membranes due to positively charged residues of first and 
second PDZ domains57, 58. Similar observation was made for human HTRA1 where positive charges on 
the surface distal from the active-site were assumed for localization on liposomes31. This localization 
could be relevant for cell migration by processing signaling molecules, as well as molecules of the 
extracellular matrix59. Although human HTRA1 possesses a signal sequence that translocates it to the 
extracellular matrix, about 20 % is located in the cytoplasm55. Interestingly, HTRA1 was observed to be 
co-localized to tubulin31. The mechanism for the cellular distribution remains unclear. 
2.1.3. Role of HTRA1 in Disease 
HTRA1 expression was observed to be altered in various human diseases40. Elevated expression levels 
were detected in osteoarthritis (OA), age-related macular degeneration (AMD), rheumatoid arthritis 
(RA) and preeclampsia48, 56, 59, 60. Additionally a mutation resulting in a loss-of-function variant of 
HTRA1 causes the inherited neuronal defect cerebral autosomal recessive arteriopathy that is 
associated with subcortical infarcts and leukoencephalopathy (CARASIL)19. 
Lower expression levels up to total loss of HTRA1 is observed in different cancers and results in 
reduced sensitivity to chemotherapy, indicating a role as a tumor suppressor61. This observation is 
confirmed by inhibition of proliferation in vitro and reduced tumor growth in vivo by overexpression of 
HTRA143. Low expression levels of HTRA1 were reported in ovarian and endometrial cancer compared 
to healthy tissue62-64. Ductal glands usually highly express HTRA1, while its expression is reduced or 
even totally lost in ductal carcinoma in situ as well as in invasive breast carcinoma65. Additionally 
downregulation of HTRA1 is associated with poor survival in cancer. This was shown for mesothelioma 
and hepatocellular cancer66, 67. It is presumed that poor survival is especially caused by the strongly 
reduced response to chemotherapy by HTRA1 downregulation. This is reported for ovarian and gastric 
cancer61, 68. It is suggested that the reduced response 
promote apoptosis by degradation of X-linked inhibitor of apoptosis (XIAP). Additionally, migration of 
cancer cells is enhanced by absence of HTRA116, 41. In non-neoplastic epithelial cells, detachment 
causes apoptosis. Loss of HTRA1 contributes to survival after dissemination of these cells in metastatic 
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cancer69. The co-localization of HTRA1 and microtubules mentioned before could be correlated with 
cell motility. Enhanced HTRA1 expression is correlated with reduced cell motility while low HTRA1 
expression is correlated with enhanced motility. This finding lead to the assumption that binding of 
HTRA1 to microtubules affects microtubule stability and dynamics41. Moreover, it was shown recently 
that loss of HTRA1 in breast cancer results in epithelial-to-mesenchymal transition (EMT). This 
acquisition of mesenchymal features promotes growth and increases migration of cells65. Additionally, 
the EMT process activates DNA damage response pathways resulting in poor response to 
chemotherapy65. These results in summary indicate that HTRA1 acts as a tumor suppressor although 
the mechanism of downregulation remains unclear. It is conceivable that mechanisms like loss of 
heterozygosity or epigenetic modulations are responsible for downregulation62, 65. 
In opposite to downregulation in many cancers, HTRA1 levels were found to be elevated in 
rheumatoid arthritis (RA) and osteoarthritis (OA)49, 70. In OA articular cartilage is degraded due to a 
trauma caused by an accident or obesity for example. The mammalian cartilage consists predominantly 
of type-II collagen and further pericellular matrix proteoglycans as aggrecan70, 71. These pericellular 
matrix molecules surround the small amount of chondrocytes in the cartilage which are responsible for 
its homeostasis72, 73. It was shown that HTRA1 is the most abundant protease in human arthritic 
cartilage with substrate specificity to many extracellular matrix molecules such as aggrecan as 
mentioned above74. A model by Polur et al. suggests that HTRA1 is involved in the early progression of 
OA75. In this model HTRA1 expression is assumed to be induced through damage of the articular 
cartilage and leads to degradation of the pericellular matrix. When the pericellular matrix breaks 
down, DDR2 receptors of chondrocytes bind to type-II collagen fibrils which are separated by the 
pericellular matrix in the healthy cartilage. This receptor tyrosin kinase (TRK) initiates after ligand 
binding cell proliferation as well as expression and secretion of matrix metalloproteinase 13 (MMP-
13). This metalloproteinase promotes further degradation of the extracellular matrix of the articular 
cartilage75. Although this process is better understood than involvement in cancer, the role of HTRA1 
in OA and its consequences have yet to be investigated in more detail. 
Interestingly, it was shown that HTRA1 is the first known protease that degrades protein aggregates, 
since it was shown to degrade aggregates of Tau protein which seems to be involved in 
neurodegenerative diseases like Alzheimer Disease or Parkinson Disease76, 77. 
2.2. Antibodies and Scaffolds 
Recombinant protein therapeutics became first relevant with the FDA approval of recombinant 
expressed human insulin in 198278, 79. The technological advance in the past thirty years in this area 
lead to monoclonal antibodies first developed in mice followed by humanization to prevent 
immunogenicity. Monoclonal antibodies which were developed first by Koehler and Milstein80 in 1975 
through immortalization of a mouse B-Lymphocyte have important advantages compared to small 
molecules. They show a longer plasma half-life, enhanced efficacy, increased safety and the success 
rates in the early clinical development phases are higher. Due to this they exhibit better clinical success 
rates and higher financial turnover81. A great advantage of antibodies besides their highly specific 
binding of therapeutic relevant targets is that they can directly modulate immune responses through 
interaction of their constant region with receptors of the immune system82, 83. At the present day there 
are multiple molecular biology technologies available for antibody isolation such as phage-, yeast- 
ribosomal- and RNA-display84, 85. Moreover, a plethora of next generation protein therapeutics have 
been developed which are based on the immunoglobulin backbone or completely unrelated proteins 
for tailor-made functionalities in vivo 86-92. Figure 5 shows crystal structures of an IgG antibody, its 
fragments and related molecules of vertebrates, as well as some alternative scaffolds in the same scale 
in comparison to the HTRA1 homologue of E. coli, the DegP 24-mer with its cage-like structure. The 
main advantage of alternative scaffolds compared with antibodies is a smaller size, which allows a 
better tissue penetration of solid tumors and binding to grooves and active-sites of receptors and 
enzymes. A further advantage concerns potentially lower costs in production and purification as well 
as circumventing complex intellectual property issues93. 
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Figure 5 X-ray crystal surface structure of DegP 24-mer (gold). Each monomer consists of 1 protease and 2 PDZ domains. DegP 
is surrounded by ribbon structures of different molecules used as scaffold for introducing new functionalities. Molecules in 
clockwise: IgG antibody (green), FAB fragment (yellow), SFTI (blue), ocMcoTI-II (orange), vNAR (silver), VHH (bronze) and scFv 
(magenta). All molecules are shown in identical scale (PDB entries 3CS0, 1IGT, 3WIF, 1JBL, 1HA9, 1VES, 1I3V, 1X9Q). 
While in antibodies target binding is mainly mediated by loop regions that are defined as 
complementarity derived regions (CDRs)94, the designer of an alternative scaffold can choose one or 
multiple regions of the protein scaffold of choice to be used for the generation of a binding site which 
should be insensitive against sequence variation in view of stable folding. Most abundant are 
approaches where loops connecting secondary structure elements are randomized90, 95-98 but there are 
also concepts randomizing surface-exposed residues of helical structures or β-sheets90, 95, 96, 98. For the 
design of these alternative strategies it is indispensable to study the three-dimensional structure of a 
scaffold to categorize regions important for a stable fold and for residues which are considered for 
target binding. 
While antibodies are predominantly generated by immunization of an animal with an antigen, there 
are two completely different ways to engineer a scaffold protein, namely rational design or directed 
evolution. A typical process of a directed evolution experiment is shown in figure 6a. Additionally a 
directed evolution approach can be combined with functional optimization based on rational design 
and/or structural knowledge. For example, random exchange of amino acids can be restricted to 
regions involved in target binding. 
Besides the library design the method for isolating the protein of interest is crucial. The biggest 
challenge in directed evolution is the isolation of molecules with desired properties from a large set of 
candidates which is comparable with finding a needle in a haystack. To overcome this problem, it is 
necessary to establish a screening procedure that allows one to separate the wanted from the 
unwanted molecules. The fact that it is impossible to sequence one single protein molecule leads to the 
 almost invisible and so impossible to analyze and reconstruct 
it. The biggest achievement to overcome this problem is the linkage between the molecule of interest 
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and its encoding genetic information, namely its desoxyribonucleic acid (DNA), named genotype-
phenotype linkage. DNA has the benefit compared to proteins that it is easy to amplify in vivo and in 
vitro and additionally it is easy to obtain its sequence. Almost thirty years ago Smith et al. developed a 
system, where molecules were presented on the surface of phage particles after they were cloned into a 
vector and transformed in E. coli99. Due to the fact that the information-storing DNA for the presented 
molecule is combined in one phage particle it is possible to re-infect a bacterium and amplify the single 
DNA copy by divisions of the host followed by DNA-sequencing100. In a typical directed evolution 
experiment, conceptually each phage particle displays a different molecule. The protein of interest can 
be enriched during repeated selection cycles and finally isolated. In a typical experimental setting for 
the isolation of binding proteins, the target structure is immobilized on a surface where binding phages 
are captured and nonbinding phage particles could be washed away101. 
Besides phage display there are also cell-free systems as the RNA and the ribosomal display102. Further 
cell-based systems are the bacterial and the yeast cell surface display (YSD)103, 104. The latter was 
invented in 1997 by Wittrup et al105 and has become, together with phage display, one of the most 
powerful tools in academic and industrial drug development for biological pharmaceuticals. 
Particularly the YSD platform emerged as a powerful tool for engineering affinity, specificity and 
stability of antibodies and other scaffold proteins103, 106. The basic idea of YSD is the linkage of a 
protein of interest on the yeast cell wall where it is exposed for interaction with labeled target 
molecules in solution. The linkage is mediated by the genetic fusion of the potential binding protein to 
the mating protein agglutinin alpha 2p (Aga2p) which is anchored in the cell wall via covalent linkage 
with the Aga1p protein (Aga1p)107. The schematic construct presented on the yeast surface is shown in 
figure 6b. Both mating proteins are expressed under control of the GAL1 promoter, allowing an 
inducible over-expression. Essential components of the YSD are the shuttle vector pCTCON and its 
derivates allowing the fusion of Aga2p and the protein of interest by cloning or gap-repair as well as 
the yeast strain EBY100 and its derivates with the genomic integrated Aga1p under the control of an 
inducible promoter105, 108. Libraries constructed by homologous recombination reach a size of at least 
1010 transformants which is relatively small compared to other display systems101, 109, 110, but can be 
compensated by its general advantages as well as several additional techniques like affinity maturation 
for example. In addition, there are three basic approaches for library screening through different 
labeling, namely equilibrium binding, competition for limited antigen and kinetic competition, each 
addressing different kinetic parameters103. 
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Figure 6 a) Scheme of the workflow of a typical directed evolution experiment. b) Schematic construct presented on the yeast 
surface in yeast surface display. Aga1p is anchored in the yeast cell wall and is covalently linked to Aga2p by cystines. The 
displayed scaffold library is flanked by a HA and a myc tag for evaluation of surface presentation via labeling with antibodies. 
Target molecules and antibodies are typically fluorescently labeled for isolation of molecules by fluorescent-activated cell 
sorting (FACS). 
The main advantage of YSD compared to cell-free systems and phage display is the use of fluorescence-
activated cell sorting (FACS) for the isolation of binders of fluorescently labeled target proteins. 
Furthermore, analysis of isolated single clones is simplified by FACS because the binding properties of 
their molecules can be easily evaluated on the yeast surface without soluble expression. Acquired data 
is consistent with measurements using BIAcore or enzyme-linked immunosorbent assay (ELISA)105, 
111-113. Beyond that the quality control mechanisms of eukaryotic cells residing in the endoplasmatic 
reticulum ensures removal of misfolded protein variants, a feature that is particularly important for 
disulfide-containing proteins114. A competition of a pre-immune single-chain variable fragment (scFv) 
gene library in screening of HIV antigen gp120 resulted in 3-fold more specific binding molecules 
isolated with YSD compared with phage display115. 
Although the most suitable antibody fragment for YSD are scFvs, in the early days of of this technique 
there are methods and formats reported for successful display of fragment antigen-binding (Fab) 
fragments116, 117, single chain Fabs (scFab)118, fragment crystallizable (Fc) fragments119, whole 
immunoglobulin G (IgG)109 and variable heavy chains of a heavy chain antibody (VHH)120, 121. The 
power of YSD is further documented by the successful generation of scFvs with affinities in the pico- 
and femtomolar range achieved by error-prone PCR and DNA shuffling112, 122, 123. 
Several antibodies are now in clinical phase III trials and some are already approved and marketed 
that were developed by phage display such as Belimumab, Briakinumab and Adalimumab, 
respectively87. The fact that approving a drug by the Food and Drug Administration (FDA) or the 
European Medicines Agency (EMA) takes more than a decade, combined with the twenty years 
chronological advance of phage display compared with yeast surface display and YS
advantages against phage display it is likely that the next generation of therapeutic antibodies will 
contain a significant fraction of molecules that were developed by YSD. 
Moreover, YSD proved its versatility for the development of non-antibody proteins. In detail there are 
reports on the identification of mutations transmitting activated conformations on cell adhesion 
molecules or engineering the properties of hormones and cytokines124-128. Additionally, alternative 
binding agents based on non-antibody scaffolds as knottins129-132, fibronectin type III domain133, 134, and 
hyperthermophilic DNA-binding protein Sso7p135, as well as the surface presentation of several 
enzymes136-140; engineering of human immunological proteins and the major histocompatbility complex 
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were reported141-143. Furthermore epitope mapping of designed ankyrin repeat proteins (DARPins) 
against epidermal growth factor receptor ectodomains144 and screening of human and insect cDNA 
libraries have been performed145, 146. 
2.2.1. Immunoglobulin G (IgG) 
Immunoglobulins or antibodies are one supporting pillar of the mammal immune system, which has 
evolved to protect the host from pathogens and toxic substances. They were first described by von 
Behring and Kitasato in 1890 by the observation that a compound of the blood was able to neutralize 
diphtheria toxin147. Further characterization of immunized serum was carried out by Tiselius and Kabat 
in 1939 through electrophoresis, size-exclusion chromatography and depletion experiments, revealing 
that Immunoglobulin G (IgG) is an immunologic active substance148. IgGs are a tool of the adaptive 
immune system which ensures the exquisite specificity for antigens. They are encoded by genes that 
are assembled by somatic rearrangement of germline gene elements to form B-cell antigen receptors, 
or IgGs respectively. The combination of a few hundred gene elements leads to the formation of a 
million IgGs with unique specificity against different antigens. IgGs bind to microbes or particles 
trigger their neutralization by recruiting phagocytic cells of the immune system as neutrophils, 
monocytes and macrophages. IgG producing B-cells represent 15 % of peripheral blood leukocytes and 
differentiate in the bone marrow from heamatopoietic stem cells149. B-cell lineage is induced by 
Interleukine-7 (IL-7) secreted by marrow stromal cells which is followed by sequential heavy and light 
chain gene rearrangement150, 151. 
Each IgG molecule is built-up of two identical heavy chains and two identical κ or λ light chains with a 
molecular weight of each about MW 50,000 and MW 25,000, respectively152. Crystal structure of a 
murine IgG is shown in figure 7. The heavy and the light chain are interconnected by a disulfide 
bridge. In detail, each light chain contains an amino-terminal variable (V) and one constant carboxyl-
terminal domain (C) while the heavy chain constant domain contains three C domains. Each domain 
possesses 110 to 130 amino acid residues and shows an Ig-fold characterized by a sandwiched 
3-strand/4-strand β-sheet intra-connected via a disulfide bridge153. The heavy chain additionally bears 
a hinge region in the linker between amino-terminal constant heavy chain domain (CH) 1 and CH2 
where the heavy chains are interconnected by at least one disulfide bridge. Papain was found as a 
protease separating an IgG into two antigen binding fragments (Fab) consisting of VH, CH1, VL and CL 
domains as well as one crystallizable fragment (Fc) consisting of two CH2 and two CH3 domains
154. 
Further separation of the Fab results in a variable fragment (Fv) consisting of VH and VL which are used 
as single chain Fv (scFv) in engineering approaches for recapitulating monovalent IgG 
characteristics155. Individual fragments of an IgG are indicated by bars in figure 7. 
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Figure 7 X-ray crystal ribbon structure of murine IgG (PDB entry 1IGT). The heavy chains are shown in blue and red, the light 
chains are shown in green. Bars indicate the IgG derived scaffolds Fc, Fab and scFv. 
The variable parts of an IgG molecule responsible for antigen binding are located at the amino 
terminus of the heavy and the light chain designated as VH, Vκ and Vλ. Each variable region is divided 
into three sub-regions, called complementarity-determining regions (CDRs) which are highly variable 
and form the antigen-binding site situated between four regions of stable sequence, called framework 
regions (FRs). In human Igs heavy and light chains genes are separated on different chromosomes and 
the individual V domains which constitute the CDRs are encoded by independent VJ elements for the 
two loci of the light chain and VDJ elements for the heavy chain while the C domains are encoded by 
individual gene elements each156, 157. Recombination of the V domains is a complex procedure and 
leads to highly diverse target affinities due to the complex and individual arrangement for λ, κ and H 
chain94. The ensemble of CDRs of the heavy and the light chain mediating antigen binding are 
designated as paratope while the counter part of the antigen involved in binding is designated as 
epitope. The majority of Igs are produced against intact antigens leading to the detection of a 
conformational epitope while the unfolded linear antigen sequence is not detected. The carboxyl 
terminal parts of the heavy and the light chain are constant for each class of Ig whereas the heavy 
different Fc receptors (FcR) on effector cells or activating other immune mediators, such as 
complement158. Thus, alterations in the Fc region lead to significant changes in the response of 
antibody-antigen interaction. Additionally the Fc part influences the binding properties of V domains 
against an antigen159. There are five different constant parts of antibodies allowing a classification into 
IgA, IgD, IgE, IgG and IgM isotypes differing in their properties including size, complement activation, 
FcR binding and antigen interaction. Isotype switching is influenced by the localization, the antigen 
and the activated downstream signaling pathways160, 161. IgG is the most abundant Ig existing in the 
human body where it shows the longest serum half-life of all Igs making it the most interesting starting 
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point for antibody therapeutics. There are four subclasses of IgG (IgG1, IgG2, IgG3 and IgG4) differing 
in their constant region domains CH1 and CH3 resulting in structural, functional and antigenic 
differences. IgG subclasses were ranked according to their distribution in the human body whereas 
IgG1 is the most abundant. The IgG subclasses differ in the flexibility of the Fab because of the 
different CH1 domains which results in an altered interaction with potential antigens. IgG subclasses 
distinguish themselves in their ability of complement activation or in secondary antibody response 
where IgG1 and IgG3 are predominantly expressed for protein antigens while IgG2 and IgG4 are 
expressed for antigens associated with polysaccharides. Another difference is their ability to bind the 
three classes of FcγRs (FcγRI, II and III). While IgG1 and IgG3 bind to all FcγRs, IgG4 only binds FcγRI 
and FcγRII as well as IgG2 only binds FcγRII. There is an additional FcR, the neonatal FcR (FcRn), 
which regulates the serum level of IgG by endocytosis after binding. For higher IgG serum level the IgG 
bound by FcRn in the endosom is recycled or for a lower IgG serum titer IgG-FcRn is neutralized by the 
lysosome. 
Moreover, Igs are glycosylated especially in the Fc region, which has been shown to influence antibody 
function 162. Although all CH2 domains of 
IgGs heavy chain correspond in glycosylation site Asn297, the glycosylation extent alters by different 
sugars in different positions leading to 32 unique glycosylation patterns. IgG structure is stabilized 
through glycosylation, giving a longer serum half-life. Degree of stabilization changes with different 
glycosylation patterns163, 164. Beyond that, it was shown that IgG glycosylation is indispensable for 
binding to FcRs. The two main effector functions mediated through FcR for IgGs (FcγR) are antibody-
dependent cellular cytotoxicity (ADCC), in which antibody-labeled antigens activate immune cells like 
monocytes or natural killer cells and complement-dependent cytotoxicity (CDC), where IgG is binding 
to C1q an initial key player of the complement system. For both effector functions a specific 
glycosylation pattern is crucial165-167. 
The fully mature Igs have an additional carboxyl-terminal transmembrane domain allowing surface 
presentation named Igα and Igβ which enables an intracellular signaling of the presenting B-cell after 
antigen binding168, 169. These presented antibodies of naïve B-cells are the isotypes IgM and IgD 
constructed by alternative splicing of the same VHDHJH exon to the µ and δ heavy chain exons resulting 
in a membrane-bound variant. This alternative splicing called class-switch recombination (CSR) allows 
the B cell to switch all isotypes between membrane-bound and secreted Igs by a DNA rearrangement 
mediated by several enzymes, which is induced by T cell-derived cytokines and T helper cells. This 
allows a grafting of a functional VHDHJH binding unit to different antibody isotypes with the same 
antigenic specificity170. T cell-derived IL-10 causes switching to IgG1 and IgG3 isotype, while 
Interferon-γ (IFN-γ) and other molecules from T helper cells causes switching to IgG2, for example. 
Parallel to CSR the B cell introduces actively random mutations in the antigen-binding segments 
mediated by activation-induced cytidine deaminase, uracil DNA glycolyase, APE1 and DNA repair 
enzymes171. A mutation resulting in a loss of antigen binding results in a loss of growth signals 
important for survival and in opposite mutations leading to increased binding affinity to the antigen 
results in signaling molecules for proliferation of the B cell172. The consequence of this is a clonal 
selection of B cells expressing antibodies with a high affinity and specificity located in the center of the 
secondary lymphoid tissue like the spleen, adenoids, tonsils and the skin173. Most often T cells induce 
activation and maturation of B cells as well as the isotype of antibody they produce. In case of repeated 
exposure to an antigen a T cell mediated maturation event occurs, which is called somatic 
hypermutation (SHM) and delivers 10-3 changes per base pair for each maturation round involving two 
mechanisms. On the one hand there is targeting of mutation hotspots made up by a RGYW 
(purine/G/pyrimidine/A) motif and on the other hand error-prone DNA synthesis174, 175. Besides CSR 
and SHM, T cells mediate differentiation of B cells into continuing plasma cells or into continuing 
memory B cells, the latter especially after a repeated antigen exposure176. This memory response is 
responsible for the extraordinary effect of vaccination. Without T cell stimulation B cells differentiate 
in short-living plasma cells with limited class switching opportunities emphasizing the importance of 
T cell communication. 
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2.2.2. Variable Domain of a Heavy Chain Antibody (VHH) 
The members of the Camelidae family Camelus dromedarius, Camelus bactrianus, Lama glama, Lama 
pacos, Lama guanicoe and Lama vicugna show a unique feature in the mammal immune system 
concerning their IgGs. While IgGs usually consists of two heavy chains and two light chains, in the 
1990s emerged an additional variant in camelids that only consists of two heavy chains, named heavy-
chain antibodies (HCAbs)177. HCAbs, named isotypes IgG2 and IgG3 are delivered by B cells during a 
classical immunization reaction as well as common IgG molecules namely IgG1177. The ratio of HCAbs 
compared to IgGs varies from camels with around 50 80 % to lamas and alpacas with an amount of 
around 10 25 %178. The organization of the variable heavy chain (HV) is quite similar of both, 
common IgG and HCAb. Interestingly, a disorder was observed in humans leading to HCAbs 
constructed by genetic deletion events resulting in a pathological disorder179, 180. The important 
differences explaining the equivalent binding properties of an antigen by lack of a light chain is 
compensated by a more extended CDR1 and CDR3 compared with a classical IgG. Moreover, the 
canonical loop structures of the CDRs deviate in sequence and structure from hypervariable regions of 
VH in mouse and human181, 182. An extra conformational difference occurring mainly in dromedaries is 
an additional intramolecular disulfide bond of CDR1 and CDR3183, 184. Furthermore, the area of the 
heavy chain which is responsible for interaction with the light chain by highly conserved hydrophobic 
residues in framework 2 is substituted to ressemble a more hydrophilic surface183-185. Hence, these 
mutations show no conformational rearrangements of the Ig-fold but overcome instabilities and regain 
solubility resulting from the lack of a light chain186, 187. Another difference to IgGs is that the heavy 
chain consists only of three instead of four globular domains found in IgG, whereas the CH1 domain is 
missing. The CH2-CH connected to 
VH domain in HCAbs referred as variable domain of a heavy chain antibody (VHH)
188, 189. It was shown 
that the VHH is a functional antigen binding unit183-185, 189, 190. 
The antigen binding unit of an HCAb, the VHH also called Nanobody (Nb) reveals a number of benefits 
compared to the Fab and scFv of classical antibodies. VHHs typically denature between 60-80 °C but 
there are also stable VHHs described resisting temperatures above 90 °C, demonstrating their high 
stability191, 192. Corresponding to this shelf life for months as well as incubations for several weeks at 
37 °C do not reduce the antigen binding capacity193. Immunogenicity was not observed by injection of 
VHHs to human and mouse as it was supposed due to its stable behavior, high sequence homology to 
human VH and its small size leading to a rapid renal clearance194-196. Additionally, there are approaches 
for humanization of the non-homologous amino acid residues197. Its molecular weight (MW) of about 
15,000 is half of the MW of the smallest antigen binding unit of classical antibodies, namely scFv and 
delivers a molecule able to protrude into cavities like active-sites of enzymes or buried epitopes, 
respectively. This ability is enhanced by its paratope architecture formed by the CDRs giving a 
preference for binding of cavities. These reasons making them interesting as scaffolds for affecting 
enzyme activity by designing inhibitors and activators194, 198-203. The small size further leads to a better 
tissue penetration compared with Igs with the consequence of better antigen neutralization204-206. 
Furthermore scFvs tend to dimerize in contrast to VHHs. Access to VHHs is easy because of their 
biotechnological handling, as multiple expression systems as bacteria, yeast, plants or mammalian cell 
lines in sufficient laboratory scales are described207-210. The most convenient strategy to obtain highly 
specific and affine VHH molecules is immunization of camelids followed by cloning into a directed 
evolution system as phage display193, 211. Moreover, synthetic and non-immunized libraries obtained 
and pooled from various individuals were described212, 213. Isolated VHHs usually display equilibrium 
dissociation constants in the sub-nanomolar range. There are published approaches where two VHHs 
with different specificity were genetically fused, resulting in bivalent molecules as well as bi- or 
multivalent fusions that enlarge binding affinity by avidity effects91, 200, 214, 215. Finally it was shown that 
fusions to the Fc combine the advantages of an Ig and the VHH which were previously described216, 217. 
These properties are crucial making VHHs an interesting molecule for various applications as research 
tools and in diagnostic and therapeutic applications218-220. In applications as research tools, VHHs were 
used to stabilize membrane proteins for structure determination by crystallization, or in subcellular 
localization and therapeutic target validation through intracellular co-expression221-227. The diagnostic 
   18 
use of VHHs is fostered by its rapid renal clearance due to its small size. The resulting short plasma 
half-life in blood makes it possible to use radio-labeled VHHs as probes for in vivo imaging with 
positron emission tomography, which was already demonstrated by mouse xenograft experiments228-231. 
The most interesting field for VHHs is their therapeutic application because of the benefits compared 
to classical antibodies, while the disadvantages of short plasma half-life and missing effector functions 
can be overcome by pegylation, fusion to albumin binding units or Fc domains232. VHHs that are able 
to cross the blood-brain barrier or lead to transcytosis across epithelia are published215, 233-235. 
Furthermore, there are several VHH-based therapeutics in clinical phase I and II trials against IL6R, 
TNFα, RANKL or von Willebrand factor236. Finally, oral or inhalative administrations which are more 
patient-friendly are conceivable. 
2.2.3. Variable Novel Antigen Receptor (vNAR) 
Sharks are the oldest vertebrate taxon that possess the key components of an adaptive immune system 
as described for mammals. That includes the combination of detecting invading molecules by low 
affine receptors followed by their maturation to highly specific and affine neutralizing compounds. As 
previously described this task is fulfilled by TCRs, Igs, RAGs, MHC as well as somatic hypermutation 
occurring in specialized compartments as the primary and secondary lymphoid tissue237. After 
Greenberg discovered IgM molecules in sharks it was shown by Flajnik et al. that in nurse sharks which 
are members of the order Orectolobiforme, there also exist heavy chain antibodies. These Ig molecules 
characterized by the lack of a light chain were designated Immunoglobulin novel antigen receptor 
(IgNAR) and were found in sharks at an amount of around 30-fold less than IgM238-240. In detail IgNARs 
were found in spiny dogfish and in nurse shark which are separated phylogenetically by approximately 
200 million years which indicates distribution over most elasmobranchs241. According to vertebrate 
antigen receptors there exist soluble and B-cell presented IgNAR molecules. Research on IgNARs 
revealed that the membrane bound variant has three or five domains while the soluble variant always 
consists of five domains242. Additionally there is an antigen driven selection mechanism indicated 
through a higher degree of mutations in the soluble variant243. Nevertheless IgNARs show only low 
sequence homology to human antibodies but also homology to cell adhesion molecules and TCRs240. 
Thus it is likely that IgNAR evolved independently of vertebrate antibodies by the elasmobranch 
immune system244. Similar to VHHs there are residue substitutions at the interface region of IgGs VH 
and VL domains, where hydrophobic residues are exchanged against hydrophilic amino acids. 
Combined with further differences like the extremely shortened CDR2 region the IgNAR binding 
domain, called variable domain novel antigen receptor (VNAR), is the smallest described independent 
antigen binding unit in animal kingdom. Besides these sequence differences there are different rarely 
replaced cysteine residues allowing a separation into three defined types of IgNAR (I, II, II)245-247. Type 
III was only observed in neonates, while Type I was exclusively observed in nurse sharks. Also in 
families of the same order there were only Type II IgNARs described. All Types share a highly 
conserved disulfide bond at residue 35 and 107 that stabilizes the Ig fold of the VNAR domain. Type I 
carries two further disulfides comprised by cysteines in framework 2 and 4 which are connected to two 
cysteines encoded by CDR3. Type II is connected by one additional disulfide bond encoded by CDR1 
and CDR3. While CDR3 of Type I is bent down due to its two disulfides, the CDR3 of Type II is 
presented in a protruding manner, stabilized by the connection to CDR1 giving them completely 
different binding properties. As mentioned previously, there is no defined CDR2 in VNAR but there are 
two elements located between CDR1 and CDR3 which are similar to hypervariable loops (HV) 2 and 4 
found in TCRs248. Studies revealed that Type I CDR3 is on average about six residues longer than 
Type II, while Type II shows higher frequency of mutations in CDR1. Moreover sequence variation of 
HV2 from Type I is greater compared with Type II249.  
Sharks have three heavy chains of which two (IgM and IgW) are combined with four light chain 
loci238, 250. The organization of these elements is different of that compared to the mammalian systems, 
because in sharks they are clustered251. In detail, sharks possess only one V segment which is combined 
in a cluster with at least one D segment, one J segment and a set of C segments which are rearranged 
exclusively by RAG recombinase240, 252-258. As a big difference compared with vertebrates there is no 
isotype switching between the clusters observed. The most effective mechanisms for the heterogeneity 
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of the naïve repertoire of shark antibodies are the N-addition and the D-region rearrangement. 
vertebrates258. The lack of a light chain in IgNARs is compensated by the number of recombination 
events and the presence of additional D segments240. Besides these recombination events there is also 
an extensive N and P nucleotide addition, which predominantly enhances naïve diversity of CDR3. 
Particularly important for secreted IgNAR selectivity and affinity is affinity maturation by somatic 
hypermutation. The mutational patterns are similar to those of mammals but unusual base changes 
occur in tandem245. Besides affinity maturation, sharks possess a secondary feature of an adaptive 
immunity, the memory of recognized antigens. An antigen-specific response was observed in different 
elasmobranch species when challenged by IgM serum analysis239, 259-261. Similar to IgM an adaptive 
response was shown for IgNAR by repeated immunizations with hen egg lysozyme (HEL) with an 
expression plateau after 4 months. In further re-immunizations antigenic-memory was proved262. 
Interestingly, sharks are the only vertebrates with an adaptive immune system which shows no class 
switch recombination. The epigonal organ attached to the gonads and the Leyding organ, which is 
localized at the oesophagus, are the critical tissues for lymphopoiesis in elasmobranches that possess at 
least one of them. These organs are composed and organized like the primary lymphoid tissue in 
higher vertebrates263. The epigonal organ exhibits large numbers of secretory B-cells in adult sharks 
suggesting an analog function to mammalian bone marrow. Although there are no germinal centers for 
B-cell activation observed, it is highly indicative that the spleen is the compartment for B-cell activation 
due to its mammalian like structure264. 
vNAR domains combine many interesting features, among them high stability against denaturing 
agents and the capability to refolding after heat denaturation. Due to high urea concentrations in 
sharks blood, vNARs are extremely stable and according to their hydrophilic surface they are highly 
soluble resulting in high expression levels already in bacterial expression systems265-267. They are 
slightly smaller than VHHs giving them the opportunity to access buried epitopes and binding pockets. 
Having a significantly different binding loop composition compared to VHHs, they are not only an 
alternative to VHHs but also an additional scaffold for designing proteins with high specificity and 
affinity for difficult to address target molecules and for recessed epitopes such as the active site of 
enzymes266, 268-272. A vNAR phage display library constructed of nurse shark RNA previously immunized 
with HEL allowed the isolation of vNAR variants in the nanomolar range against HEL. Sequences of 
HEL binding vNARs were analyzed and mutations were separated into those occurred through somatic 
hypermutation and to class switch recombination253. Additionally, crystal structures of a matured vNAR 
and its germline ancestor in complex with HEL revealed positions important for highly specific and 
affine binding254. Another approach using the naïve repertoire of wobbegong sharks combined with 
random mutagenesis delivered a selective IgNAR against Gingipain K protease273. Additionally, vNARs 
from naïve and semi-synthetic libraries from spiny dogfish delivered binding molecules against cholera 
toxin and ricin in the nanomolar range265. vNARs can be produced in various formats and strategies 
already used for VHHs or other scaffold proteins such as dimerization can be applied274. 
Oligomerization of binding molecules specific for different targets, is interesting for enlarging the 
specificity to a neoplastic cell that overexpress surface receptors that are not unique on the cell for 
example. Another strategy is to enlarge serum half-life of molecules by fusion to polyethylene glycol, 
serum albumin binding molecules or Fc parts. For the above-mentioned reasons it is beneficial to have 
small and stable monomeric molecules because of an easier expression with higher yields of active 
molecules with high stability for chemical or biological conjugation compared with classical antibodies. 
The phylogenetical distance of 400 million years to the mammalian adaptive immune system results in 
little sequence homology, which makes them a powerful alternative to VHHs which clearly evolved 
from antibodies. 
2.2.4. Momordica cochinchinensis Trypsin Inhibitor II (McoTI-II) 
Momordica cochinchinensis Trypsin Inhibitor II belongs to the family of knottins. These peptides of 28 
to 35 amino acids in length are connected by three disulfide bridges, resulting in a defined three-
dimensional structure leading to the name cystine knot miniproteins. Knottins are found in many 
different kingdoms of nature as fungi, plants, insects, mollusci, mammalia and viruses with more than 
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2000 reported sequences until now275-278. The most interesting property of these molecules is the 
extremely high chemical and biological stability which results from their unique structure. It was 
shown that most members of this family are stable against boiling, storage at 65 °C over months or 
extremely unphysiological pH values (1 M HCl, 1 M NaOH). Additionally many of them are resistant 
against degradation of serum proteases22, 279-281. All cystine knot miniproteins share the same cystine 
pattern where cys #1 is connected to cys #4, cys #2 to cys #5 and cys #3 to cys #6. This results in a 
pseudo-knotted center, which is further defined by three antiparallel β-strands connected by loops that 
vary in sequence and length. Nevertheless the backbone of peptide bonds is highly structural 
rigid282.Crystal structure of the open chain variant of knottin McoTI-II is shown in figure 8. Disulfide 
bridges and side chains of loop 1 residues are outlined. 
 
Figure 8 X-ray crystal structure (PDB entry 1HA9) of open chain variant of McoTI-II (top). Amino acid side chains of the 
inhibitor loop are shown in red. Disulfide bridges are shown in light grey. Color code belongs to amino acid sequence 
(bottom) that reflects the degree of randomization in a combinatorial library approach described in chapter 5.3 of this work. 
Cystines are indicated by black bars. Yellow letters 50 % randomisation, green letters 10 % ramdomization and red letters 
100 % randomization of all 19 amino acids (without cysteine). 
McoTI-II is a knottin that belongs to a special class of knottins, the cyclotides. These share an 
additional feature that is an additional loop that emerges by cyclization of the amino- and the 
carboxyl-terminus by a peptide bond283-286. McoTI-II is a trypsin inhibitor isolated from the seeds of the 
squash Momordica cochinchinesis287. Further cyclotides were observed in other plant families namely 
Rubiaceae and Violaceae with a broad range of biological properties such as insecticidal, antimicrobial 
and hemolytic activity288-290. Due to the biological function, McoTI-II is also grouped into the family of 
inhibitor cystine knots (ICK). Several members of this family such as EETI-II291, 292 and CMTI292, 293 are 
not cyclic but share extensive similarities in the three-dimensional structure291-293. The inhibitory 
activity against trypsin-like proteases is mediated by the loop located between cys #1 and cys #2 
composed of 6 amino acid residues 21, 277. Besides the structural conserved core, the solvent-exposed 
residues are susceptible for alterations of amino acids277. Thus, it becomes possible to generate variants 
with different biological activities by protein engineering approaches. These variants could serve as 
therapeutics or diagnostic agents in clinical applications22, 279, 281, 294. Accordingly, designed knottins 
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were reported that address targets of medical relevance such as a McoTI-II-based molecule that inhibits 
tryptase β which is involved in allergen driven asthma131, 294-299. Recently another McoTI-II-based 
variant was isolated from a combinatorial library by YSD against the tumor associated protease 
matriptase-1 with a sub-nanomolar inhibitory constant129. 
Interestingly, there was also a non-cyclic variant in the seeds of Momordica cochinchinesis abundant 
called McoTI-III. To make McoTI-II accessible for protein engineering, an open chain variant was 
synthesized with the result of a 10-fold loss in biological activity which was in opposite to the cyclotide 
kalata B1 where biological activity was completely lost after opening the cyclic structure21. The X-ray 
crystal structure of McoTI-II open chain variant (ocMcoTI-II) is shown in figure 8. A special advantage 
of knottins compared with other proteins is the accessibility to solid-phase peptide synthesis additional 
to recombinant expression277, 300. 
2.3. Aim of this Work 
This work aimed at modulating the activity of human serine protease High Temperature Requirement 
A1 (HTRA1), because it is suggested to be involved in several diseases of high relevance16-20. Several 
approaches are conceivable for HTRA1 functional modulation, such as competitive binding to the 
active-site, allosteric disordering of the catalytic triad as well as allosteric stabilization of the enzyme  
active state. At present there is only one single immunoglobulin derived inhibitor335, but no 
proteogenic activator described, that act specifically at the catalytic domain. To close this gap, protein 
libraries of independent scaffold molecules should be screened by yeast surface display for obtaining 
binding molecules towards HTRA1. 
However, HTRA1 is a protease with different and not well characterized higher oligomeric states. 
Preferably a monomeric variant should be used for screening in order to work with an easier to handle 
and more controllable target protein. Moreover, a stable monomeric HTRA1 variant with only minor 
alterations compared to native sequence would serve as a preferred target since molecules recognizing 
the oligomerization interfaces that would all be accessible in the monomeric variant could be 
identified. Such modulators of oligomerization would also most likely influence enzyme activity since 
it was shown for human HTRA1 that the oligomeric state of this enzyme has an impact on proteolytic 
activity31. As a consequence, one major goal of this work was the design of HTRA1 with reduced or 
preferably abolished oligomer forming properties. 
Binders should be isolated from libraries based on the cystine knot, the VHH and the vNAR scaffold. 
Additionally, for molecules obtained from the vNAR library a stepwise affinity maturation should be 
applied to obtain high affinity binders272 through variation of CDR1 and HV2 of obtained binding 
molecules with variant CDR3 regions and a combination of both. 
Finally, successful candidates should be soluble expressed and characterized in view of the influence 
on HTRA1 proteolytic activity. Modulators of HTRA1 activity would become valuable tools for analysis 
of protease function and the evaluation, whether this enzyme might serve as a therapeutic target. 
Particularly, an activator would represent a novel tool for evaluation of HTRA1. 
  
   22 
3. Material  
3.1. Bacterial Strains, Yeast Strains and Cell Lines 
3.1.1. Bacterial Strains 
DH5α 
F  Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK , mK+) phoA supE44 λ  thi-1 gyrA96 
relA1 
 
BL21 (DE3) 
F  ompT hsdSB(rB , mB ) gal dcm (DE3) 
 
BMH 71-18 
supE thi Δ(lac -proAB) [mutS::Tn10] [F' proAB+ laclq lacZΔM15] 
 
3.1.2. Yeast Strains 
EBY100 
MATa GAL1-AGA1::URA3 ura3-52 trp1 leu2_1 his3_200 pep4::HIS2 prb1_1.6R can1 GAL, Trp-Leu- 
 
3.1.3. Human Cell Lines 
HEK293EBNA1-6E (HEK293-6E) 
Human embryonic kidney cells stably expressing EBNA1301 
 
3.2. Cultural Media 
dYT Yeast extract 10 g/l, peptone/tryptone 
16 g/l, NaCl 5 g/l h  
LB Yeast extract 5 g/l, peptone/tryptone 
10 g/l, NaCl 10 g/l 
YPD Yeast extract 10 g/l, peptone/tryptone 
20 g/l, dextrose 20 g/l  
SD-CAA Yeast nitrogen base without amino acids 
and ammonium sulfate 1.7 g/l, ammonium 
sulfate 5 g/l, casamino acids 5 g/l, dextrose 
20 g/l, NaH2PO4 × H2O 8.6 g/l, Na2HPO4 
5.4 g/l 
SG-CAA Yeast nitrogen base without amino acids 
and ammonium sulfate 1.7 g/l, ammonium 
sulfate 5 g/l, casamino acids 5 g/l, 
galactose 20 g/l, NaH2PO4 × H2O 8.6 g/l, 
Na2HPO4 5.4 g/l, polyethylene glycol 8000 
10 % (w/v) 
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FreeStyle F17 Expression Medium Life Technologies, Carlsbad, USA (add. 25
50 µg/ml G418, 4 mM L-glutamine) 
  
3.3. Plasmids 
3.3.1. pET21d 
 
Figure 9 Vector map for bacterial expression plasmid based on pET21d-HTRA1-cd. Arrows indicate orientations of genetic 
elements encoding for: Bacterial origin of replication (F1 ori), ampicillin resistance (AmpR), lac operator of lac operon (LacO), 
human Htra1 catalytic domain (hHTRA1 cd), histidine tag (His(6)) and stop codon (Stop). NcoI and XhoI recognition 
sequences for restriction enzymes. 
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3.3.2. pCT 
 
Figure 10 Vector map for yeast surface display plasmid based on pCT-HTRA1-VHH-KV07. Arrows indicate orientations of 
genetic elements encoding for: Yeast origin of replication (CEN6/ARS4), ampicillin resistance (AmpR), Galactose1 Promoter for 
protein expression in yeast (Gal1 Promoter), A-agglutinin-binding subunit 2 for presentation of fused protein by attachment 
to A-agglutinin-binding subunit 1 in the cell wall (Aga2p), Linker (Linker), recognition site for cleavage by Factor Xa (Factor 
Xa), hemagglutinin epitope (HA-tag), 3 repeats of 4 glycine 1 serine linker ((Gly4Ser)3 Linker), isolated HTRA1 binding VHH 
clone 7 (HTRA1-VHH KV07), myc epitope (myc-tag), stop codon (Stop), S. cerevisiae terminator of transcription (terminator), 
bacterial origin of replication (F1 ori) and auxotrophic selection marker (Trp1). NheI and BamHI recognition sequences for 
restriction enzymes. 
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3.3.3. pMX 
 
Figure 11 Vector map for Maltose-binding Protein-encoding plasmid based on pMX-HTRA1-vNAR-K07. Arrows indicate 
orientations of genetic elements encoding for: Chloramphenicol resistance (CmR), Maltose-binding Protein (Maltose-binding 
Protein), recognition site for tobacco etch virus protease (TEV Site), isolated HTRA1 binding vNAR clone 7 (HTRA1-vNAR-K07), 
spacer of three alanines (Ala-Linker), histidine tag (His(6)), stop codon (stop) and a bacterial origin of replication (F1 ori). 
Acc65I and XbaI recognition sequences for restriction enzymes. 
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3.3.4. pExpress-Fc 
 
Figure 12 Vector map for Fc-encoding plasmid based on pEXPR-H12-HTRA1-VHH-KV07. Arrows indicate orientations of genetic 
elements encoding for: Ampicillin resistance (AmpR), cytomegalovirus promoter (CMV promoter), signal sequence for protein 
secretion (BM40), isolated HTRA1 binding VHH clone 7 (HTRA1-VHH-KV07), IgG1 hinge region (H12 Linker), CH2 and CH3 
domains of human IgG1 (Fc), sortase A recognition sequence  (Sortase Site), stop codon (Stop), resistance against neomycin 
(Kan/neoR)  and a bacterial origin of replication (pUC origin). NheI and ApaI recognition sequences for restriction enzymes. 
3.4. Enzymes, Proteins, Protein Conjugates, Nucleic Acids and Standards 
Acc65I New England Biolabs, Beverly, USA 
Albumin Fraktion V (pH 7,0) (BSA) AppliChem GmbH, Darmstadt, Germany 
Anti-Mouse IgG−Alkaline Phosphatase (goat) Sigma-Aldrich, St. Louis, USA 
Anti-Mouse IgG−Biotin (rabbit) Sigma-Aldrich, St. Louis, USA 
Anti-Mouse Ig−FITC (rabbit) Sigma-Aldrich, St. Louis, USA 
Anti-myc IgG (mouse) Sigma-Aldrich, St. Louis, USA 
ApaI New England Biolabs, Beverly, USA 
BamHI New England Biolabs, Beverly, USA 
CutSmart® Buffer New England Biolabs, Beverly, USA 
dNTPs Carl Roth GmbH, Karlsruhe, Germany 
ExtrAvidinTM-alkaline phosphatase conjugate Sigma-Aldrich, St. Louis, USA 
Gel Filtration HMW Calibration Kit GE Healthcare, Little Chalfont, UK 
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Gel Filtration LMW Calibration Kit GE Healthcare, Little Chalfont, UK 
NcoI New England Biolabs, Beverly, USA 
NEBuffer 3.1 New England Biolabs, Beverly, USA 
NheI New England Biolabs, Beverly, USA 
Lambda DNA Eco47I (AvaII) Marker Fermentas, Vilnius, Lithuania 
Lysozyme from chicken egg white Sigma-Aldrich, St. Louis, USA 
 Fermentas, Vilnius, Lithuania 
Oligonucleotides Sigma-Aldrich, St. Louis, USA 
Penta·His Alexa Fluor 488 conjugate QIAGEN, Hilden, Germany 
Penta·His Antibody, BSA-free QIAGEN, Hilden, Germany 
Phusion® High-Fidelity PCR Kit New England Biolabs, Beverly, USA 
Prestained Protein Marker, Broad Range 
7-175 kDa 
New England Biolabs, Beverly, USA 
Protein A, HRP conjugate Sigma-Aldrich, St. Louis, USA 
Streptavidin-Allophycocyanin conjugate 
(SAPC) 
eBioscience, San Diego, USA 
Streptavidin-R-Phycoerythrin conjugate (SPE) Sigma-Aldrich, St. Louis, USA 
T4 DNA Ligase New England Biolabs, Beverly, USA 
T4 DNA Ligase Reaction Buffer (10x) New England Biolabs, Beverly, USA 
Taq-Polymerase in-house 
TEV-Protease in-house 
Trypsin-EDTA Gibco, Karlsruhe, Germany 
XbaI New England Biolabs, Beverly, USA 
XhoI New England Biolabs, Beverly, USA 
Yeast Lytic Enzyme MP Biomedicals, Santa Ana, USA 
3.5. Oligonucleotides 
CDR1rand_up 
ACCATCAATTGCGTCCTAAAA(X)5TTGGGTAGCACGTACTGGTATTTCACAAAGAAG 
 
FR1_up 
ATGGCCGCACGGCTTGAACAAACACCGACAACGACAACAAAGGAGGCAGGCGAATCACTGACCATCAAT
TGCGTCCTAA 
 
GR_up 
GTGGTGGTGGTTCTGCTAGCATGGCCGCACGGCTTGAACA 
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GR_lo 
ATAAGCTTTTGTTCGGATCCWTTCACAGTCASARKGGTSCCSCCNCC 
 
hHtrA1_cd_NcoI_up 
GCGCGCCCATGGGCCAAGGGCAGGAAGATCC 
 
hHTRA1_cd_Y169A_F171A_NcoI_up 
GCGCGCCCATGGGGCAGGAAGATCCCAACAGTTTGCGCCATAAAGCTAACGCTATCGCGG 
 
hHTRA1_cd_XhoI_lo 
CGCGCGCTCGAGTTTTCCTTTGGCC 
 
hHTRA1_cd_F278A_SOE_lo 
GGGCTTCCGATGGCGACCAC 
 
hHTRA1_cd_F278A_SOE_up 
CCGGGAGAGGCCGTGGTCGCCATCGGAAGCCCG 
 
hHTRA1_PDZ_XhoI_lo 
CGCGCGCTCGAGTGGGTCAATTTCTTCGGG 
 
HV2_SOE_lo 
GCCCTTCTTTGTGAAATACCA 
 
HV2_SOE_rand_up 
TGGTATTTCACAAAGAAGGGC(X)9GCGGACGATACTCGGACACA 
 
MASKO_rd5_VHH-K1_NheI_up 
GCGCGCGCTAGCCGCTGAGGTGCAGCTGCAGGCGTCTGG 
 
MASKO_rd5_VHH-K1/7_ApaI_lo 
CGCGCGGGGCCCGCCCAGCAGTTCAGGGGCAGGGCTAGGGGGGCTGGTGTGGGATCCGCTGGAGACGG
TGACC 
 
MASKO_rd5_VHH-K7_NheI_up 
GCGCGCGCTAGCCGCTGATGTTCAGTTGCAGGCGTCTGG 
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pCT_Seq_up 
AGGACAATAGCTCGACGATT 
 
pCT_Seq_lo 
GCGCGCTAACGGAACGAAAAATAGAAA 
 
pEXPR_Seq_for 
GAGAACCCACTGCTTACTGGC 
 
pEXPR_Seq_rev 
TAGAAGGCACAGTCGAGG 
 
pMX_seq_up 
TGGTATGCCGTGCGTACTGC 
 
pMX_seq_lo 
TGAATTAGCTTGGAATTGCG 
 
SloII_HTRA1_K1_NheI_up 
GCGCGCGCTAGCCGCTATCACACTGTGCTTCTAC 
 
SloII_HTRA1_K1_ApaI_lo 
CGCGCGGGGCCCGCCCAGCAGTTCAGGGGCAGGGCTAGGGGGGCTGGTGTCCGAGGCCGAGCCGCAGT 
 
T7_Pomoter_seq_up 
TAATACGACTCACTATAGGG 
 
T7_Terminator_seq_lo 
TAGAGGCCCCAAGGGGTTAT 
 
vNAR_Acc65I_TEV_up 
GCGCGCGGTACCCGAAAACCTGTATTTTCAGAGCATGGCCGCACGGCTTGAACAA 
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vNAR_His_Stop_XbaI_lo: 
CGCGCGTCTAGATCATTAATGATGATGATGATGATGATTCACAGTCACAAGGGTCCC 
 
X: triplet codon for all natural amino acids without cysteine; K: G/T; N: A/G/C/T; R: A/G; S: G/C; W: 
A/T. 
3.6. Chemicals 
2-Mercaptoethanol  Carl Roth GmbH, Karlsruhe, Germany  
3,3′,5,5′-tetramethylbenzidine (TMB) Sigma Aldrich, St. Louis, USA 
5-Bromo-4-chloro-3-indolyl phosphate (BCIP) Carl Roth GmbH, Karlsruhe, Germany 
7-(Carboxymethoxy)-4-methylcoumarin (MCA) Sigma Aldrich, St. Louis, USA 
Acetic Acid  Carl Roth GmbH, Karlsruhe, Germany  
Acetonitrile Carl Roth GmbH, Karlsruhe, Germany 
Acrylamide/Bisacrylamide (37,5:1)  Carl Roth GmbH, Karlsruhe, Germany  
Agar-Agar  Carl Roth GmbH, Karlsruhe, Germany  
Agarose Carl Roth GmbH, Karlsruhe, Germany  
Ammonium acetate  Carl Roth GmbH, Karlsruhe, Germany  
Ammonium hydrogene carbonate  Carl Roth GmbH, Karlsruhe, Germany  
Ammonium sulfate Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin, sodiumsalt  Carl Roth GmbH, Karlsruhe, Germany  
Ammonium persulfate (APS)  Carl Roth GmbH, Karlsruhe, Germany  
Anisole Sigma Aldrich, St. Louis, USA 
Bacillol plus  Carl Roth GmbH, Karlsruhe, Germany  
Bromophenol blue  Carl Roth GmbH, Karlsruhe, Germany  
Calcium chloride  Carl Roth GmbH, Karlsruhe, Germany  
Casaminoacids  Becton Dickinson GmbH, Heidelberg, 
Germany  
Chloramphenicol Carl Roth GmbH, Karlsruhe, Germany  
Citric acid Carl Roth GmbH, Karlsruhe, Germany  
Coomassie Brilliant Blue-R250  Carl Roth GmbH, Karlsruhe, Germany  
Cupric sulfate penta-hydrate Sigma Aldrich, St. Louis, USA 
Dichloromethane (DCM) Sigma Aldrich, St. Louis, USA 
Diethyl ether Sigma Aldrich, St. Louis, USA 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, St. Louis, USA  
Dimethylformamide (DMF) Carl Roth GmbH und Co KG, Karlsruhe 
Dithiothreitol (DTT) Carl Roth GmbH, Karlsruhe, Germany  
Disodium hydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany  
Ethanol  Carl Roth GmbH, Karlsruhe, Germany  
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Ethidium bromide  Carl Roth GmbH, Karlsruhe, Germany  
Ethylenediaminetetraacetic acid (EDTA)  AppliChem GmbH, Darmstadt, Germany  
Fetal bovine serum Sigma-Aldrich, St. Louis, USA  
Fluorescein isothiocyanate Sigma-Aldrich, St. Louis, USA 
Fmoc-L-Lys(Boc)-Wang Resin IRIS Biotech GmbH, Marktredwitz 
Fmoc-Lys(Dnp)-OH Merck Millipore, Darmstadt, Germany 
Fmoc protected amino acids IRIS Biotech GmbH, Marktredwitz 
Galactose  Sigma-Aldrich, St. Louis, USA  
Gel loading dye (6x)  New England Biolabs (NEB), Beverly, USA  
Glucose  Carl Roth GmbH, Karlsruhe, Germany  
Glycerin  Carl Roth GmbH, Karlsruhe, Germany  
Glycine Carl Roth GmbH, Karlsruhe, Germany 
Glycerol  Carl Roth GmbH, Karlsruhe, Germany  
Hydrochloric acid (HCl)  Carl Roth GmbH, Karlsruhe, Germany  
Imidazole  Carl Roth GmbH, Karlsruhe, Germany  
Isopropanol  Carl Roth GmbH, Karlsruhe, Germany  
Isopropyl β-D-1 thiogalactopyranoside (IPTG)  Carl Roth GmbH, Karlsruhe, Germany  
Lithium acetate  Carl Roth GmbH, Karlsruhe, Germany  
L-Glutamine  Sigma Aldrich, St. Louis, USA  
Magnesium chloride  Carl Roth GmbH, Karlsruhe, Germany  
Meliseptol B. Braun Melsungen AG, Melsungen 
Methanol  Carl Roth GmbH, Karlsruhe, Germany  
Nickel chloride  Merck KGaA, Darmstadt, Germany  
Nitro blue tetrazolium chloride (NBT) Sigma Aldrich, St. Louis, USA 
Paraffin oil  Carl Roth GmbH, Karlsruhe, Germany  
Piperazine-N,N′-bis(2-ethanesulfonic acid) 
(PIPES) 
Carl Roth GmbH, Karlsruhe, Germany 
Penicillin/Streptomycin (100x)  Life Technologies, Carlsbad, USA 
Peptone/Tryptone  Carl Roth GmbH, Karlsruhe, Germany  
Polyethylene glycol 8000  Carl Roth GmbH, Karlsruhe, Germany  
Polyethylenimine, 25 kDa, linear (PEI) Polysciences, Eppelheim, Germany 
Potassium chloride  Carl Roth GmbH, Karlsruhe, Germany  
Potassium dihydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany  
Potassium hydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany  
Potassium hydroxide  Carl Roth GmbH, Karlsruhe, Germany  
Sucrose  Carl Roth GmbH, Karlsruhe, Germany  
Sodium bicarbonate Sigma Aldrich, St. Louis, USA 
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Sodium bicinchoninate  MP Biomedicals, Santa Ana, USA 
Sodium carbonate Sigma Aldrich, St. Louis, USA 
Sodium chloride  Carl Roth GmbH, Karlsruhe, Germany  
Sodium dihydrogen phosphate di-hydrate  Carl Roth GmbH, Karlsruhe, Germany  
Sodium dodecyl sulfate (SDS) Carl Roth GmbH, Karlsruhe, Germany  
Sodium hydroxide Carl Roth GmbH, Karlsruhe, Germany  
Sodium tartrate Sigma Aldrich, St. Louis, USA 
Sorbitol  Carl Roth GmbH, Karlsruhe, Germany  
Sulfo-NHS-LC-Biotin  Thermo Fisher Scientific, Geel, Belgium  
SYPRO Orange Sigma Aldrich, St. Louis, USA  
Tetramethylethylenediamine (TEMED) Merck KGaA, Darmstadt, Germany  
Triethylsilane Sigma Aldrich, St. Louis, USA 
Trifluoroacetic acid (TFA) Carl Roth GmbH und Co KG, Karlsruhe 
Tris(hydroxymethyl)aminomethan (Tris) Carl Roth GmbH, Karlsruhe, Germany  
Trisodium citrate Carl Roth GmbH, Karlsruhe, Germany 
Triton X-100  Carl Roth GmbH, Karlsruhe, Germany  
Tri-sodium citrate  Carl Roth GmbH, Karlsruhe, Germany  
Trypan Blue Solution, 0.4 % Life Technologies, Carlsbad, USA 
Tryptone Becton Dickinson GmbH, Heidelberg, 
Germany 
Tryptone/Peptone Carl Roth GmbH, Karlsruhe, Germany 
TWEEN-20  Carl Roth GmbH, Karlsruhe, Germany  
Yeast extract  Carl Roth GmbH, Karlsruhe, Germany  
Yeast Nitrogen Base  Becton Dickinson GmbH, Heidelberg, 
Germany  
3.7. Solutions and Buffers 
AP-Buffer Tris 100 mM, NaCl 100 mM, MgCl2 50 mM 
(pH 9) 
APS-stock  10 % (w/v)  
BCA-stock 1 Sodium bicinchoninate (BCA) 10 g/l, 
sodium carbonate 20 g/l, sodium tartrate 
1.6 g/l, NaOH 4 g/l, and sodium 
bicarbonate 9.5 g/l, pH 11.25, adjusted 
with NaOH 
BCA-stock 2 Cupric sulfate penta-hydrate 40 g/l 
BCIP-stock 50 g/l in 70 % DMF 
dNTP Mix Adenine 2.5 mM, Cytosine 2.5 mM, 
Guanine 2.5 mM, Thymine 2.5 mM 
Ethidiumbromide-stock 1 g/l 
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IMAC EDTA Solution EDTA 100 mM 
IMAC Elution Buffer Imidazol 1 M in Protease Buffer (pH 8) 
IMAC Nickel chloride solution Nickel chloride 100 mM 
IPTG-stock IPTG 1 M 
LiAc/DTT buffer  Lithium acetate 100 mM, Dithiothreitol 
10 mM 
NBT-stock 75 g/l in 70 % DMF 
PAGE Buffer A (4x) Tris/HCl 3 M (pH 8.85), SDS 4 g/l  
PAGE Buffer B(4x) Tris/HCl 0.5 M (pH 6.8), SDS 4 g/l  
PAGE Destaining Solution  Acetic acid 10 % (v/v), Isopropanol 25 % 
(v/v) 
PAGE Running Buffer (5x) Tris 50 mM, Glycin 190 mM, SDS 1 g/l 
PAGE Staining Solution Acetic acid 10 % (v/v), methanol 40 % 
(v/v), Coomassie brilliant blue R250 0.25% 
(w/v) 
PEI-stock Polyethylenimine 1 g/l, pH 7.5 adjusted 
with HCl 
Phosphate Buffered Saline (PBS) NaCl 8.1 g/l, KCl 0.75 g/l, Na2HPO4 1.13 
g/l and KH2PO4 0.27 g/l, (pH 7.4) 
PBST PBS, Tween-20 0.05 % (v/v) 
Periplasm Prep Buffer Sucrose 0.5 M, Tris/HCl 0.1 M, EDTA 1 M 
Protease Buffer Tris 100 mM, NaCl 150 mM (pH 8) 
Protein A Elution Buffer (pH 2.2) Glycine 0.1 M (pH 2.2) 
Protein A Neutralization Buffer (pH 9.0) Tris/HCl 1 M (pH 9.0) 
Protein A Running Buffer Sodium dihydrogen phosphate dihydrate 
1.08 g/l, Disodium hydrogen phosphate 
1.72 g/l (pH 7.0)  
Protein Loading Buffer (5x) Tris/HCl 0.25 M (pH 8), SDS (7.5 % (w/v), 
Glycerin 25 % (w/v), bromphenol blue 0.25 
mg/ml, 2-mercaptoethanol 12.5 % (w/v) 
TAE Buffer (Agarosegelectrophoresis) Tris 2 M, acetic acid 1M, EDTA 0.1 M 
Taq Buffer (10x) Tris 100 mM, KCl 500 mM, MgCl2 25 mM, 
Triton X-100 1 % (v/v) (pH 8.8) 
TEV-Protease Buffer (10x) Tris 500 mM, NaCl 1.5 M, (pH 7.5) 
Trypan blue solution  Trypan blue 4 % (w/v)  
Western blot Transfer Buffer Tris 25 mM, glycine 192 mM, methanol 
20 % (v/v) 
Yeast electroporation buffer Sorbitol 1 M, calcium chloride 1 mM  
Yeast freezing solution  Glycerol 2 % (v/v), yeast nitrogen base 
0.67 % (w/v)  
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Yeast Lysis Buffer Sorbitol 1 M, PIPES 10 mM (pH 6.5) 
 
All buffers and solutions were solved in di-distilled H2O. Buffers and solutions were autoclaved or 
sterile filtered. 
3.8. Laboratory Materials and Kits 
Amicon Ultra-15, miscellaneous Merck Millipore, Darmstadt, Germany 
Centrifuge tubes (50 ml) with screw caps  Carl Roth GmbH, Karlsruhe, Germany 
Corning cell culture flasks (25 or 75 cm2) Sigma-Aldrich, St. Louis, USA 
Corning Erlenmeyer cell culture flasks Sigma-Aldrich, St. Louis, USA 
Electroporation cuvettes  Bio-Rad, München, Germany 
Filtropure filter devices  Sarstedt, Nümbrecht, Germany  
Glassware Schott AG, Mainz, Germany 
Glass-beads (500 µm) Carl Roth GmbH, Karlsruhe, Germany 
HiLoad Superdex 200 pg 16/60, SEC column GE Healthcare, Little Chalfont, UK 
HiLoad Superdex 75 pg 16/60, SEC column GE Healthcare, Little Chalfont, UK 
HisTrap HP, 1 ml column GE Healthcare, Little Chalfont, UK 
HiTrap Protein A HP, 1 ml column GE Healthcare, Little Chalfont, UK 
Nitrocellulose membrane Carl Roth GmbH, Karlsruhe, Germany 
Nunc MaxiSorp ELISA plates eBioscience, San Diego, USA 
Microscope slides  Carl Roth GmbH, Karlsruhe, Germany 
Parafilm®  Laboratory Film American National Can., 
Chicago, USA 
PD-10 Desalting Columns GE Healthcare, Little Chalfont, UK 
Petri dishes, miscellaneous Sarstedt, Nümbrecht, Germany 
Pierce Polyacrylamide Spin Desalting Columns Thermo Fisher Scientific, Waltham, USA 
Pipet tips, miscellaneous Sarstedt, Nümbrecht, Germany 
Reaction tubes, miscellaneous Sarstedt, Nümbrecht, Germany 
RP-HPLC columns, miscellaneous Phenomenex Aschaffenburg, Germany 
Seals AirOtop  BioSilta Oy, Oulu, Finnland 
 Spherotech Inc, Lake Forest, USA  
Superdex 200 10/300 GL, SEC column  GE Healthcare, Little Chalfont, UK 
Syringes, miscellaneous B. Braun Melsungen AG, Melsungen 
Ultra-Yield flask, miscellaneous BioSilta Oy, Oulu, Finnland 
Whatman® chromatography paper Carl Roth GmbH, Karlsruhe, Germany 
Wizard® SV Gel and PCR Clean-Up System Promega, Fitchburg, USA 
Wizard® Plus SV Midipreps DNA Purification 
System  
Promega, Fitchburg, USA 
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Wizard® Plus SV Minipreps DNA Purification 
System 
Promega, Fitchburg, USA 
Zellu Trans dialysis membranes, miscellaneous Carl Roth GmbH, Karlsruhe, Germany  
Further materials comprised common laboratory equipment. 
3.9. Equipment 
Äkta Basic UV900 P900 Frac 900, Unicorn 3.1 
software 
GE Healthcare, Little Chalfont, UK 
Äkta Purifier UPC-900 P900 Frac-920, 
Unicorn 5 software 
GE Healthcare, Little Chalfont, UK 
B 5061 EC/CO2 incubator Heraeus, Hanau, Germany 
BioPhotometer  Eppendorf, Hamburg, Germany 
Bio-Rad 96CFX Connect qPCR detection system Bio-Rad Laboratories, Hercules, USA 
BioSpec-nano Micro-volume UV-Vis 
Spectrophotometer 
Shimadzu, Kyoto, Japan 
BIOWIZARD SilverLine BlueSeries Kojair, Vilppula, Finland 
Cell Disrupter Constant Systems Ltd, Daventry, UK 
Centrifuge 6K15 Sigma-Aldrich, St. Louis, USA 
Centrifuge Eppendorf 5415 R Eppendorf, Hamburg, Germany 
Centrifuge Heraeus Megafuge 1.0 Heraeus Holding GmbH, Hanau, Germany 
Fluorescence Activated Cell Sorter (FACS), 
MoFlo® Cytometer with Cyclone sorting unit, 
Summit® v4.3 Software package  
Dako Cytomation, Fort Collins, USA  
Gel documentation system, Gel Jet Imager  INTAS Science Imaging Instruments GmbH, 
Göttingen  
Gene Pulser Xcell und pulse controller Bio-Rad Laboratories, Hercules, USA 
Incubator CertomatR BS-1  Sartorius AG, Göttingen, Germany 
MCO-19AICUV CO2 incubator Panasonic, Kadoma, Japan 
Microscope Axioskop  Carl Zeiss Microscopy GmbH, Jena, 
Germany  
Operating Manual Freeze Dryer ALPHA 2-4 
LSC 
Martin Christ GmbH, Osterode am Harz, 
Germany 
PCR Cycler Eppendorf Mastercycler Eppendorf, Hamburg, Germany 
Peptide synthesizer CEM Liberty CEM GmbH, Kamp-Lintfort, Germany 
Plate reader  Tecan, Männedorf, Switzerland 
Plate reader Infinite M1000 Tecan, Männedorf, Switzerland 
Puranity PU 20 Basic Water purification system  VWR, Radnor, USA 
Shimadzu LCMS-2020 with Phenomenex 
Jupiter 5µ C4 LC column 
Shimadzu, Kyoto, Japan 
Varian LC920 System with Phenomenex Varian Medical Systems GmbH, Darmstadt, 
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Synergi 4μ Hydro-RP Germany 
Varian LC 940 System with Phenomenex Luna 
C18 column 
Varian Medical Systems GmbH, Darmstadt, 
Germany 
Wisd WiseShake SHO-2D Witeg, Wertheim, Germany 
Further instruments comprised common laboratory equipment. 
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4. Methods 
4.1. Expression, Purification and Characterization of HTRA1 Variants 
4.1.1. Cloning of HTRA1 Variants 
HTRA1 catalytic domain was provided by Prof. M. Ehrmann in expression vector pET21d31. Human 
full-length HTRA1 clone was supplied by Imagenes (Berlin). Catalytic and PDZ domain (HTRA1 
cd+PDZ) were amplified using primers hHtrA1_cd_NcoI_up and hHTRA1_PDZ_XhoI_lo. PCR protocol 
was as followed: 95 °C for 5 min, 35 cycles of 30 s at 95 °C, 30 s at 52 °C and 60 s at 72 °C, followed 
by 72 °C for 5 min. 
PCR product was purified using Wizard® SV Gel and PCR Clean-Up System (Promega) followed by 
digestion with 2 units of NcoI and XhoI for 1 h at 37 °C in suggested buffer. After heat inactivation for 
10 min at 70 °C the PCR product was ligated with T4 DNA Ligase into Wizard® SV Gel and PCR Clean-
Up System (Promega) gel purified vector pET21d HTRA1 after digestion with NcoI and XhoI. 
E. coli cells were grown to OD600 of 0.6 and prepared for electroporation by washing 3-times with ice-
cold distilled water. 5 µl of ligated vector was mixed with electro-competent E. coli DH5α in an 
electroporation cuvette on ice. Transformation protocol was the preset for bacteria on the Gene Pulser 
Xcell (Bio-Rad). Cells were incubated immediately after pulsing in 1 ml dYT media for 1 h at 37 °C. 
Afterwards cells were plated out on LB-Agar containing ampicillin (100 mg/l) and incubated over 
night at 37 °C. 
Single clones were verified by colony PCR using insert specific primer and T7_Terminator_seq_lo. 
Positive clones were incubated in dYT media containing ampicillin (100 mg/l) over night at 37° C and 
180 rpm. Plasmids were isolated using Wizard® Plus SV Minipreps DNA Purification System 
(Promega). Sequences were analyzed by Sanger sequencing (seqlab, Göttingen) using primer 
T7_Promoter_seq_up or T7_Terminator_seq_lo. 
Mutants HTRA1 cd-mono2 and HTRA1 cd-mono3 were generated using pET21d-HTRA1 cd+PDZ as 
template. First the mutations for HTRA1 cd-mono2 were introduced by PCR using primers 
hHTRA1_cd_Y169A_F171A_NcoI_up and hHTRA1_cd_XhoI_lo. PCR protocol was as followed: 95 °C 
for 5 min, 35 cycles of 30 s at 95 °C, 30 s at 52 °C and 60 s at 72 °C, followed by 72 °C for 5 min. 
Finally the mutant was cloned into pET21d as described above and verified by sequencing. 
The additional mutation for HTRA1 cd-mono3 was introduced by amplification of HTRA1 cd-mono2 in 
two parts using primer sets hHTRA1_cd_Y169A_F171A_NcoI_up / hHTRA1_cd_F278A_SOE_lo and 
hHTRA1_cd_F278A_SOE_up / hHTRA1_cd_XhoI_lo. PCR products were gel purified with Wizard® SV 
Gel and PCR Clean-Up System (Promega). Then PCR products were mated in a PCR without primers 
while 1 µl of each product of previous PCR was inserted into reaction. After 10 cycles primers 
hHTRA1_cd_Y169A_F171A_NcoI_up and hHTRA1_cd_XhoI_lo were added. Protocol for first and 
second PCR was as followed: 95 °C for 5 min, 45 cycles of 30 s at 95 °C, 30 s at 52 °C and 60 s at 
72 °C, followed by 72 °C for 5 min. Finally the mutant was cloned into pET21d and verified by 
sequencing as described above. 
4.1.2. Expression of HTRA1 Variants 
E. coli cells were grown to OD600 of 0.6 and prepared for electroporation by washing 3-times with ice-
cold distilled water. 1 µl of sequence verified pET21d of each HTRA1 variant was mixed with electro-
competent E. coli BL21 in an electroporation cuvette on ice. Transformation protocol was the preset for 
bacteria on the Gene Pulser Xcell (Bio-Rad). Cells were incubated immediately after pulsing in 1 ml 
dYT media for 1 h at 37° C. Afterwards cells were plated out on LB-Agar containing ampicillin 
(100 mg/l) and incubated over night at 37° C. 
A single clone was incubated in 50 ml dYT media containing ampicillin (100 mg/l) over night at 37° C 
and 180 rpm. 10 ml of culture were used for starting production culture in 1 L LB media containing 
ampicillin (100 mg/l) at 180 rpm at 37° C. Optical density at 600 nm (OD600) was measured until 
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OD600 between 0.8-1. Then temperature was decreased to 16 °C and 1 mM IPTG was added to induce 
protein expression for 24 h. 
4.1.3. Purification of HTRA1 Variants and Determination of Oligomeric States 
Cells were harvested using a centrifuge (Sigma) for 20 min at 16000 g and 4 °C. After decanting the 
supernatant cells were resuspended on ice with 30-40 ml Protease Buffer and lysed using a Multi Shot 
cell disruptor (Constant Systems Ltd). Lysis was done by 5 repeats with 35 kpsi. Suspension was 
centrifuged at 19000 g at 4°C for 20 min. Supernatant containing soluble protein was filtered using 
0.45 µm syringe filter (Sarstedt) and applied on an equilibrated HisTrap column (GE Healthcare) using 
Äkta FPLC-System (GE Healthcare). Bound protease was washed with Protease Buffer and eluted using 
a linear gradient by addition of IMAC Elution Buffer. Eluted protein was collected using automated 
fractionator Frac900 (GE Healthcare). Fractions containing HTRA1 variant were concentrated by ultra-
filtration using Amicon Ultra-15 10000 (Merck Millipore). 
Evaluation and separation of different oligomeric states was done using a HiLoad Superdex 200 
16/60 pg (GE-Healthcare) size-exclusion chromatography column on an Äkta FPLC-System 
(GE-Healthcare). Different oligomeric states were collected separately and concentrated by ultra-
filtration using Amicon Ultra-15 10000 (Merck Millipore). 
Recombinant expressed proteins were analyzed by SDS-PAGE and Western blot. Pooled fractions were 
applied on SDS gel (15 % v/v) after incubation with 5x Protein Loading Buffer for 10 min at 95 °C. 
After electrophoresis gel was either stained with PAGE Staining Solution or electrically blotted on a 
nitro-cellulose membrane by usage of Western Blot Transfer Buffer. Expressed proteins were detected 
by monoclonal anti-penta-His antibody (QIAGEN), followed by anti-mouse alkaline phosphatase 
conjugate. Antibodies were solved in 1:10000 dilution in PBS milk powder solution (1 % w/v) and 
incubated for 1 h each. After first and secondary antibody membrane was washed 10-times with PBST. 
Membrane was washed with water before addition of 30 ml AP-Buffer, 12.5 μl NBT and 70 μl BCIP 
solution for developing the Western blot. Reaction was stopped by washing with water.
After concentration determination by photometric and BCA-Assay (4.1.5), HTRA1 variants were 
aliquoted and stored at -80°C. 
Stability of different oligomeric states that were collected separately was analyzed using analytical gel 
filtration column Superdex 200 10/300 GL (GE Healthcare) in combination with Äkta FPLC-System 
(GE Healthcare). 
4.1.4. Melting Curve Analysis of HTRA1 Variants and Isolated Binding Molecules 
For determination of thermal stability of expressed proteins the melting temperatures were measured. 
Purified proteins were diluted with Protease Buffer to 1 mg/ml if being concentrated above. Samples 
were mixed with SYPRO Orange (Sigma-Aldrich) to a final dye concentration of 1:1000. For each 
duplicate two times 25 µl were used for analyses in a real-time PCR Cycler CFX Connect (Bio-Rad). 
Gradient was from 30° C to 95° C with a ramp rate of 0.5 °C/min. Data was evaluated using CFX 
Manager software (Bio-Rad). 
4.1.5. Protein Concentration of HTRA1 Variants and Isolated Binding Molecules by BCA-Assay 
and Optical Density 
For determination of protein concentration by Bicinchoninic Acid (BCA) Assay 100 volumes of BCA 
Solution A were mixed with 2 volumes of BCA Solution B to obtain a working solution. Then 1 ml of 
working solution was mixed with 20 µl sample and incubated for 30 min at 60° C. After cooling sample 
to room temperature 200 µl were used for measurement of absorption at 562 nm using multi-plate 
reader Infinite M1000 PRO (Tecan). Protein concentration was determined according to a standard 
curve of serial dilutions of Bovine Serum Albumin. When concentration of sample was above highest 
concentration of standard curve the sample was diluted with Protease-Buffer. 
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4.1.6. Labeling of HTRA1 Variants 
HTRA1 variants were labeled with fluorescein or biotin for isolation of binding molecules via yeast 
surface display and characterization of isolated clones. Buffer of GFC purified protease variants was 
exchanged using 0.5 ml 7K ZebaTM Spin Desalting Columns (Thermo Fisher) or PD-10 Desalting 
Columns (GE Healthcare). 
For fluorescein labeling by fluorescein isothiocyanate (FITC)302 the protease was eluted in 100 mM 
sodium carbonate buffer (pH 9.0) and adjusted to a concentration of 2 mg/ml. FITC was solved in 
DMSO at a concentration of 2 mg/ml. 20 µl of FITC solution were slowly added to each milliliter of 
protein solution. Reaction was carried out for 8 h at 4 °C in the dark. Afterwards protease was purified 
using 0.5 ml 7K ZebaTM Spin Desalting Columns (Thermo Fisher) or PD-10 Desalting Columns 
(GE Healthcare). Buffer was exchanged against Protease Buffer. 
For biotin labeling by NHC-LC-Biotin303 the protease was eluted in 100 mM sodium phosphate, 
150 mM NaCl buffer (pH 7.5) and adjusted to a concentration of 2 mg/ml. NHC-LC-Biotin was solved 
in DMF to a concentration of 40 mg/ml. 5 µl of NHS-LC Biotin solution were slowly added to each 
milliliter of protein solution. Reaction was carried out for overnight at 4 °C. Afterwards protease was 
purified using 0.5 ml 7K ZebaTM Spin Desalting Columns (Thermo Fisher) or PD-10 Desalting Columns 
(GE Healthcare). Buffer was exchanged against Protease Buffer. 
Labeled protease variants were aliquoted and stored at -80 °C. 
4.1.7. Activity Measurements of HTRA1 Variants and Isolated Binding Molecules 
For determining functionality of expressed protease variants and the effect of binding molecules the 
proteolytic activity of HTRA1 variants was measured using substrate H2Opt-K (Mca-
IRRVSYSF(Dnp)KKK). H2Opt-K is based on H2Opt53 and was chemically synthesized by automated 
solid-phase peptide synthesis according to Merrifield synthesis strategy304 using a Liberty Synthesizer 
(CEM). Coupling of amino carboxymethoxy-methylcoumarin was according to the protocol of Knight 
et al305. Only difference was using a lysine pre-loaded resin for addition of an additional carboxyl
terminal lysine. After cleavage from resin peptide substrate was purified by reversed-phase HPLC 
(Varian) using a C18 column (Phenomex) followed by lyophilization. Synthesized substrate was 
verified by LC ESI-MS (Shimadzu). 
Activity measurement was carried out using a multimode microplate reader Infinite M1000 PRO 
(Tecan). Substrate was solved in Protease Buffer and mixed with HTRA1 variants to described 
concentrations using a black 384-well microtiter plate. Final volume of 40 µl was adjusted with 
Protease Buffer. Reaction was started by addition of substrate followed by measurement immediately 
at 18-20 °C. Wavelength for measurement was 328 nm for excitation and 393 nm for emission. For 
measuring the influence of isolated molecules on HTRA1 activity, protease was incubated with each 
molecule 15 min at RT previous to addition of substrate. 
4.2. Library Screening  
4.2.1. Serum Titer 
For evaluation of the immunization of Llama, it was checked if antibodies against HTRA1 were 
produced. Therefore serum before and after immunization were analyzed for their ability to bind 
HTRA1 variants. Thus 100 ng of HTRA1 cd and 1 mg of BSA were immobilized in separate wells of a 
maxi-sorb microtiter plate (Nunc) over night at 4 °C. Then wells were blocked with 2 % milk powder 
for 1 h and washed 3-times with an automated plate washer (Tecan). Afterwards wells were incubated 
for 1 h with serial dilutions of sera containing 1 % milk powder. Then wells were washed 10-times 
with PBS and incubated for 1 h with Protein A-HRP conjugate in 1:10000 dilution containing 1 % milk 
powder. Then wells were washed 10-times with PBS followed by addition of 100 µl TMB One solution 
(Promega). Reaction was stopped with 100 µl HCl (0.1 %) and absorption was measured using a plate 
reader (Tecan). 
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4.2.2. Screening of McoTI-II, VHH and vNAR Libraries as well as vNAR Sub-Libraries 
For induction of library presentation on the yeast cell surface the cells of the different libraries were 
incubated overnight with 180 rpm at 30 °C in SD-CAA media and then transferred into SG-CAA media 
with 180 rpm at 20 °C for 1-2 days. 
For isolation of antigen-specific binding molecules from different libraries the cells were double labeled 
with biotinylated or fluorescein conjugated antigen HTRA1 and additionally for myc epitope to check 
surface presentation of full-length construct. Biotin and fluorescein conjugation to HTRA1 variants is 
described in section 4.1.6. For the first rounds of enrichment the quantity of cells of library or sub-
library size were labeled with monoclonal anti-myc antibody (in-house), washed with 1 ml ice-cold 
Protease Buffer and then labeled with 1:10 dilution of secondary anti-mouse antibody (Sigma-Aldrich) 
that was biotinylated or conjugated with fluorescein, respectively. After labeling with biotinylated 
secondary antibody cells were washed with 1 ml ice-cold Protease Buffer and labeled with streptavidin-
allophycocyanin conjugate (eBioscience) in 1:10 dilution. After labeling of myc epitope cells were 
washed with 1 ml ice-cold Protease Buffer and labeled with different concentrations of biotinylated or 
fluorescein conjugated HTRA1 variant. After labeling with biotinylated HTRA1 variant cells were 
washed with 1 ml ice-cold Protease Buffer and labeled with streptavidin-allophycocyanin conjugate 
(eBioscience) in 1:10 dilution. Finally cells were washed with 1 ml ice-cold Protease Buffer. All 
incubation steps were incubated for 10 min on ice. For Successive rounds of screening lower quantity 
of cells were labeled, but at least 100-fold excess of cells than isolated in the previous round. 
Labeled cells were kept on ice until screening by using a fluorescence activated cell sorter (FACS) 
(DakoCytomation) that was controlled by Summit software version v4.3. After sorting the efficiency 
was determined by dilution plating. Cells were incubated in SD-CAA medium with 180 rpm at 30 °C 
and used for successive rounds. 
4.2.3. Single Clone Analysis of Isolated Clones 
For analyses of single clones for antigen binding the single clones from dilution plating were incubated 
and induced for surface presentation in SD-CAA media and SG-CAA media, respectively. Single clones 
were labeled as described for library screening (4.2.2) whereby about 106 cells were labeled. Analyses 
were carried out using fluorescence activated cell sorter (DakoCytomation) that was controlled by 
Summit software version v4.3. S. cerevisiae single clones binding to antigen were lysed in 20 µl Yeast 
Lysis Buffer with a final concentration of 1 mg/ml yeast lytic enzyme (MP-Biomedicals) at 37 °C for 
30 min. Then 5 µl were added to PCR using primers pCT_Seq_up and pCT_Seq_lo. PCR protocol was 
as followed: 95 °C for 5 min, 35 cycles of 30 s at 95 °C, 30 s at 52 °C and 60 s at 72 °C, followed by 
72 °C for 5 min. PCR product was verified by gel electrophoresis and cleaned using Wizard® SV Gel 
and PCR Clean-Up System (Promega). Sequences were analyzed by Sanger sequencing (seqlab, 
Göttingen) using primer pCT_Seq_up or pCT_Seq_lo. 
4.2.4. Binding of Single Clones for Different HTRA1 Variants 
For evaluation if isolated McoTI-II and vNAR derived molecules also bind HTRA1 variants that were 
not used during screening the yeast single clones were labeled with these variants on the cell surface. 
Here only single labeling by antigen was performed after previous analysis of myc presentation, which 
was labeled as described in section 4.2.2. For HTRA1 labeling around 106 cells per clone were labeled 
with 1 µM of each variant, followed by washing with 1 ml ice-cold Protease Buffer. Then cells were 
labeled with Alexa488 conjugated anti-Penta His antibody (QIAGEN) that was 1:10 diluted, followed 
by washing with 1 ml ice-cold Protease Buffer. All incubation steps were incubated for 10 min on ice. 
Analyses were carried out using fluorescence activated cell sorter (FACS) (DakoCytomation) that was 
controlled by Summit software version v4.3. 
4.2.5. Affinity Titration of Isolated VHH, vNAR and McoTI-II Derived Molecules 
Affinities towards antigens of isolated molecules were determined by affinity titration using yeast 
single clones as reported by Chao et al. 111, 306. Only yeast cells expressing sufficient amounts of myc 
epitope were included into calculation of equilibrium dissociation constant (KD) by gating with 
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evaluation software Summit v4.3. Thus, around 107 cells were labeled with anti-myc antibody, 
secondary anti-mouse antibody and streptavidin-allophycocyanin conjugate as described in section 
4.2.2. Then cells were divided on 106 cells each and incubated with decreasing concentrations of 
fluorescein conjugated HTRA1 for 15 min on ice. Finally cells were washed with 100 µl ice-cold 
Protease Buffer directly before analyses. Analyses were carried out using fluorescence activated cell 
sorter (FACS) (DakoCytomation) and mean fluorescence of fluorescein signal (FL1) was used in 
equation: y = ymin+(ymax*x/(x+KD)) for determination of KD. 
4.2.6. Affinity Maturation of Isolated vNAR Molecules (HV2, CDR1, HV2+CDR1) 
Affinity maturation of initial binding molecules of HTRA1 was performed by isolating plasmids of 
populations after promising rounds of enrichment by FACS. Cells were grown in SD-CAA media for 
1 day at 180 rpm at 30 °C. After incubation 1 ml yeast suspension was centrifuged and resuspended in 
250 µl Cell Resuspension Buffer from Wizard® Plus SV Minipreps DNA Purification System (Promega). 
Glass beads were added and cell suspension was vortexed for 5 min. Then liquid was transferred into a 
new reaction tube and plasmids were isolated according to the kits manual. 
CDR1 matured library was constructed using isolated plasmids as template with primers CDR1rand_up 
and GR_lo. This was followed by two sequential PCRs using primers FR1_up / GR_lo for the second 
and GR_up / GR_lo for the third elongation. PCR protocol for all elongation steps was: 95 °C for 5 min, 
35 cycles of 30 s at 95 °C, 30 s at 55 °C and 40 s at 72 °C, followed by 72 °C for 5 min. Same strategy 
was applied for HV2 matured clones that were subsequently matured in CDR1. 
For HV2 maturation CDR1 and CDR3 containing regions were amplified separately using primers 
HV2_SOE_rand_up and pCT_Seq_lo as well as pCT_Seq_up and HV2_SOE_lo, respectively. PCR 
protocol was as followed: 95 °C for 5 min, 35 cycles of 30 s at 95 °C, 30 s at 55 °C and 40 s at 72 °C, 
followed by 72 °C for 5 min. PCR products were gel purified using Wizard® SV Gel and PCR Clean-up 
System (Promega). Both fragments were mated in a PCR without primers while 1 µl of each product of 
previous PCR was inserted into reaction. After 10 cycles primers pCT_Seq_up and pCT_Seq_lo were 
added for amplification of full-length sequence. PCR protocol was the same as for the first step. 
The PCR products of the three independent maturation approaches were each purified using Wizard® 
SV Gel and PCR Clean-up System (Promega).  
The cloning of the constructs was done by homologous recombination into yeast cells according to the 
protocol of Benatuil et al.110. Therefore 250 µl pCT vector with a concentration of 20 ng/µl were 
linearized by 100 U of restriction enzymes Nhe I and Bam HI (NEB) according to the manufacturers 
protocol. Yeast cells were made competent for electroporation according to the protocol of Benatuil 
et al. and mixed with 2 µg of linearized plasmid and 10 µg of PCR product. Gene Pulser Xcell (Bio-
Rad) was used for electroporation with settings 2.5 kV and 25 μF which resulted in time constants 
between 3.0 to 4.5 ms. After transformation yeast cells were incubated for 2 days at 180 rpm and 
30 °C in SD-CAA media. Cells were harvested by centrifugation and resuspended in yeast freezing 
solution for storage at -80 °C. 
Library size was determined by serial dilution plating 2 days after electroporation. 
For induction of yeast surface presentation yeast cells were incubated overnight with 180 rpm at 30 °C 
in SD-CAA media and then transferred into SG-CAA media with 180 rpm at 20 °C for 1-2 days. 
4.3. Expression, Purification and Characterization of Isolated VHH and McoTI-II Derived 
Molecules in HEK293 Cells 
4.3.1. Cloning of Isolated VHH and McoTI-II Derived Molecules as Fc Fusion Protein 
Isolated VHH and McoTI-II derived molecules binding HTRA1 were soluble expressed as amino-
terminal Fc-fusion proteins for evaluation. Plasmids of isolated clones containing VHH and McoTI-II 
derived molecules were isolated from single clones from 1 ml yeast SD-CAA culture that was grown 
over-night at 180 rpm and 30 °C. Cells were harvested by centrifugation that was followed by 
resuspension of yeast cells with 250 µl Cell Resuspension Buffer from Wizard® Plus SV Minipreps DNA 
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Purification System (Promega). Glass beads were added and cell suspension was vortexed for 5 min. 
Then liquid was transferred into a new reaction tube and plasmids were isolated according to the kits 
manual. 
Sequences were amplified from plasmids in a 3-step PCR with following protocol: 95 °C for 5 min, 
35 cycles of 30 s at 95 °C, 30 s at 52 °C and 40 s at 72 °C, followed by 72 °C for 5 min. The primers 
MASKO_rd5_VHH-K1_NheI_up, MASKO_rd5_VHH-K7_NheI_up, MASKO_rd5_VHH-K1/7_ApaI_lo, 
SloII_HTRA1_K1_NheI_up and SloII_HTRA1_K1_ApaI_lo were used for amplification and addition 
of restriction sites NheI and ApaI. PCR products were purified using Wizard® SV Gel and PCR Clean-
Up System (Promega) followed by digestion with 2 units of NheI and ApaI for 1 h at 37 °C in suggested 
buffer. The PCR product was ligated with T4 DNA Ligase into vector pExpress-Fc containing McoTI-II 
wild-type sequence307. Vector was previously digested with 2 units of each NheI and ApaI for 1 h at 
37 °C and gel purified with Wizard® SV Gel and PCR Clean-Up System (Promega). E. coli cells were 
grown to OD600 of 0.6 and prepared for electroporation by washing 3-times with ice-cold distilled 
water. 5 µl of ligated vector were mixed with electro-competent E. coli DH5α in an electroporation 
cuvette on ice. Transformation protocol was the preset for bacteria on the Gene Pulser Xcell (Bio-Rad). 
Cells were incubated immediately after pulsing in 1 ml dYT media for 1 h at 37 °C. Afterwards cells 
were plated out on LB-Agar containing ampicillin (100 mg/l) and incubated over night at 37 °C. Single 
clones were verified by colony PCR using primers pEXPR_Seq_for and MASKO_rd5_VHH-
K1/7_ApaI_lo. Positive clones were incubated in dYT media containing ampicillin (100 mg/l) over 
night at 37 °C and 180 rpm. Plasmids were isolated using Wizard® Plus SV Minipreps DNA Purification 
System (Promega). Sequences were analyzed by Sanger sequencing (seqlab, Göttingen) using primer 
pEXPR_Seq_for or pEXPR_Seq_rev. 
4.3.2. Expression of Isolated VHH and McoTI-II Derived Molecules as Fc Fusion Protein 
Mammalian HEK293 cells were cultured at 37 °C at 5 % CO2 and 100 rpm in Freestyle
TM
 293 media. 
About 106 cells/ml were grown in 25 ml media for 24 h. Transfection was done with 25 µg plasmid 
and 75 µg PEI that were diluted to a total volume of 2.5 ml with FreestyleTM 293 media followed by 
incubation for 15 min at room temperature. Then mixture was added slowly to the cells and incubated 
at 37 °C at 5 % CO2 and 100 rpm for 24 h. Afterwards 700 µl tryptone solution (20 % in Freestyle
TM
 
293 media) was added and cells were incubated for another 4 days. 
4.3.3. Purification of Isolated VHH and McoTI-II Derived Molecules as Fc Fusion Protein 
For purification of Fc fusion proteins the expression culture was centrifuged at 4500 g for 10 min at 
4 °C. Supernatant was applied on a HiTrap Protein A HP column (GE-Healthcare) using an Äkta FPLC-
System (GE-Healthcare). Column was washed with 5 volumes PBS, followed by elution with Protein A 
Elution Buffer (pH 2.2). Eluted fractions of 1 ml were collected in tubes that contain 200 µl Protein A 
Neutralization Buffer (pH 9.0). Purification process was monitored using Unicorn Software 
(GE-Healthcare) by measurement of absorption at 280 nm. Collected fractions containing Fc-fusion 
protein were pooled and dialyzed (ZelluTrans, Carl Roth GmbH, MWCO 3500) against 5 L Protease 
Buffer (pH 8.0) overnight at 8 °C. Protein purity was evaluated by SDS-PAGE (4.1.3) and quantity was 
determined by photometric measurement (4.1.5). 
4.3.4. ELISA of Fc Fusion Proteins of Isolated VHH and McoTI-II Derived Molecules 
For evaluation of binding properties of isolated VHH and McoTI-II derived molecules an ELISA was 
performed with soluble expressed Fc-fusion proteins. Thus 100 ng of HTRA1 cd, HTRA1 cd-mono3 and 
lysozyme were immobilized in separate wells of a maxi-sorb microtiter plate (Nunc) over night at 4°C. 
Then wells were blocked with 2 % milk powder for 1 h and washed 3-times with Protease Buffer using 
a plate washer (Tecan). Afterwards wells were incubated for 1°h with serial dilutions of purified Fc-
fusion proteins containing 1 % milk powder. In the next step wells were washed 10-times with 
Protease Buffer and incubated for 1 h with Protein A-HRP conjugate (Sigma-Aldrich) in 1:10000 
dilution containing 1 % milk powder. Then wells were washed 10-times with Protease Buffer. After 
washing 100 µl TMB One solution (Promega) was added to each well. Finally reaction was stopped 
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using 100 µl HCl (0.1 %) and absorption was measured using a plate reader (Tecan). All proteins and 
blocking solution were solved and/or diluted in Protease Buffer. 
4.4. Expression, Purification and Characterization of Isolated vNAR Molecules 
4.4.1. Cloning of Isolated vNAR Molecules as MBP Fusion Protein 
For evaluation of isolated vNAR molecules they were soluble expressed as Maltose-binding Protein 
(MBP) fusion proteins. Plasmids containing isolated vNAR molecules were isolated from single clones 
from 1 ml yeast SD-CAA culture that was grown over-night at 180 rpm and 30 °C. Cells were harvested 
by centrifugation that was followed resuspension of yeast cells with 250 µl Cell Resuspension Buffer 
from Wizard® Plus SV Minipreps DNA Purification System (Promega). Glass beads were added and cell 
suspension was vortexed for 5 min. Then liquid was transferred into a new reaction tube and plasmids 
were isolated according to the kits manual. 
Sequences were amplified from plasmids in a 3-step PCR with following protocol: 95 °C for 5 min, 
35 cycles of 30 s at 95 °C, 30 s at 52 °C and 40 s at 72 °C, followed by 72 °C for 5 min. The primers 
vNAR_Acc65I_TEV_up and vNAR_His_Stop_XbaI_lo were used for amplification and addition of 
restriction sites Acc65I and XbaI. PCR products were purified using Wizard® SV Gel and PCR Clean-Up 
System (Promega) followed by digestion with 2 units of Acc65I and XbaI for 1 h at 37 °C in suggested 
buffer. The PCR product was ligated with T4 DNA Ligase into Wizard® SV Gel and PCR Clean-Up 
System (Promega) gel purified vector pMX-EETI that was previously digested with Acc65I and XbaI. 
E. coli cells were grown to OD600 of 0.6 and prepared for electroporation by washing 3-times with ice-
cold distilled water. 5 µl ligated vector were mixed with electro-competent E. coli DH5α in an 
electroporation cuvette on ice. Transformation protocol was the preset for bacteria on the Gene Pulser 
Xcell (Bio-Rad). Cells were incubated immediately after pulsing in 1 ml dYT media for 1 h at 37 °C. 
Afterwards the cells were plated out on LB-Agar containing chloramphenicol (25 mg/l) and incubated 
over night at 37 °C. Single clones were verified by colony PCR using primers vNAR_Acc65I_TEV_up 
and pMX_seq_lo. Positive clones were incubated in dYT media containing chloramphenicol (25 mg/l) 
over night at 37 °C and 180 rpm. Plasmids were isolated using Wizard® Plus SV Minipreps DNA 
Purification System (Promega). Sequences were analyzed by Sanger sequencing (seqlab, Göttingen) 
using primer pMX_seq_up or pMX_seq_lo. 
4.4.2. Expression of Isolated vNAR Molecules as MBP Fusion Protein 
E. coli BMH 71-18 cells were grown to OD600 of 0.6 and prepared for electroporation by washing 
3-times with ice-cold distilled water. Then 1 µl plasmid was mixed with electro-competent E. coli 
BMH 71-18 in an electroporation cuvette on ice. Transformation protocol was the preset for bacteria 
on the Gene Pulser Xcell (Bio-Rad). Cells were incubated immediately after pulsing in 1 ml dYT media 
for 1 h at 37 °C. Afterwards cells were plated out on LB-Agar containing chloramphenicol (25 mg/l) 
and incubated over night at 37 °C.  
A single clone was selected and incubated in 50 ml dYT media containing chloramphenicol (25 mg/l) 
overnight at 37 °C and 180 rpm. Then 1 L LB-media containing chloramphenicol (25 mg/l) was 
inoculated with 20 ml of overnight culture and grown until OD600 of 0.8 at 37 °C at 180 rpm. At an 
OD600 about 0.8, protein expression was induced by addition of IPTG to a final concentration of 1 mM 
for 24 h at 30 °C and 180 rpm. 
4.4.3. Purification of Isolated vNAR Molecules as MBP Fusion Protein 
After expression of MBP fusion proteins the E. coli cells were harvested by centrifugation at 16000 g 
for 15 min at 4 °C. Cells were resuspended in ice-cold Periplasm Prep Buffer containing Lysozyme 
(100 mg/l). Cells were incubated on a tumbling shaker for 30 min on ice followed by centrifugation at 
19000 g for 15 min at 4 °C. Supernatant was sterile filtered before it was applied on a HisTrap column 
(GE Healthcare) using an Äkta FPLC-System (GE-Healthcare). Column was washed with 5 volumes 
PBS, followed by elution with a linear gradient of PBS/PBS 1 M imidazole. Eluted protein was 
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collected in fractions of 1 ml each. Purification process was monitored using Unicorn Software (GE-
Healthcare) by measurement of absorption at 220 nm. 
For cleavage of vNAR from MBP with tobacco etch virus protease (TEV protease) the collected 
fractions were pooled and 10-fold TEV Buffer was added as well as TEV protease in a ratio of 1:10. 
Cleavage of fusion protein was carried out overnight at 8 °C. 
For separation of both proteins the cleavage reaction was concentrated by ultra-filtration with Amicon 
Ultra-15 10000 (Merck Millipore). Then cleavage mix was applied on a gel filtration column HiLoad 
Superdex 75 pg 16/60 (GE-Healthcare) that was equilibrated with Protease Buffer. Eluted vNAR 
molecules were collected in fractions of 1 ml and pooled. Protein purity was evaluated by SDS-PAGE 
(4.1.3) and quantity was determined by photometric measurement (4.1.5). 
  
   45 
5. Results 
5.1. Expression and Purification of HTRA1 Variants 
To investigate the influence on activity of the different oligomeric states of HTRA1, variants were 
generated that lack amino acid residues important for trimerization. In contrast to oligomers, 
monomers present surfaces that are masked in the oligomeric state. Molecules that bind to that region 
might therefore stabilize the monomeric state and preclude oligomer formation. This type of molecules 
might be valuable tools for the study of HTRA1 function. Moreover, exploratory experiments revealed 
no enrichment of specific binders from VHH nanobody libraries using oligomeric HTRA1 as target, 
neither in phage display, nor in yeast display screens (results not shown). Only nonspecifically binding 
or unstable VHH molecules were obtained by screening of a phage display library of naïve VHH 
domains (results not shown). Likewise, in yeast surface display problems occurred during rounds of 
enrichment. In detail, HTRA1 oligomer particles were detectable in the cell sorter upon common side 
scatter triggering that is used for cell detection, complicating FACS screening of yeast cells (results not 
shown). Thus mainly protein particles were isolated and not cells needed for following rounds. These 
findings strongly supported the motivation to design a monomeric variant of HTRA1. 
The gene for the protease domain of HTRA1 was provided by Prof. M. Ehrmann in expression vector 
pET21d with a carboxyl-terminal His-tag31. Residues that were identified by inspection of the 3D 
structure to be involved in trimerization31 were replaced by alanine to generate a monomeric variant. 
The three hydrophobic residues that are suggested to mediate trimerization of catalytic domains are 
shown in figure 4b. For the first variant HTRA1 cd-mono2 the two amino-terminal residues tyr169 and 
phe171 were substituted by alanine using site-directed mutagenesis. The second variant HTRA1 
cd-mono3 additionally replaced phe278 by an alanine and was generated through splicing by overlap 
extension (SOE) PCR using HTRA1 cd-mono2 as template. Additionally a variant HTRA1 cd+PDZ was 
amplified from the human HTRA1 full-length clone IRATp970G0933D delivered from GenomeCube 
that additionally contains the carboxyl-terminal Post Synaptic Density, Discs Large and Zonula 
Occludentes-1 domain (PDZ) but is lacking the native amino-terminal Insulin-like Growth Factor 
Binding Protein (IGFPB) and Kazal-like Inhibitor Domain (KI). The schematic illustration in figure 13 
shows the domain arrangement of the human full-length HTRA1 and the variants generated in this 
work. 
 
Figure 13 Schematic domain arrangement of human full-length HTRA1 and its recombinant derived variants. Insulin-like 
Growth-Factor Binding Protein (green), Kazal-like Inhibitor Domain (light blue), Trypsin-like Protease Domain (blue), Post 
Synaptic Density, Discs Large and Zonula Occludentes-1 domain (red) and 6 Histidine-Tag (grey). Amino acid exchanges are 
indicated by black bars in the protease domain with position and residue above. 
All constructs were cloned into pET21d vector by NcoI and XhoI cleavage sites, verified by sequencing 
and transformed in expression host E. coli BL21. Expression was carried out for 24 h at 16 °C in Low 
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Broth (LB) media under continuous shaking at 180 rpm. After harvesting cells they were lysed using 
cell-disruptor instrumentation followed by removing cell debris through centrifugation. HTRA1 
variants were isolated from the supernatant by immobilized metal ion affinity chromatography (IMAC) 
using ÄKTA FPLC system with Hi-Trap columns. Fractions containing eluted protease were pooled, 
concentrated by ultra-filtration and further separated by preparative size-exclusion chromatography 
(SEC). SEC chromatograms for different expressed HTRA1 variants are shown in figure 14. For 
determination of size of different fractions calibration proteins were purified on SEC column. For each 
variant an oligomeric population was observed eluting with the dead volume of the used column at 
around 45 ml indicating an apparent molecular weight of approximately (MW) 500,000. A second 
elution peak was observed at 78 ml for HTRA1 cd and its mutants indicating to an apparent molecular 
weight of 75,000. A third elution peak was observed for the two mutants of HTRA1 cd at 90 ml 
indicating to an apparent molecular weight of MW 25,000. For HTRA1 cd+PDZ three elution peaks 
additionally to the first were observed at 54 ml, 67 ml and 84 ml in preparative SEC (Figure 14). 
Pooled fractions were further analyzed by SDS-polyacrylamide gel electrophoresis (PAGE). PAGE of 
standardized protein concentrations is shown in figure 17a in section 5.1.3. PAGE confirmed the 
molecular weight of the denatured monomeric protein of MW 25,000 for HTRA1 cd and both mutants, 
as well as of 37,000 for HTRA1 cd+PDZ as expected. Some fractions contain co-purified proteins from 
IMAC and fragments that most likely result from the HTRA1 proteolytic activity. Additionally it was 
confirmed by Western blot with an anti-His antibody that purified proteins of correct size are 
His-tagged molecules (results not shown). 
For the variant HTRA1 cd the detected apparent molecular weight of 75,000 corresponds to the trimer 
as well as for HTRA1 cd+PDZ the detected apparent molecular weight of 110,000. These results 
confirm the two different oligomeric states (trimer and higher oligomer) previously reported31. For the 
mutants of HTRA1 cd additionally monomeric states with apparent molecular weight of 25,000 were 
detected and isolated, but still higher oligomers and trimers are present. HTRA1 cd-mono3 shows a 
similar peak pattern compared with HTRA1 cd-mono2. Interestingly ratios of the peak-areas which 
correlate to the amount of protein are shifted from trimer to monomer by the additional mutation of 
HTRA1 cd-mono3. Through multiple SEC runs, sufficient amounts of the three different HTRA1 
cd-mono3 fraction could be collected. 
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Figure 14 Size-exclusion chromatography (SEC) of his-tagged HTRA1 variants after immobilized metal ion affinity 
chromatography (IMAC). Chromatograms of calibrator proteins, HTRA1 cd, HTRA1 cd-mono2, HTRA1 cd-mono3, HTRA1 
cd+PDZ (from top to bottom). Different HTRA1 fractions that were confirmed by SDS-PAGE are indicated by their oligomeric 
states. Detection was at 220 nm wavelength. 
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5.1.1. Determination of Stability of HTRA1 Oligomeric States by SEC 
Preparative SEC analysis in section 5.1 (figure 14) revealed that the ratio of the amount of different 
oligomeric states altered by the exchange of residues residing at the trimer interface. 
To determine whether separated oligomeric states are stable or equilibrate upon storage, the different 
fractions obtained from SEC separation were frozen at -20 °C and thawed after 24 h followed by 
storage at 8 °C for 7 days. Subsequently an analytical SEC was performed using the ÄKTA FPLC system 
with an analytical column. Figure 15 shows the SEC plot of all four variants and their different 
oligomeric states. All higher oligomeric fractions and the monomeric fractions of the mutants of 
HTRA1 cd that were previously purified were found to be stable and no gross re-equilibration was 
observed. Nevertheless trimer fraction of HTRA1 cd and HTRA1 cd+PDZ showed a slight shift towards 
a lower molecular weight fraction. This may be due to proteolytic degradation. While the monomeric 
fraction of HTRA1 catalytic domain mutant variants remained monomeric upon storage, the trimer 
fractions showed some equilibration between the trimeric and the monomeric states. 
 
Figure 15 Plots of size-exclusion chromatography (SEC) of previously separated HTRA1 variant fractions of different oligomeric 
states. Chromatograms of HTRA1 cd (top-left), HTRA1 cd-mono2 (bottom-left), HTRA1 cd-mono3 (top-right), HTRA1 cd+PDZ 
(bottom-right). Specific oligomeric states are indicated. Detection was at 220 nm wavelength. 
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5.1.2. Melting Curves of HTRA1 Variants 
To determine the thermal stability of the expressed HTRA1 variants, thermal melting was measured 
using SYPRO-Orange. Temperature gradient and data recording were carried out on a real-time PCR 
instrument. SYPRO-Orange that provides fluorescence excitation and emission after intercalation with 
hydrophobic patches of proteins was added before HTRA1 variants were exposed to the temperature 
gradient. All variants show denaturation in a temperature range between 54-63 °C (figure 16). The 
trimeric fraction of HTRA1 cd displayed a melting point of 62 °C as well as the trimeric fraction of 
HTRA1 cd-mono3 and HTRA1 cd+PDZ with around 60 °C. The melting points of the monomeric 
fractions of HTRA1 cd-mono2 and cd-mono3 were 8-10 °C lower than the one for the trimeric 
fractions. This indicates that the generated variants are stable as monomers. Additionally, trimerization 
enhanced thermal stability of the monomeric folding unit. The higher oligomeric fraction of HTRA1 
cd-mono3 is with 62 °C comparable with the trimeric fractions of HTRA1 cd and HTRA1 cd+PDZ with 
respect to melting temperature. 
 
Figure 16 Melting curve analysis of HTRA1 variants using SYPRO-Orange. Melt points (Tm) were measured in duplicates and 
values are indicated in the plots. 
5.1.3. Protein Concentration of HTRA1 Variants (BCA/OD280) 
After SEC the pooled fractions were concentrated by ultra-filtration and concentrations were 
determined using measurement of optical density (OD) at 280 nm with specific extinction 
coefficient (ε) of the different variants. Specific ε was calculated using algorithm of vector NTI 
Software (Invitrogen)308. Due to a high divergence of protein amount of different HTRA1 variants that 
was observed in SDS-PAGE after normalization according to OD280 indicating presence of contaminants 
absorbing at 280 nm, a bicinchoninic acid assay (BCA) was executed (figure 17a). By this method a 
colorimetric signal is measured that is proportional to distinct amino acids and peptide bonds. The 
normalization based on BCA assay indicated similar concentrations for tri- and monomeric fractions 
while the higher oligomeric fractions were much lower concentrated as shown by SDS-PAGE 
(figure 17a). Additionally the SDS-PAGE revealed several impurities at the higher oligomeric fractions. 
These were possibly co-purified by HTRA1 during purification due to unspecific binding to the protease 
as well as degradation products. The concentration of the relatively pure HTRA1 cd-mono3 was 
determined under consideration of its specific ε280 of 3840 M-1cm-1 to be 2 mg/ml. With a volume of 
about 6 ml the total yield for HTRA1 cd-mono3 monomeric fraction was after two-step purification 
(IMAC and SEC) approximately 12 mg per Liter. For the other HTRA1 variants and their different 
monomeric and trimeric fractions the yield was lower, but at least 2.5 mg per Liter for trimeric HTRA1 
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cd-mono2 and HTRA1 cd-mono3 could be isolated. Due to the impurities no yields for the higher 
oligomeric fractions were calculated. 
 
Figure 17 HTRA1 variants after separation by size-exclusion chromatography (SEC). Standardization of protease amount on 
optical density (OD280) (top) and BCA-Assay (bottom) (a). Verification of labeling with biotin by Western blot (middle) and 
labeling with fluorescein by PAGE under UV-light (right) (b). 
5.1.4. Labeling of HTRA1 Variants 
For the directed evolution method of yeast surface display that is carried out on a fluorescence 
activated cell sorter (FACS), it is necessary to label the target molecule with a fluorescence dye. One 
possibility for covalent labeling is the linkage mediated by an amine reactive group. In this work 
fluorescein was coupled through an isothiocyanate moiety (FITC) to HTRA1, whereas biotin was 
coupled through N-hydroxysuccinimide moiety (NHS-LC-Biotin). Biotin is strongly bound by 
streptavidin which is commercially available as a conjugate to many prominent fluorescent dyes such 
as phycoerythrin or allophycocyanin. Both moieties are amine reactive, so they react with lysine as well 
with the amino-terminus of a polypeptide. The labeling procedure was carried out as described in 
section 4.1.6. 
For labeling of HTRA1 cd-mono3 purification buffer was exchanged by gravity desalting columns to 
obtain optimal reaction conditions for labeling. The ratio for both labeling approaches was 5 labeling 
molecules per target molecule. Although not all labeling reagents are attached during the labeling 
process a low ratio was chosen to prevent loss of protease activity by extensive protein modification. 
FITC labeling was verified by SDS-PAGE which was exposed to UV-light. NHS-biotin labeling was 
verified by SDS-PAGE followed by Western blot using an ExtrAvidinTM-alkaline phosphatase conjugate. 
Both results are shown in figure 17b in the previous section (5.1.3). Labeling of HTRA1 variants was 
successful for both reagents although it remains unclear how many molecules are attached to a 
protease molecule and whether each protease molecule is at least labeled once. 
5.1.5. Measurement of HTRA1 Activity 
To determine, whether expressed HTRA1 cd+PDZ, HTRA1 cd and its mutants are active enzymes an 
activity assay was performed. The most sensitive reported substrate is a quenched fluorogenic peptide 
substrate named H2Opt. This substrate was originally found by screening a substrate library against 
human HTRA2, but it was shown that it also works well with HTRA130, 53. The substrate was 
synthesized using automated solid phase peptide synthesis (SPPS), purified by reversed-phase HPLC 
and verified by LC ESI-MS (results not shown). Its sequence is Mca-IRRVSYSF(Dnp)KK, where 
m-coumaric acid (Mca) is amino-terminally attached as a fluorophore and dinitrophenol linked to a 
lysine side-chain is introduced as a quencher. After cleavage of the peptide bond between these 
molecules excitation of the fluorophore with 328 nm results in emission of light with a wavelength of 
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393 nm. The synthesized substrate was modified compared to the literature53 by introducing an 
additional lysine at the carboxyl-terminus to enhance the solubility and was designated as H2Opt-K. 
For measurement of proteolytic activity, a protease concentration of 0.625 µM was found to be optimal 
when using 12.6 µM of H2Opt-K (results not shown). Measurement was performed for 1 h at room 
temperature using a microtiter plate reader. Substrate background fluorescence was recorded without 
addition of protease to verify that no autolysis of the substrate occurs (results not shown). For all 
measurements a double determination was performed and the average value is shown in all plots, as 
well as the standard deviation by error bars. The plots for the three different purified HTRA1 fractions 
are shown in figure 18a, b and c. The higher oligomeric fractions showed high activity since a 
significant fraction of the substrate was cleaved already prior to start of recording. For higher 
oligomeric fractions it is important to note that the actual concentration of HTRA1 most likely is 
underestimated due to presence of contaminating impurities, a fact that corroborates the notion that 
higher oligomeric HTRA1 displays higher proteolytic activity compared to trimeric HTRA1.  
The trimeric fractions of HTRA1 cd and HTRA1 cd+PDZ showed similar activity towards substrate 
H2Opt-K. However, HTRA1 cd-mono2 and cd-mono3 are inactive at comparable concentrations, as 
well as monomeric fractions of both mutant variants. Due to this observation all monomeric fractions 
of HTRA1 cd-mono3 were measured again using higher substrate and/or higher protease 
concentrations. At 63.5 µM substrate concentration the trimeric fraction showed substrate processing 
comparable to higher oligomeric fraction at 12.6 µM when using a protease concentration of 0.625 µM 
(figure 18d). Interestingly, the monomeric fraction showed comparable activity when substrate 
concentration is raised to 63.5 µM and additionally protease concentration is raised to 10 µM. 
Nevertheless standard deviation for HTRA1 cd-mono3 monomeric fraction is extremely high. No 
further experiments were performed aimed at investigating, whether monomeric HTRA1 variants re-
equilibrate at high protein concentrations to for trimers or higher oligomers. 
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Figure 18 Activity measurement of HTRA1 variants and their different oligomeric states. Higher oligomeric states (a), trimeric 
states (b), monomeric states (c) and HTRA1 cd-mono3 with its 3 fractions with different protease and substrate 
concentrations (d). Activity was measured with H2Opt-K as fluorescence substrate over time in duplicates. Substrate 
concentration is increased for trimeric and monomeric fraction to 63.5 µM. Protease concentration of monomeric fraction is 
increased to 10 µM. For all plots only every second data point is shown. 
5.2. Screening of an Immunized Llama VHH Library 
In 2011, a llama was immunized with four different disease-related proteins initiated by the 
workgroup of Prof. Harald Kolmar309. The immunization was done with 1 mg of each protein followed 
by two boosting steps after several weeks. In this immunization, trimeric fraction of HTRA1 cd was 
administered. After the second boost blood was collected and B-cells were isolated bearing the 
information of matured IgG and as well as VHH molecules. RNA was isolated and transcribed with 
VHH specific primers in cDNA that serves as a template for the construction of a variant library in yeast 
cells that could be displayed on the cell surface. 
5.2.1. Serum Titer against HTRA1 
To verify whether the immunization against trimeric fraction of HTRA1 cd was successful the titer of 
antibodies against the protease was determined. To this end, HTRA1 cd trimeric fraction and BSA as 
negative control were immobilized on the surface of a microtiter plate (MTP). In the next step cavities 
were incubated with serial dilutions from 1:10-1:1000 of serum collected before and after 
immunization. The binding of antibodies was detected using a protein A horseradish-peroxidase 
conjugate and TMB One as substrate. The chart for antibody titer is shown in figure 21a in section 
5.2.3. The pre-immune serum showed no specific binding in any dilution. The post-immune serum 
showed strong signal against HTRA1 cd trimeric fraction in 1:10 dilution as well as clear signal in 
1:100 dilutions. In 1:1000 dilutions no signal was observed. This indicates a concentration-dependent 
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binding of antibody molecules induced by immunization of llama. However, it is important to note that 
this assay does not allow one to distinguish between classical antibodies and single domain antibodies 
recognizing HTRA1. 
5.2.2. Library Generation and Screening 
The VHH library used in this work was obtained by immunization of a llama with a combination of 
four different antigens including a trimeric fraction of protease domain of human HTRA1 which was 
recombinantly expressed in E. coli. The collection of blood was performed 54 days post immunization. 
Approximately 100 ml whole blood was collected with two different methods, either by extracting and 
stabilizing mRNA directly after collection, or stabilizesing the blood until mRNA extraction in the 
laboratory was performed. After reverse transcription by oligo(dT)20 and random hexamer primers 
VHH genes were amplified with addition of homologous ends for library generation in yeast110 (4.2.6). 
Library size was estimated to be approximately 2.8x108 independent clones. 
Using biotinylated HTRA1 cd for library screening caused unexpected problems. Obviously, the target 
protein formed large aggregates that were detectable by FACS hampering the isolation of labeled yeast 
cells. As a consequence, in following experiments monomeric fraction of HTRA1 cd-mono3 was 
exclusively used for library screening. 
Additionally to fluorescein labeled monomeric fraction of HTRA1 cd-mono3 a carboxyl-terminal myc 
epitope that is expressed by each variant was used for detection of VHH expression and cell surface 
presentation using a second fluorescent label addressing the myc epitope. The FACS allows for 
isolation of variants from the library that show both features, which are cell surface presentation and 
target binding. The isolated yeast cells can be amplified by culturing and screened again for several 
rounds until a population of binders emerges. Ideally, the enriched population should contain full-
length VHH molecules with the ability of binding the HTRA1 variant used for screening. 
For the isolation of VHHs recognizing the monomeric HTRA1 cd-mono3 fluorescein labeled protease 
and a biotinylated anti-myc antibody were used for the first two rounds of enrichment. While 
fluorescein has an emission maximum around 520 nm the biotinylated antibody was stained using a 
streptavidin-allophycocyanin (SAPC) conjugate with an emission maximum around 680 nm. In the 
next three rounds staining of the yeast cells, the mode of cell detection was inverted by using a 
combination of an anti-myc antibody labeled with a fluorescein conjugated anti-mouse antibody and 
the biotinylated HTRA1 cd-mono3 monomeric fraction, followed by cell labeling with SAPC. For all 
five enrichment steps the protease concentration was 1 µM. The alternation of the labeling strategy 
should prevent enrichment of yeast cells that present VHHs binding to the secondary antibody, 
streptavidin or fluorophores as well as misinterpretation of artefacts. The two dimensional (2D) 
consideration of binding properties allows an emphasis of distinction between surface presentation and 
target binding. 
After the incubation steps with the different labeling agents the yeast cells were washed finally and 
sorted with the FACS at a rate of about 30,000 cells per second. After sorting of the fourth round an 
additional resorting was performed directly. Besides demonstrating that enrichment was successful this 
resorting removes false sorted cells and enlarges enrichment success. The histograms of the sorts and 
resorts of the different rounds are summarized in figure 19. The gate that resembles the decision for 
region of sorted cells was chosen arbitrarily. The fraction of isolated cells is displayed as percentage in 
the gate. 
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Figure 19 Histograms of enrichment of HTRA1 cd-mono3 binding cells presenting VHH library. Sorting rounds 1-5 (top) and 
resorts of round 4 and 5 (bottom). FL1 channel for HTRA1 cd-mono3 (round 1, 2 and 4) and myc-tag (round 3 and 5) on the 
x-axis. FL3 channel for myc-tag (round 1, 2 and 4) and HTRA1 cd-mono3 (round 3 and 5) on the y-axis. Gates for sorted cells 
are indicated by percentage of events that were isolated. 
In the first round 2x108 cells were screened and 0.13 % were collected on the basis of a trade-off 
between surface presentation and binding to HTRA1 cd-mono3. In the second round slight enrichment 
of HTRA1 cd-mono3 binding molecules in fluorescence channel 1 (FL1) was observed, since 3.3 % of 
the cells were found to be in the sorting window. The altered cell staining procedure in round three 
showed significantly less binding of HTRA1 compared to round two (0.07 %). Staining was altered 
again in the fourth as well as in the fifth round. About 3 % of the cells were sorted out in the fourth 
round. The successive resort revealed a strong enrichment since 56.6 % of the cells were found in the 
selection gate. Finally, a fifth sorting round revealed a high degree of enrichment of target binding 
cells as well as surface presentation (23.9 % in the sorting gate). A resort was performed to control 
successful enrichment process of this final round resulting in a population of 78.2 %. 
For determination of the properties of enriched clones, 12 single clones were randomly picked from 
plates and cultured after the fifth sorting round. The induced cells were labeled with an anti-myc 
antibody and with HTRA1 cd-mono3 to investigate, whether their corresponding VHH is displayed in 
full-length and has the ability to bind to HTRA1 cd-mono3 monomeric fraction. About 50,000 cells of 
each labeled single clone were analyzed using FACS. By using a target concentration of 1 µM as it was 
used during the initial rounds of enrichment it could be qualitatively determined whether the isolated 
clones present a VHH variant that binds HTRA1 cd-mono3. 10 of the 12 clones showed presentation of 
myc-tag as well as target binding (Results not shown). 
Sanger sequencing of the HTRA1 cd-mono3 binding clones revealed two unique sequences (figure 20). 
Sequence of clone KV01 was found six times, while clone KV07 was found four times. The amino acid 
sequence alignment of both clones is shown in figure 20. To find more sequences of HTRA1 cd-mono3 
binding VHH molecules additionally 10 clones of the fourth round were sequenced. This only resulted 
in same sequences with a similar distribution. Both clones showed totally different framework residues 
in many positions. The CDRs show little conserved areas such as a methionine in position 6 of CDR1, 
an alanine in position 2 of CDR2 and a glycine in position 6 of CDR3. The CDR3 of KV07 is with only 
seven residues about five residues shorter than CDR3 of KV01. 
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Figure 20 Amino acid sequence alignment of HTRA1 cd-mono3 binding VHH molecules isolated by FACS. Clone name, 
selection round and occurrence are designated for each clone Positions that are unique in framework are indicated in red. 
CDR1 is shown in light grey, CDR2 in dim grey and CDR3 in black. 
5.2.3. Characterization of Isolated VHH Molecules 
By cell labeling using varying concentrations of the target protein, a binding curve can be generated by 
plotting mean fluorescence versus target protein concentration that allows for a calculation of the 
equilibrium dissociation constant (KD). For this affinity titration (4.2.5), cells of clones KV01 and KV07 
were stained for myc-tag and HTRA1 binding using decreasing concentrations of protease. The mean 
fluorescence of the labeled HTRA1 cd-mono3 cells from the gated population of cells with equivalent 
levels of VHH surface accumulation was recorded and correlated with labeling concentration of 
protease. KD values were determined by fitting method of K. D. Wittrup using Sigma Plot Software
306. 
The plots are shown in Appendix A and the KD values in table 1 (5.4.4). Both VHH molecules showed 
KD values in the triple-digit nano-molar range against HTRA1 cd-mono3 monomeric fraction when 
being presented on the yeast surface. 
Both VHH variants were additionally expressed as Fc fusion proteins in HEK293 cells described in 
detail in section 5.5.2 of this work. Only expression of KV07 resulted in amounts that were sufficient 
for further investigations. 
First an ELISA for Fc-fused KV07 was performed with immobilized HTRA1 cd trimeric fraction and 
HTRA1 cd-mono3 monomeric fraction. In the next step cavities were incubated with serial dilutions of 
cell culture supernatant of HEK293 cells producing KV07-Fc fusions from 1:10-1:1000, followed by 
incubation with a protein A horseradish-peroxidase conjugate. Presence of HTRA1 binding Fc-VHH 
fusion was detected by incubation with horseradish-peroxidase substrate TMB. The chart is shown in 
figure 21b. Interestingly, only the monomeric variant of HTRA1 is detected by KV07-Fc in a 
concentration dependent manner. HTRA1 cd trimeric fraction and the negative control showed no 
signal, even at the highest KV07-Fc concentration. 
Additionally for Fc-fused KV07 an activity measurement towards HTRA1 cd trimeric fraction in 
presence of purified KV07-Fc was carried out (Figure 21c). An Fc lacking a fused VHH was used as 
negative control. Conditions were the same as for determination of activity of HTRA1 variants 
described in section 5.1.5 of this work (0.625 µM protease; 12.6 µM substrate). Concentration of Fc 
and KV07-Fc was 14 µM. No influence on activity of HTRA1 cd was observed in presence of KV07-Fc. 
Due to the observation in ELISA that KV07 selectively binds HTRA1 cd-mono3, but not HTRA1 cd an 
activity measurement of HTRA1 cd-mono3 monomeric fraction in presence of purified KV07-Fc was 
carried out (figure 21d). Conditions were the same as for HTRA1 cd trimeric fractions. In this 
experiment, it was investigated whether KV07 binding allosterically activates HTRA1 cd-mono3 
monomeric fraction, as for the substrate and protease concentration chosen no activity was observed 
for this variant. No allosteric modulation of HTRA1 activity was detected upon co-incubation with 
KV07. 
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Figure 21 Analysis of HTRA1 cd-mono3 binding VHH. Titer of Llama Serum against HTRA1 cd (Trimer) previous to building 
library (a), ELISA of Fc fusion KV07-Fc against HTRA1 cd (Trimer) and HTRA1 cd-mono3 (Monomer)(b), Activity measurement 
of HTRA1 cd (Trimer) with addition of KV07-Fc (c) and activity measurement of HTRA1 cd-mono3 (Monomer) with addition of 
KV07-Fc (d). Cleavage of fluorescence quenched substrate H2Opt-K was recorded over time in duplicates. Only every second 
data point is shown. 
5.3. Screening of a Combinatorial McoTI-II Library 
The screening of the library of VHH variants from an immunized llama only revealed one characterized 
single clone that recognized the monomeric HTRA1 variant, albeit with low affinity. Since no 
inhibition of proteolytic activity was observed, we concluded that its binding site does not overlap with 
the active-site. In an effort to obtain inhibitors of HTRA1 proteolytic activity, a library of variants 
derived from the cystine-knot miniprotein McoTI-II was screened using the same display and screening 
format as described in the previous chapter. 
To this end, a miniprotein library was used that was successfully applied previously to the isolation of 
binders against several targets129, 310. In this library, the protease inhibitor loop that consists of six 
residues was fully randomized for all natural occurring amino acids except cysteine with an equal 
distribution (figure 8)
mutations on different positions of a protein. Thus the rims of the inhibitor loop were randomized with 
50 % frequency, while 50 % were kept with wild-type codon. The fourth and last loop containing five 
residues was randomized by only 10 % frequency. Two further exposed positions in loop two were 
changed by 50 % frequency. The combinatorial library was amplified by PCR with addition of 
homologous regions for recombination in cell surface presentation vector pCT resulting in a library 
diversity of 2.4x108 clones which was determined by serial dilutions on cultural plates129. Predicted 
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structure and primary sequence with a color-coded randomization are shown in figure 8 in section 
2.2.4. 
5.3.1. Screening of the McoTI-II Library 
For isolation of McoTI-II derived molecules binding HTRA1 cd-mono3 the screening procedure was 
performed as described for VHH molecules (4.2.2). In this enrichment process labeling of myc-tag and 
HTRA1 cd-mono3 was not alternated during the successive rounds as it was performed for VHH 
library. Thus for all rounds of enrichment the FITC labeled protease was used with additional staining 
of myc-tag by biotinylated anti-myc antibody and streptavidin-allophycocyanin conjugate. The 
histograms of the sorting rounds are shown in figure 22. In the first three rounds the target 
concentration was kept at 1 µM. 3x108 cells were analyzed in the first round and the gate for sorting 
covered 0.5 % of total events. For each round a resort was performed, resulting for the first round in 
8.9 % of cells in the sorting gate. In the second round approximately 5.3x107 cells were analyzed and 
1.2 % of cells were isolated. The resort resulted in an accumulation of cells in the sorting gate of 
25.2 %. In the third round 3.2 % of cells were isolated and enriched to 42.9 % of the cells in the 
sorting gate after resort. In the fourth round, the target concentration was decreased to 100 nM 
resulting in 1.2 % of isolated cells with 30.8 % positive cells in the resort. A fifth round with 40 nM 
target concentration was finally executed which resulted in a cell population that displayed 
miniprotein expression (shown by myc-tag/SAPC labeling), but no target labeling (results not shown). 
 
Figure 22 Histograms of enrichment of HTRA1 cd-mono3 binding cells presenting McoTI-II derived library. Sorting rounds 1-4 
(top) and corresponding resorts (bottom). FL1 channel for HTRA1 cd-mono3 on the x-axis and FL3 channel for myc-tag on the 
y-axis. Gates for sorted cells are indicated by percentage of events that were isolated. 
Due to the negative result of the fifth round, 10 clones of round four were randomly chosen. After 
induction of gene expression by cell incubation in galactose containing media, cells were double 
labeled for detection of full-length presentation by myc-tag and binding of HTRA1 cd-mono3. All 
clones showed target binding as well as a myc-tag presentation (results not shown). DNA sequences of 
these clones revealed that all 10 analyzed clones were identical. The unique sequence is shown in 
figure 23. The isolated McoTI-II derived molecule, called KS01, contains four aromatic amino acids out 
of six residues in the inhibitor loop. Its amino-terminal rim region of three residues is completely 
changed by two large aliphatic residues separated by threonine. All further randomized positions 
remained unchanged. 
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Figure 23 Amino acid sequence alignment of HTRA1 cd-mono3 binding McoTI-II derived molecule KS01 isolated by FACS. 
Loop 1 with 100 % randomization is highlighted in black, fourth loop and two positions in the second loop with 10 % 
randomization are highlighted in light grey. Flanking regions of loop 1 with 50 % randomization are highlighted in dim grey. 
5.3.2. Characterization of Isolated McoTI-II Derived Molecule 
For determination of the affinity of KS01 an affinity titration was executed (4.2.5). As for isolated 
HTRA1 cd-mono3 binding VHH molecules (5.2.3), a single clone was stained for myc-tag and 
decreasing concentrations of FITC labeled target protease. The plot in Appendix A shows relative 
fluorescence signal against protease concentration. The transition point indicated an equilibrium 
dissociation constant (KD) of 650 nM for KS01. The results of affinity titration of all isolated molecules 
in this work are summed up in table 1 in section 5.4.4. 
Additionally cells presenting KS01 were stained with 10 µM fluorescein labeled HTRA1 cd, HTRA1 
cd+PDZ and HTRA1 cd-mono3 as well as unlabeled cells as negative control. Interestingly, only 
HTRA1 cd-mono3 showed KS01 binding. The merged histograms are shown in figure 24d. 
 
Figure 24 Analysis of HTRA1 cd-mono3 binding McoTI-II derived molecule KS01. ELISA of Fc fusion KS01-Fc against 
HTRA1variants (a), Activity measurement of HTRA1 cd (Trimer) with addition of KS01-Fc (b) and activity measurement of 
HTRA1 cd-mono3 (Monomer) with addition of KS01-Fc (c). Cleavage of fluorescence quenched substrate H2Opt-K was 
recorded over time in duplicates. Only every second data point is shown. Histogram of presented KS01 on the yeast surface 
labeled with HTRA1 cd-mono3 (black), HTRA1 cd (red), HTRA1 cd+PDZ (blue) and unlabeled (green). Relative fluorescence 
intensity is on the x-axis and counts are on the y-axis (d). 
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Finally, isolated KS01 was produced as Fc fusion protein in HEK293 cells as described in detail in 
section 5.5.2 of this work. 
For functional characterization, an ELISA was performed with immobilized HTRA1 cd trimeric fraction 
and HTRA1 cd-mono3 monomeric fraction. In the next step cavities were incubated with serial 
dilutions of cell culture supernatant from 1:2-1:1000. The chart is shown in figure 24a. As found for 
the cell surface exposed KS01, only monomeric variant is bound by the Fc fusion of KS01 in a 
concentration-dependent manner. HTRA1 cd trimeric fraction and the negative control showed no 
signal, even at highest KS01-Fc concentration. 
Finally, an activity measurement of HTRA1 cd trimeric fraction in presence of purified KS01-Fc was 
carried out (Figure 24b). As negative control wild type ocMcoTI-II fused to Fc was used. Conditions 
were the same as for determination of activity of HTRA1 variants described in section 5.1.5 of this 
work (0.625 µM protease; 12.6 µM substrate). Concentration of both Fc fusion molecules was 14 µM 
each. No influence on activity of HTRA1 cd was observed in presence of KS01-Fc. 
Analogous to VHH molecule KV07, the isolated KS01 selectively binds HTRA1 cd-mono3, but not 
HTRA1 cd as observed by flow cytometric analyses with cells presenting KS01 (Figure 24d). According 
to this, an activity measurement of HTRA1 cd-mono3 monomeric fraction in presence of purified KS01-
Fc was carried out (Figure 24c). Conditions were the same as for HTRA1 cd trimeric fractions. In this 
assay, it was investigated whether KS01 binding allosterically activates HTRA1. For the substrate and 
protease concentration chosen no enzyme activity was observed (5.1.5). Hence, as for the isolated 
VHH variant KV07 no activation of HTRA1 was observed. 
5.4. Screening of a Synthetic vNAR Library Followed by Affinity Maturation 
Another interesting scaffold for generating target-specific binders is the antigen binding domain of 
single chain antibodies of cartilaginous fish (vNAR). This binding unit shares structural similarity with 
mammalian antibodies like VHH domains, although they are only comprised of CDR1 and CDR3. The 
library was assembled by using the whole framework of a non-immunized bamboo shark272. After 
reverse transcription of mRNA CDR3 composed of 12 residues was randomized synthetically by codon-
based oligonucleotide mixtures. The 12 residue CDR3 length corresponds to the most frequent loop 
length found in bamboo sharks as revealed by next-generation sequencing of the vNAR repertoire of 
three non-immunized bamboo sharks272, 311. After introducing randomization in CDR3 the DNA 
construct was extended by PCR to the full length of the vNAR gene and additional nucleotides were 
added for homologous recombination in yeast. Transformation of S cerevisiae EBY100 together with 
the expression plasmid resulted in 2x108 independent yeast clones. This library was successfully used 
by Zielonka et al. for the isolation of binders against several targets272, 311. Since only a single loop is 
randomized, low to medium affinity binders in the triple digit nanomolar to micromolar range are 
commonly obtained. Hence, for the isolation of high affinity antibodies the population of binders 
obtained from library screening is further randomized in CDR1 or another neighboring loop HV2 in an 
effort of affinity maturation and clones with elevated affinity are subsequently isolated by several 
rounds of FACS screening with steadily decreasing target protein concentrations312, 313. 
5.4.1. Screening of the Synthetic vNAR Library 
For isolation of vNAR-based molecules binding to HTRA1 cd-mono3 the screening procedure was 
performed as previously described for VHH and McoTI-II derived molecules. In the first round 1 µM 
FITC labeled target was used for staining in combination with anti-myc antibody, biotinylated 
secondary antibody and SAPC. 2x108 cells were analyzed and the sorting gate covered 0.2 % of cells 
(figure 25). A resort was not performed after the initial round. For the second round induced yeast 
cells were alternatively labeled (as described before 4.2.2) resulting in an accumulation of 0.2 % of the 
cell population in the sorting window. The resort of this population indicated a successful enrichment 
(1.5 %). In the third and fourth round staining was switched back to FITC labeled target. The target 
concentration in these rounds was successively decreased to 100 nM and 10 nM, respectively. About 
2.7 % of analyzed cells were isolated in the third round and the resort revealed 18.7 % positive cells. 
In the fourth round 0.5 % and in the successive resort about 27.2 % of cells were isolated. 
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Figure 25 Histograms of enrichment of HTRA1 cd-mono3 binding cells presenting CDR3 randomized library of vNAR scaffold. 
Sorting rounds 1-4 (top) and corresponding resorts (bottom). FL1 channel for HTRA1 cd-mono3 (round 1, 3 and 4) and myc-
tag (round 2) on the x-axis. FL3 channel for myc-tag (round 1, 3 and 4) and HTRA1 cd-mono3 (round 2) on the y-axis. Gates for 
sorted cells are indicated by percentage of events that were isolated. 
Fifteen single clones after the fourth round were analyzed by staining for surface presentation and 
target binding as described previously for VHH and McoTI-II based scaffolds. Of these, thirteen 
revealed HTRA1 cd-mono3 binding (Results not shown). Sequences of these clones were obtained 
from analysis of DNA sequencing after previous amplification by PCR of the respective vNAR coding 
sequence. Six different variants were found, while clone K10 appeared five times, K03 was found twice 
as was K07 and K09. Clone K13 and K14 were only found once in the thirteen analyzed sequences. 
Sequences are shown in figure 26. Besides different CDR3 regions also different framework residues 
were observed. Sequences were all individual over all twelve residues allowing no deviation of a 
consensus sequence regarding HTRA1 cd-mono3 binding. In position 2 large aliphatic residues were 
present in four individual clones. In position 4 an asparagine was observed 3 times. In position 6 there 
was two times a negatively charged aspartic acid as well as two times a positively charged lysine 
present. Further on position 3, 7, 10 and 12 aromatic amino acid residues were observed. Clones K09 
-
position 11-12 and position 10- sition 4-5 of K09 
and position 9-10 of K14. Besides these small stretches of sequences identity no significant similarities 
were found. 
 
Figure 26 Alignment of unique amino acid sequences of HTRA1 cd-mono3 binding CDR3 randomized vNAR molecules isolated 
by FACS. Clone name, selection round, randomized region and occurrence are designated for each clone. Framework 
mutations are indicated in red, CDR1 is indicated in dim grey, HV2 in grey and CDR3 in black. 
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Cells from all unique clones except K14 were stained with 10 µM fluorescein labeled HTRA1 cd, 
HTRA1 cd+PDZ and HTRA1 cd-mono3, respectively. Cells were additionally labeled and gated for 
myc-tag presentation using primary and secondary antibodies in combination with SAPC. Merged 
histograms of myc-tag gated cell populations are shown in figure 27. All analyzed clones showed a 
clear shift in fluorescence intensity for all different targets compared with negative controls. Cell 
populations of clones K03, K10 and K13 showed the highest mean fluorescence when labeled with 
HTRA1 cd-mono3 while the native variants displayed lower levels of cell staining. Interestingly, the 
mean fluorescence for K09 is the highest for HTRA1 cd, while HTRA1 cd-mono3 and HTRA1 cd+PDZ 
display the same level of cell staining. For K07 the mean fluorescence is similar for all HTRA1 variants. 
Afterwards an affinity titration was performed. Results are described in section 5.4.4. 
 
Figure 27 Histograms of clone K03, K07, K09, K10 and K13 labeled with HTRA1 cd-mono3 (black), HTRA1 cd (red), HTRA1 
cd+PDZ (blue) and unlabeled (green). Relative fluorescence intensity is on the x-axis and counts are on the y-axis. 
5.4.2. Affinity Maturation of CDR1 and HV2 and Screening 
The total repertoire of cells from the third sorting round was used as template for randomization of 
CDR1 and HV2, respectively aimed at isolating clones with enhanced affinity. The naturally observed 
lengths of these regions were maintained with five residues each. For generation of the HV2 library the 
maintain a stable fold. Further the identified framework variability of the amino-terminus was kept by 
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using a set of different oligonucleotides, to preserve the natural properties of the library. Both sub-
libraries covered a low diversity of about 50,000 independent clones. 
The enrichment of CDR1 and HV2 sub-libraries were performed by labeling and sorting as described 
previously (4.2.2) with the modification that in each round FITC-labeled HTRA1 cd-mono3 was used 
for cell staining. In the first round, the target concentration was kept at 100 nM as in the third round 
of CDR3 screening which was used for sub-library construction. This strategy was chosen for getting 
rid of vNAR molecules that could not be displayed anymore in full-length as well as those that lost 
their ability to bind HTRA1 cd-mono3 by misfolding caused by newly introduced amino acids. 
Approximately 107 cells were screened for each sub-library. 
For the enrichment of CDR1 matured clones the gate for cells sorted out was selected to cover 1.1 % of 
cells. In the resort the dual labeled population made up about 15.1 % of cells. In a second round target 
concentration was dropped to 10 nM. In this round the gate for cells sorted out was selected to cover 
4.3 % of cells. In the resort the population made up about 18.8 % of cells. The histograms of the CDR1 
maturation screening are shown in figure 28a. 
For the enrichment of HV2 matured clones the gate for cells sorted out was selected to cover 1.4 % of 
cells. In the resort the dual labeled population made up about 56.8 % of cells. In a second round target 
concentration was dropped to 10 nM, as it was done for CDR1 sub-library. In this round the gate for 
cells sorted out was selected to cover 5.2 % of cells. In the resort the population made up about 30.4 % 
of cells. The histograms of the CDR1 maturation screening are shown in figure 28b. 
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Figure 28 Histograms of enrichment of HTRA1 cd-mono3 binding cells presenting matured CDR1 (a) and HV2 (b) vNAR 
scaffolds. Histograms for cells presenting CDR1 matured vNAR molecules binding HTRA1 cd-mono3 previously matured in HV2 
(c). Sorting rounds 1 and 2 (top) and corresponding resorts (bottom). FL1 channel for HTRA1 cd-mono3 is shown on the x-axis. 
FL3 channel for myc-tag is shown on the y-axis. Gates for sorted cells are indicated by percentage of events that were isolated. 
After the second sorting round five clones of each affinity maturation were tested for presentation of 
full-length construct as well as for HTRA1 cd-mono3 binding. For CDR1 and HV2 four out of five 
clones displayed target binding. Positive clones KH01-03 and KH05 for HV2 and KC01-03 and KC05 
for CDR1 were amplified by PCR and sequenced. Sequences of CDR1 matured clones are shown in 
figure 29a. The CDR3 of CDR1 matured clones KC01, KC02 and KC05 are derived from clone K07. In 
KC03 CDR3 sequence of K14 was found. No consensus sequence in CDR1 could be derived. 
Interestingly the framework of the three molecules derived from K07 showed single exchanges 
that is present in CDR1 of KC02 in position 3-5 is also found in CDR1 of HV2 matured clone KH05 at 
-5. Although CDR1 
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was not randomized for HV2 sub-library the oligonucleotides for elongation introduced different 
residues derived from the naïve repertoire. 
 
Figure 29 Alignment of amino acid sequences of CDR1 (a), HV2 (b) and HV2-CDR1 (c) matured HTRA1 cd-mono3 binding 
vNAR molecules isolated by FACS. Clone name, selection round, randomized region and occurrence are designated for each 
clone. Framework mutations are indicated in red, CDR1 is indicated in dim grey, HV2 in grey and CDR3 in black. 
Sequences for CDR1 matured clones are shown in figure 29b. All of the KH clones were identical in 
their CDR3 sharing the sequence of K07 from enrichment previous to maturation as observed in three 
of four clones in HV2 maturation. KH01 and KH02 share the framework besides the naturally 
occurring framework reconstituted in CDR1, while KH03 and KH04 showed differences in their 
framework compared with KH01 and KH02 revealing that they are not derived from the same CDR3 
clone as assumed for molecules from HV2 maturation. Moreover these clones have totally different 
residues at all five positions of HV2 resulting in no conserved position of any functionality delivered by 
-2 is present in KH05 
in position 3- n 1-2 of 
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CDR1 is also found in position 2- -3 of KH02 was also 
found in position1-2 of CDR3 of clone KC03. 
Unique clones were subjected to an affinity titration. Results are presented after the subsequent affinity 
maturation of HV2 matured clones in section 5.4.4. 
5.4.3. Second Affinity Maturation of HV2 Matured Clones by CDR1 Randomization 
In theory a binding resulting from three independent regions could be stronger than one mediated by 
two regions. This strategy is performed by nature in a single domain of an antibody due to the larger 
surface that could be covered. While for a mixture of vNAR clones matured in CDR1 it is technically 
g the sequence both of CDR3 and of HV2, it 
is easily possible to apply the in vitro affinity maturation of CDR1 to the clones previously matured in 
CDR3 and HV2. 
As initial population of clones for CDR1 maturation, cells isolated from round one of the HV2 
maturation were used. Transformation of yeast cells resulted in a library size of 107 independent CDR1 
matured clones. Four rounds of enrichment were performed. Yeast cells for the first round were 
labeled with relatively high concentration of 100 nM HTRA1 cd-mono3 aimed at isolating all clones 
binding target irrespective of their affinity. Histograms of sorting rounds are shown in figure 28c. In 
the first round 1.1 % of cells were sorted out followed by a resort confirming the efficiency with 
15.1 % of cells being in the sorting window. In the next round concentration was dropped to 10 nM 
target concentration resulting in 5.4 % sorted cells and 39.4 % cells in the resort. Cells in the third 
round were labeled again with 10 nM HTRA1 cd-mono3. 8.4 % cells were isolated while 14.4 % were 
confirmed in the resort. In the fourth round target concentration was additionally dropped to 1 nM. 
3.2 % of cells were enriched and 14.1 % were confirmed in a resort. 
After the fourth round of enrichment twelve single clones were analyzed for HTRA1 cd-mono3 
binding. Clones KHC01-08 and KHC11-12 were positive in HTRA1 cd-mono3 binding when labeled 
with 100 nM target, as well as in presentation of carboxyl-terminal myc-tag. DNA sequencing revealed 
nine unique clones while clone KHC04 appeared twice, as it was identical with KHC05. Sequences are 
shown in figure 29c. Interestingly, all analyzed clones shared the same CDR3 of clone K07 from 
enrichment previous to maturation. Clones KHC04, 06 and 07 contained identical HV2, but are 
unrelated with respect to their CDR1 sequence. Nevertheless these three clones show different 
framework mutations at the carboxyl-terminus making it conceivable that they did not derive from the 
same parental HV2 clone. Further, no examined clone contained a HV2 region that was observed after 
HV2 maturation. 
With respect to the CDR1 sequence, the nine unique clones are all unique. Clone KHC01 has on 
position 3 and 4 identical residues as KC01, namely glutamine and lysine. KHC01 has in position 2 and 
3 of CDR1 a tryptophan and a glutamine. These residues were found on the same positions at KH03 in 
HV2. KHC08 shows the motif NXQS in position 1-4 in CDR1. The same motif was found at the same 
positions in HV2 of KH03. 
Conspicuously five clones carry a tyrosine on position 5 in CDR1 and six clones carry a glutamine on 
position 5 of HV2. These framework-flanking positions may have an impact on folding and stability for 
the whole vNAR molecule. 
Due to the large sequence diversity of CDR1 and HV2 after 4 rounds despite the decrease of target 
concentration to 1 nM an additional round was performed. In this round a koff screening was executed 
with incubation of yeast cells for 8 hours after labeling with 10 nM fluorescently labeled target in 
presence of 10 µM unlabeled target. The presented molecules releasing the labeled target in this time 
period will statistically bind an unlabeled target molecule next. This approach should result in the 
isolation of molecules with a low dissociation rate. 5.1 % cells were isolated and 13.9 % were 
confirmed in a resort (Results not shown). The ten clones analyzed were positive for target binding 
and DNA sequence analysis revealed that they were all identical clones, in detail KHC01 from previous 
round. 
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The unique clones of round 4 were subjected to an affinity titration. Results are described in following 
section 5.4.4. 
5.4.4. Affinity Titration 
For determination of the binding quality of different enriched vNAR molecules unique single clones 
were analyzed by affinity titration. Additionally it was investigated, whether the maturation procedure 
delivered higher affine vNAR molecules compared to isolated initial molecules. Therefore, single clones 
were labeled with decreasing concentrations of fluorescently labeled HTRA1-mono3 as described 
previously (4.2.5). After analysis fluorescence intensities were related to target concentration for 
determination of KD, using a fitting procedure applied on sigma plot software
306. Plots with acquired 
data and corresponding fitted curves for vNAR affinity titrations are shown in Appendix A. 
vNAR molecules randomized in CDR3 after the fourth sorting round showed KD values in the 
micromolar range. The highest KD was observed from variant K07 with 24.5 µM while the best was 
observed from variant K03 and K13 with 1.3 µM each. The results are summed up in table 1. 
Table 1 Summary of KD values of isolated HTRA cd-mono3 binding molecules determined by affinity titration. For vNAR 
molecules parental clones for successive rounds of affinity maturation are indicated. Clone KHC04 is identical to KHC05.  
 
After maturation of HV2 the variant KH01 displayed a KD of 470 nM while the three further analyzed 
variants remain in the low single digit micromolar range. Considering that parental molecule of all 
four analyzed molecules is K07 with KD of 24.5 µM all clones were successfully matured or enhanced in 
their affinity against HTRA1 cd-mono3, respectively. 
For CDR3 clones matured in CDR1 the highest KD was observed for variant KC01 with a value of 
3.2 µM. The three further analyzed variants revealed KD values in the triple digit nanomolar range with 
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the lowest KD of 290 nM represented by KC05. Besides KC03, which is a derivative of K14, all other 
clones were derived again from clone K07. 
In the maturation screening of double matured clones nine unique clones were titrated. Additionally 
KHC05, which is identical with KHC04, was titrated for controlling deviation of the method by two 
individual clones presenting the same vNAR molecule. Unfortunately clones KHC02 and KHC07 
showed irregularities in concentration dependent binding or insufficient surface presentation for 
accurate KD determination. The seven other clones revealed KD values in the double digit nanomolar 
range. The lowest KD was observed for clone KHC04 to be 34 nM. Nevertheless its twin clone KHC05 
revealed slightly higher KD of 90 nM. The last remaining clone after final koff screening in round five 
was KHC01 with a KD of 53 nM. 
5.5. Expression and Characterization of HTRA1 Binding Molecules 
For more detailed analysis of isolated HTRA1 binding molecules soluble expression was performed. To 
this end, DNA sequences of binding molecules were amplified by PCR from screening vector pCT using 
oligonucleotides that introduce target vector specific cloning sites. Due to experience from literature 
expression hosts were chosen specifically for the different classes of molecules. Isolated vNAR variants 
were expressed as maltose-binding protein (MBP) fusion in E. coli, while the McoTI-II derived molecule 
was expressed fused to Fc part of IgG in human embryonic kidney cells (HEK293). VHH variants were 
also cloned as Fc fusion protein because expression as MBP fusion was unsuccessful. Expression and 
purification is described in in detail in the following section 5.5.1. 
5.5.1. Expression of vNAR Molecules in E. coli 
For recombinant expression of vNAR molecules, sequences were amplified from screening vector using 
oligonucleotides introducing recognition sites for restriction enzymes Acc Xba
end for ligation into pMX vector as carboxyl-terminal fusion to MBP. Additionally a 
Tobacco-Edge-Virus (TEV) cleavage-site was introduced between both molecules as well as six 
histidine residues (His-Tag) at the carboxyl-terminus for purification using immobilized metal ion 
affinity chromatography (IMAC). Clones carrying correct insert were verified after ligation and 
transformation by sequencing. Isolated vector was transformed into strain BMH 71-18 for protein 
production in 1 L scale. Since fusion proteins are directed to the periplasm by an amino-terminal signal 
sequence, outer membrane of E. coli was enzymatically destructed by lysozyme. After isolation via 
IMAC the fusion proteins were cleaved with TEV protease and separated with size-exclusion 
chromatography (SEC). Plots of SEC are shown in figure 30. Only clones K07, K10, K13, K14 and 
KHC01 resulted in sufficient yields for further analysis under applied fermentation conditions 
(figure 30). The first elution peak corresponds to MBP and the second peak to vNAR. Only for K07 
small amounts of uncleaved protein remained. Expression of K07, K10 and K14 resulted in high yields 
as indicated by absorption intensity above 200 mAU at 220 nm, while K13 showed only low amount 
with absorption intensity about 30 mAU. Extremely low amounts were isolated from KHC01. 
Eluted fractions of each vNAR were pooled and concentrated by ultra-filtration to a final concentration 
of about 30-50 µM. Yields of purified vNARs were calculated by their OD280 in respect of their specific 
molar extinction coefficients. The yield for K07 was 12 mg, for K10 it was 7 mg, for K14 it was 4.5 mg 
and for K13 it was 1 mg. The yield for KHC01, with the lowest yield, was determined on 200 µg. 
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Figure 30 Plots of size-exclusion chromatography of successfully recombinant expressed vNAR-MBP fusion proteins after TEV 
cleavage on Superdex 75 16/60 column. First elution peak is MBP. Second elution peak is particular vNAR. Detection was at 
220 nm wavelength. 
5.5.2. Expression of VHH and McoTI-II Molecules in HEK Cells 
For recombinant expression of VHH and McoTI-II based molecules, sequences were amplified from 
screening vector using oligonucleotides introducing recognition sites for restriction enzymes Nhe
end and Apa -terminal fusion to Fc part of an IgG 
antibody. Clones carrying correct insert were verified after ligation and transformation by sequencing. 
HEK cells were transfected with high concentration of purified vector for protein production in 
Freestyle
Protein A affinity chromatography. 
For Fc part, KV07-Fc and McoTI-II wildtype sequence high yields were observed in purification by 
Protein A affinity column (figure 31). For McoTI-II-derived molecule KS01-Fc yield was significantly 
lower, but still sufficient for further analysis of influence on activity. Eluted fractions of each Fc fusion 
protein were pooled and concentrated by ultra-filtration until concentration of about 30-50 µM. Yields 
of purified Fc fusion proteins were calculated by their OD280 in respect of their specific molar extinction 
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coefficients. The yield for Fc-KV07 and Fc-McoTI were 6 mg each and for single Fc it was 2.5 mg. The 
yield for KS01-Fc, molecule with lowest yield, was determined to be 300 µg.  
 
Figure 31 Plots of Protein A affinity chromatography of successfully recombinant expressed Fc and Fc fusion proteins of VHH 
and McoTI-II derived molecules. 0-40 ml is cell culture supernatant applied to column followed by elution with citric acid. 
Elution peak of KS01-Fc is additionally shown zoomed in (inside the plot). Detection was at 280 nm wavelength. 
5.5.3. Melting Curves of Binding Molecules 
For determination of thermal stability of recombinant expressed vNAR and Fc fusion proteins melting 
curve analysis was performed (4.1.2). Melting curves are shown in figure 32. The fusion protein 
KV07-Fc denatured at 59 °C and displayed higher stability compared to K07 lacking Fc (51.5 °C). 
The thermal stability of vNAR molecules covers a broad range. Thus, K07 and K13 melted around 
51 °C, while K10 and KHC01 revealed a melting temperature above 60 °C. Variant K14 displayed a 
melting temperature of 74.5 °C, although background noise is relatively high for this sample. 
Nevertheless all molecules displayed thermal stability clearly above physiological temperature of 
humans of 36 °C. Additionally all molecules showed signal occurring through binding of SYPRO-
Orange to hydrophobic patches. That means hydrophobic patches were exposed to solvent by 
increasing temperature, indicating that these were previously buried in a protein fold. 
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Figure 32 Melting curve analysis of recombinant expressed vNAR molecules and KV07-Fc using SYPRO-Orange. Melting 
temperatures were measured in duplicates and melting point values are indicated in the plots. 
5.5.4. Influence on Activity of Soluble HTRA1 Binding vNAR Molecules 
For the investigation, whether isolated vNAR molecules binding to HTRA1 cd-mono3 monomeric 
fraction modulate activity of HTRA1 variants, an activity measurement in presence of isolated 
molecules was carried out. To this end, activity of HTRA1 cd-mono3 monomeric fraction and 
HTRA1 cd (trimeric fraction) was measured in presence of vNAR molecules. As negative control an 
unrelated vNAR molecule isolated for binding target EpCAM272 was used. Conditions were the same as 
for determination of activity of HTRA1 variants described in section 5.1.5 of this work (0.625 µM 
protease; 12.6 µM substrate). Concentration of vNAR molecules was 14 µM. 
The plots of activity measurement for vNAR molecules are shown in figure 33. No influence on activity 
of HTRA1 cd (trimeric fraction) was observed in presence of K10, K13 and negative control (EpCAM 
vNAR) compared to absence of vNAR. For K14 a slight acceleration in substrate conversion was 
observed compared to controls. For K07, the clone with highest KD of 24.5 µM of all isolated vNAR 
variants, acceleration of substrate conversion was significantly higher compared to EpCAM vNAR. 
Interestingly KHC01 with a KD of 53 nM that shares CDR3 with K07 showed most enhanced 
acceleration of H2Opt-K conversion. The 500-fold lower KD of KHC01 seems to correlate with stronger 
effect on protease activity. 
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Figure 33 Activity measurement of HTRA1 cd (Trimer) in addition with HTRA1 cd-mono3 binding vNAR variants. Concentration 
of vNAR variants was adjusted to 14 µM. Cleavage of fluorescence quenched substrate H2Opt-K over time in duplicates. 
For HTRA1 cd-mono3 (monomeric fraction) no influence on activity of vNAR variants was observed 
(results not shown). As for determination of activity of different HTRA1 variants and their gel filtration 
fractions no activity modulation of H2Opt-K cleavage was measured. Thus the activating effect of K07, 
K14 and KHC01 observed on HTRA1 cd trimeric fraction was not observed for the less active variant 
HTRA1 cd-mono3 (monomeric fraction). 
For better comparison of activating or inhibiting effects all isolated and recombinantly expressed 
molecules were analyzed for initial velocity (v0) of substrate cleavage. Initial velocity was calculated 
from slope of linear increase of substrate conversion by HTRA1 cd (trimeric fraction) in presence of 
different molecules as well as in absence. Measurement was in duplicates and standard deviation is 
indicated by bars. Value of HTRA1 cd trimeric fraction was set to 100 percent. The bar graph 
summarizing the initial velocities is shown in figure 34. 
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Figure 34 Activity of HTRA1 cd (Trimer) in presence of recombinant vNAR and Fc Fusion proteins of isolated vNAR, VHH and 
ocMcoTI-II derived molecules. V0 was measured in double determination by cleavage of fluorescence quenched substrate 
H2Opt-K over time. 
The results underline observations from activity measurements described above. K10 and K13 showed 
no shift in v0 compared to HTRA1 cd or the presence of EpCAM vNAR. Values are comparable by 
considering standard deviation. K14 showed slightly enhanced v0 (150 %). Likewise, observations for 
KHC01 and its parental molecule K07 were confirmed. K07 has almost double v0 compared to negative 
control with an acceptable standard deviation. KHC01 has a v0 of nearly 400 %. Although error is not 
small data underline clearly that KHC01 has strongest activating effect of all isolated and 
recombinantly expressed molecules. 
Additionally VHH and McoTI-II based molecules were compared with respect to their initial velocity. 
KV07-Fc and KS01-Fc seem to show slight activation compared with HTRA1 cd without addition of a 
molecule. Although showing only small standard deviation the negative control which was only Fc part 
is in the same range of v0. In conclusion no activation is mediated by isolated molecules KV07-Fc and 
KS01-Fc. 
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6. Discussion 
6.1. Expression and Characterization of Different HTRA1 Variants 
To reach the goal of isolating HTRA1 modulators/inhibitors, several characteristics of the protease 
have to be taken into consideration when performing evolutionary protein design. In a search for 
HTRA1 binders, the multi domain organization of HTRA1 enhances the likeliness for isolating 
molecules that do not bind the catalytic site but bind somewhere else. Additionally, multiple domains 
are more difficult in expression and handling. Fortunately a published method exists for expression of 
the HTRA1 catalytic domain and the catalytic domain in combination with a PDZ domain31. Moreover, 
presence of proteolytic activity could have an adverse effect, for example by auto-degradation or 
degradation of the effector peptidic molecule.  
Further problems could be caused by the unpredictable oligomeric states of the protease, as it 
appeared as a major problem when starting this work. This lead to the concept of designing the target 
molecule in a more suitable format for the subsequent screening for binders and modulators of enzyme 
function. To this end, the human HTRA1 catalytic domain with and without addition of PDZ domain 
was expressed. The combination of both domains was chosen because it was shown that the PDZ 
domain has an influence on length of the proteolytic cleavage product while having no effect on 
activity57. Nevertheless this domain seems to be involved in substrate processing. Additionally it 
remains unclear whether the PDZ domain of HTRA1 is involved in higher oligomer formation as it is 
assumed for the E. coli homologue DegP23, 314. It was shown that HTRA1 activity can be deleted by 
mutating the active-site serine of the catalytic triad into an alanine31, 315. Nevertheless, the catalytic 
triad of all expressed variants in this work was kept intact. This was done since one initial objective of 
this work was the isolation of molecules that reduce or fully block enzyme activity. If residues were 
exchanged in the active-site of HTRA1, the chance to find competitive inhibitors would be reduced 
drastically. 
The HTRA proteases are known to exist in various conformational states that relate to different 
enzyme activities. The residues of the catalytic triad of HTRA proteases are flexible in their orientation, 
resulting from localization on loops in the protease scaffold which have a high structural flexibility. 
There are four loops of HTRA1 that have been shown to change conformation when switching from 
the inactive into the active state. Thus, there are many epitopes conceivable that would have an effect 
on orientation of the catalytic triad with the consequence of retaining the active or inactive protease 
conformation31. 
Another unsolved problem for the experimental design was the presence of different oligomeric states 
of human HTRA1. A mixture of oligomeric states of various size, assembly and activity would lead to 
an unpredictable molar ratio of target to modulator, but more severe is the unpredictable accessibility 
for designed binding molecules to potential epitopes that may be surface exposed or not, depending on 
the oligomeric state. 
Although no data is available on how higher oligomeric states are assembled, the crystal structures of 
HTRA1 provided clues that three key amino acid residues located in the catalytic domain are 
responsible for trimer formation31. This lead to the idea of generating a HTRA1 catalytic domain 
mutant, that does not assemble into trimers and possibly also not into higher oligomers. Two different 
variants were generated in this work by site-directed mutagenesis. For the first variant, HTRA1 
cd-mono2, only two of the three key residues were replaced by alanine (Y169A, F171A), while the 
second variant HTRA1 cd-mono3 carried a third substitution (F278A). 
All wild-type derived and the two generated HTRA1 variants showed good expression levels in E. coli. 
In the second purification step by SEC, different oligomeric states were observed and the 
corresponding protein fractions were collected separately. Fractions containing HTRA1 variants were 
verified by SDS-PAGE. Oligomeric states were derived from the molecular weight (MW) that correlates 
with the elution volume of the fractioned molecules and the calibration proteins. For the two variants 
with native catalytic domain only trimeric and higher oligomeric states were detected. According to the 
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calibrator proteins, the higher oligomers displayed a molecular weight above 600,000. For the two 
genetically engineered variants a third fraction was isolated by SEC. This additional fraction eluted at a 
volume corresponding to the size of a monomer with a molecular weight of 25,000. This fraction made 
up the largest amount for both mutated variants. 
Although the monomeric state was successfully induced by mutations, trimeric and higher oligomeric 
states were still present. Thus, the introduced mutations did not completely prevent trimer formation, 
but shifted the equilibrium of monomeric versus oligomeric states towards the monomeric state. 
Monomeric HTRA1 was neither present in a preparation of the native HTRA1 catalytic domain, nor in 
a construct carrying the catalytic domain and the PDZ domain. Additionally, the ratio of monomeric 
state compared to oligomeric states was enhanced by the third mutation introduced in HTRA1 
cd-mono3, which emphasizes the role of the three selected residues for trimer formation. Nevertheless, 
the monomeric variants still assemble to some extent into a higher oligomer, while trimeric states are 
almost but not completely absent for both variants. Thereby the ratio of higher oligomer and monomer 
is comparable to the ratio of higher oligomer and trimer of the non-engineered variants. Thus, the loss 
of trimerization by introduction of mutations has no influence on higher oligomer formation. 
Unfortunately, due to the residual presence of trimers it remains unclear, whether high molecular 
oligomers assemble from HTRA1 trimers or monomers. 
Moreover, the collected data from size-exclusion chromatography provide no clue, whether the higher 
oligomeric state consists of a single ordered form of an oligomeric assembly or of a mixture of various 
oligomers differing in a number of monomers and assembly. It is unlikely that the truncated HTRA1 
version used in this work forms cage-like structures as observed for E. coli DegP, since these are formed 
by PDZ domain contacts, which are absent in all examined variants except one57, 316. 
Another point that is crucial for engineering HTRA1 variants as target for isolation of modulators of 
HTRA1 activity is the stability and inter-convertability of isolated monomeric/oligomeric states, 
particularly of the monomeric fraction that should serve as target for screening. Because oligomers are 
associated non-covalently, different fractions of the mutant variants associated with different 
oligomeric states could inter-convert due to thermodynamic equilibration. In this work, it was found 
that the equilibrium was shifted to the monomeric state by introduction of mutations to HTRA1 
cd-mono2 and cd-mono3. To investigate whether oligomers are stable or inter-convert, the single 
fractions were kept at 8 °C for 7 days. The low temperature was chosen to prevent auto-degradation. 
Afterwards the fractions were applied to an analytical SEC. Results showed that for all four variants 
the higher oligomeric state is stable under the mentioned conditions. No formation of trimeric or 
monomeric state was observed. Likewise, the monomers showed no equilibration towards oligomer 
formation. Only trimers of mutated variants showed a slight equilibration into monomeric, but not into 
a higher oligomeric state. This can be explained by the exchange of the residues playing a key role in 
trimerization. 
For trimeric states of protease variants HTRA1 cd and HTRA1 cd+PDZ a tail after the elution peak in 
analytical SEC for evaluation of stability of oligomeric states was detected. Since it was not a distinct 
peak and therefore did not correspond to a molecule of distinct molecular weight, which was also 
supported by PAGE (results not shown), it probably indicates auto-degradation products. This is 
further supported by the absence of this tail after the elution peak in the analytical SEC of both 
trimeric fractions of monomeric variants that have been shown to be substantial less active in 
proteolytic cleavage of a fluorescent substrate. Impurities as source of the observed tail after the 
elution peak can be excluded, because the trimeric fractions were previously isolated by preparative 
SEC and showed no impurities in the PAGE. Thus, the smaller fractions in analytical SEC should be 
proteolytic products that have been cleaved by the purified trimeric protease upon 7 days storage at 
8 °C with itself as the only present substrate. Intrestingly, only the trimeric fractions of variants with 
native protease sequence display autoproteolytic activity. Although higher oligomers also showed 
proteolytic activity in general, our findings indicate resistance to auto-cleavage which is either caused 
by altered substrate specificity of both oligomeric states or by altered accessibility of recognition sites 
for cleavage of higher oligomeric states.  
   75 
Another interesting observation was made for trimeric fraction of HTRA1 cd-mono2 and HTRA1 
cd-mono3. Both variants showed in analytical SEC equilibration of the trimeric state with the 
monomeric state, but not vice versa. Moreover, the higher oligomeric states revealed no inter-
conversion with the trimeric state or the monomeric state of both mutant variants. Presently, there is 
no data availaible, whether in its natural environment the trimeric or higher oligomeric state of HTRA1 
is predominant, or whether an altered equilibrium between both oligomeric states is a mechanism for 
tuning the proteolytic activity of HTRA1 under physiological conditions. 
Thermal stability measured by evaluation of melting points of expressed variants and their isolated 
fractions showed that all expressed variants are most likely folded having thermal transition upon heat 
denaturation that is typical for folded proteins. For detailed comparison of isolated fractions of HTRA1 
cd-mono3 that were separated by SEC, it is obvious that trimeric and higher oligomeric fractions share 
a melting point (Tm) above 60 °C. In contrast, the Tm of the monomeric fraction is reduced to 54.5 °C. 
This is confirmed by the Tm of HTRA1 cd-mono2 monomeric fraction with a value of 51.5 °C. The 
melting points of HTRA1 cd and of HTRA1 cd+PDZ trimeric fractions are in the same range as the 
trimeric and higher oligomeric fractions of HTRA1 cd-mono3 with values around 60 °C. These data 
indicate clearly a loss of stability in monomers, but not in trimers and higher oligomers by substitution 
of residues that are important for HTRA1 trimer formation. Possibly the effect of amino acid exchanges 
on the fold of the catalytic domain is compensated by stabilizing effects of higher oligomerization. 
Finally no multiple melting peaks were detected for all variants that were caused by stepwise 
conversion of higher oligomers into trimers or from trimers into monomers. 
Substrate recognition for the family of HTRA proteases is not well understood, besides that the 
mechanism is much more complicated compared to proteases like trypsin, where a single amino acid 
functional group is sufficient for cleavage behind this residue. For HTRA proteases plenty of natural 
and artificial peptidic and protein substrates are described, but no consensus recognition sequence 
could be deduced44, 46-52, 317. Comparison of peptide sequences that are cleaved by HTRA1 provided no 
indication of a prefered recognition motif and cleavage site31. It was investigated in this work whether 
isolated fractions of all variants display proteolytic activity towards fluorescence quenched peptide 
substrate H2Opt-K. Interestingly, for higher oligomeric fractions activity was detected, but for trimeric 
fractions only the variants with native protease sequence revealed activity under comparable substrate 
and protease concentrations. In contrast, the trimeric fraction of HTRA1 cd-mono3 was only active 
compared to trimeric variants with the native protease domain when substrate concentration was 
increased 5-fold. This tendency was consequently observed for the monomeric fractions which were 
only found for mutant variants. For these fractions the protease concentration had to be increased 
additionally to substrate concentration by 15-fold for comparable substrate conversion. 
There is a clear tendency for the three different states, that the higher the oligomeric state, the higher  
the activity. This was demonstrated for all variants. Moreover, it was published that activity as well as 
the formation of higher oligomers increased 2.8-fold when HTRA1 was incubated with citrate-
synthase31. A chromogenic substrate (DPMFKLV-pNA) was deduced for DegP from a peptide derived 
from citrate-synthase318 that is also cleaved by human HTRA1, but is less sensitive for activity 
measurements compared to H2Opt-K (data not shown). Truebestein et al. concluded that citrate 
synthase causes protease activation of human HTRA1 by stabilizing a higher oligomeric state31, but it is 
uncertain whether it acts only as ligand or also as substrate. 
It was shown that a monomeric variant that was generated by a single mutation of the HTRA family 
member HTRA2 is proteolytic inactive319. This finding correlates with our results of strongly reduced 
activity for mutant variants and their monomeric fractions, respectively. Even the decreased proteolytic 
activity of trimers fits to this observation, in consideration that analytical SEC of trimeric fractions of 
mutant variants revealed a shift from trimeric into monomeric state. Taken together, these findings 
provide clues for the generation of modulators of HTRA1 activity, for example by preventing or 
enhancing higher oligomerization, as well as triggering the disassembly of trimers or hampering the 
assembly of monomers by interfering with regions involved in oligomeric interactions. This would 
introduce additional modes of modulation compared to inhibitors targeting the active site, or allosteric 
   76 
activators and inhibitors addressing the orientation of the active-site of a monomer, as described 
previously. 
A reversible activation mechanism of HTRA1 protease is currently discussed in the literature based on 
substrate induced-fit or conformational selection of protease towards the substrate30, 31. While in the 
induced-fit model320, 321 the substrate is part of the mechanism that switches an enzyme into the active 
conformation, in the conformational selection model320, 321 the enzyme just equilibrates between the 
active or inactive conformation, whereas the substrate is only bound and processed by the active 
conformation. As a consequence in the induced-fit model mainly the substrate is the driving force for 
switching human HTRA1 in the active conformation, depending on how efficient it re-orientates the 
active-site. In contrast, the conformational selection model depends strongly on the equilibrium of the 
enzyme , because only the active conformation will process a substrate to a 
product upon binding. Nevertheless, both models depend on the environmental conditions as well as 
on the affinity towards a specific substrate. 
Interestingly, for the induced-fit mechanism suggested by Truebestein et al. an allosteric activation is 
suggested to be absent, because the formation of a proteolytic active conformation of the activation 
domain is directly induced by substrate binding in the active site31. This is different compared to the 
well examined HTRA1 family members DegP and DegS, which were shown to be activated by a variety 
of allosteric ligands26, 58, 322, 323. Thus a totally new mode of activation of catalytic triad in human 
HTRA1 is supposed by Truebestein et al., although they expect additional regulatory mechanisms. The 
induced-fit mechanism cannot explain the observation of allosteric HTRA1 activation by 
protoporphyrins324 as well as the irreversible inhibition by diisopropyl fluorophosphate30, which only 
attacks a serine of a catalytic triad in the active orientation. These findings and additional structural 
observations by Eigenbrodt et al. suggested a conformational selection mechanism with one or more 
inactive conformations which equilibrate with an active conformation, separated by an energy 
barrier30. The assumption of a conformational selection mechanism correlates with our result that the 
trimeric fraction of HTRA1 cd-mono3 shows increased activity compared to the monomeric fraction. 
Moreover, the higher oligomeric fraction displays further increased activity compared to the trimeric 
fraction of HTRA1 cd-mono3. This is also the case for HTRA1 cd and corroborated by findings made by 
Truebestein et al.31. Thus, it could be supposed that the higher an oligomeric state of HTRA1, the lower 
is the conformational flexibility, because the oligomers that are connected by the protease domain may 
reduce the range of different structural orientations. This assumption supports a conformational 
selection model with one active and various inactive conformations and correlates well with the 
general model that higher oligmerization of trimeric HTRA1 is a physiological activation mechanism of 
proteolytic activity31, 324. This regulation mechanism by altered oligomerization was first described for 
DegP the E. coli homologue of HTRA158, 325, 326. However, there are striking differences between DegP 
and HTRA1 in oligomer formation since in contrast to DegP for HTRA1 the PDZ domain is not required 
for higher oligomer formation31, 55, 57, 323, 325, 326. Nevertheless, mechanisms that are a mixture of induced-
fit and conformational selection models are in general conceivable320. 
For the E. coli homologue of HTRA1 DegP, additionally a cooperative effect in catalysis is suggested 23, 
55. Herein, when one subunit binds a substrate, it triggers a structural change in the neighboring 
subunit that switches it into the active conformation. If this is also applicable to human HTRA1, its 
activation mechanism fits better to the conformational selection than to the induced-fit model, because 
the protease neighboring catalytic domain is turned to an active state without presence of substrate at 
its active-site. Furthermore, presence of a cooperative effect in human HTRA1 would be an explanation 
for the observation of Truebestein31, as well as of our results, that the activity of native protease 
domain is increased by formation of higher oligomers compared to trimers. Additionally, the strongly 
reduced activity of the monomeric fraction of the monomeric variant support a cooperative effect, due 
to the missing activation of the neighboring catalytic domains present in a trimer or higher oligomer.  
In summary, the important outcome for the further work of the generation of mutant variants and 
their characterizations is that the successfully expressed and purified monomeric fraction of the 
monomeric variants is stable as individual molecule species without being arranged in a trimer. This 
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was shown by the successful expression with passing the quality control mechanisms of the expression 
host, the continuous stability of the particular oligomeric states, the thermal stability and the residual 
activity, that was measured at high substrate and protease concentrations. Moreover, the monomeric 
and both oligomeric states of all analyzed variants are mostly stable and do not equilibrate into 
another. Interestingly, the purified monomeric and trimeric states of HTRA1 cd-mono2 and HTRA1 
cd-mono3 showed significantly decreased activity compared to the purified trimeric fractions and 
oligomeric states of HTRA1 cd and HTRA1 cd+PDZ. The previously discussed results of this work and 
other groups outline four potential modes of HTRA1 activity modulation by engineered molecules that 
bind monomeric HTRA1, such as preventing or enhancing higher oligomerization, dissociation of 
oligomers into monomers, inhibitors targeting the active site, as well as allosteric activators and 
inhibitors addressing the orientation of the active-site of a single HTRA1 monomer. 
However it remains unclear how human HTRA1 monomers are arranged in higher oligomeric states, 
how formation of different oligomeric states is triggered and how the different oligomeric states 
contribute to regulation of protease activity. 
6.2. Isolation and Characterization of HTRA1 Binding Molecules from a VHH Library 
Besides the classical scaffolds used for selection of binding molecules that were derived from the 
mammal immune system such as IgG antibodies or more recent camelid single chain antibodies, there 
is large interest for finding alternative scaffolds for therapeutics and diagnostic applications. Along that 
line, vNAR molecules derived from shark single chain antibodies together with the open chain variant 
of squash trypsin inhibitor McoTI-II were used as scaffold for the design and screening of 
combinatorial libraries129, 272, 311. 
The best understood scaffold molecule employed in this work was the camelid-derived binding unit of 
a single chain antibody, the so called VHH molecule that was engineered in a classical way by 
immunization of a llama193, 211. The library constructed for yeast surface display technology cloned from 
the B-cell repertoire after immunization with catalytic domain of HTRA1 delivered no VHHs binding 
HTRA1 cd (data not shown). Problems were accredited to the target molecule because ELISA of serum 
that also contains classical antibodies against HTRA1 cd showed successful immunization. Additionally 
it was shown that VHHs against other targets that were combined for the immunization of a single 
animal were successfully isolated from the same library 309. Therefore isolation of VHH molecules was 
repeated by changing the target to the monomeric state of the engineered variant HTRA1 cd-mono3. 
This delivered two independent clones after five rounds of enrichment. Occurrence of both clones was 
four and six, respectively, out of ten sequenced clones. KV01 that was found six times revealed a 
longer CDR3 with 12 residues compared with KV07 that has only seven residues. However CDR1 and 
CDR2 had the same length. Furthermore, many different framework mutations are present that 
demonstrate the distant lineage of both clones which underlines the complexity of the library. 
Nevertheless, only two different molecules were isolated. The immunization with the native protease 
domain could be one reason for the low variety of clones, because screening was performed with 
HTRA1 cd-mono3 with three substituted residues. But also library generation and immunization with 
multiple targets could influence the content and quality of HTRA1 binding molecules in the library, as 
well as stringency of HTRA1 binding during screening. 
The ELISA of Fc-fused KV07 revealed only binding to HTRA1 cd-mono3, but not to the variant used for 
immunization. Evaluation of the post-immune serum towards HTRA1 cd-mono3 would give interesting 
insights in the distribution of the library of matured VHH candidates binding native or mutant variant. 
Eventually the peptides generated by the immune system for maturation of KV07 VHH in vivo 
represent epitopes that are buried in an HTRA1 oligomer. 
KV07 had no effect on HTRA1 cd activity. Additionally no activating effect was observed on HTRA1 
cd-mono3 under applied conditions. Nevertheless measurement with elevated substrate and protease 
concentrations for HTRA1 cd-mono3 were not performed. Unfortunately, KV01 was not expressed in 
sufficient amounts to investigate, whether this molecule is binding both targets or has an effect on the 
protease with native or mutant sequence, respectively. Furthermore KV01 has a 5-fold lower KD 
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towards HTRA1 cd-mono3 compared with KV07. This and its different CDR sequences indicate that 
KV01 and KV07 address different epitopes of HTRA1. Hence, it might be worth to further optimize 
conditions for expression of KV01 to obtain sufficient protein amounts for further evaluation 
6.3. Isolation and Characterization of HTRA1 Binding Molecules from McoTI-II Library 
The squash trypsin inhibitor library based on open chain variant of McoTI-II delivered only one single 
binding molecule against HTRA1 cd-mono3, KS01. This scaffold was chosen due to its natural function 
which is protruding into the active-site of serine proteases such as trypsin or matriptase-1129. Variants 
binding and inhibiting other serine proteases were generated either by rational or evolutionary design 
methods129, 327. However these variants share common sequence features not observed in KS01. 
Furthermore loop 1 of KS01 that is mainly involved in inhibition of serine proteases has a totally 
different sequence compared with reported variants. Here large aromatic amino acids are 
predominant, in detail four of six. Interestingly the position 1 is changed from proline to phenylalanine 
although this position is suggested to be important for formation of the canonical inhibitor loop 
conformation21, 22. 
The isolated variant KS01 revealed a KD value of 650 nM by affinity titration on the yeast surface. The 
100-fold lower KDs reported for McoTI-II derived protease inhibitors are due to the specific mechanism 
of competitive inhibition. Interestingly monoclonal antibodies with six much longer CDRs that are 
mediating target binding have comparable KD values
328, 329. Especially the later discussed results of the 
affinity maturation of a vNAR library demonstrate the power of the selected McoTI-II derived 
molecule, because vNARs prior to maturation show at least 10-fold higher KDs against HTRA1 
cd-mono3. Even if antibodies mediate their binding by up to six independent segments there are 
examples where single domains or even single loops are powerful enough for affinities in the low 
nanomolar range129, 272, 330-332. 
Miniprotein KS01 was synthesized by solid-phase peptide synthesis. Establishing the three disulfides in 
this short sequence is difficult to apply300. Nevertheless after in vitro folding it was shown that three 
cystines were formed (data not shown), while having no information whether the disulfide bond 
connectivity 1-4, 2-5 and 3-6 prevails. Unfortunately solubility was very poor for further evaluation 
which made the recombinant expression as Fc fusion protein necessary. Analysis of the Fc fusion of 
KS01 showed specific binding of HTRA1 cd-mono3, but no binding of HTRA1 cd, similar as it was 
observed for VHH candidate KV07. This result was confirmed by yeast cells presenting KS01 on their 
surface when being labeled with the different HTRA1 variants. Only labeling with HTRA1 cd-mono3 
displayed an increase in fluorescence intensity compared to the unlabeled cells. Furthermore, no effect 
was measured on HTRA1 cd activity and HTRA1 cd-mono3, respectively. These findings are 
comparable with those for VHH molecule KV07. Similar to the VHH library, isolation of miniproteins 
binding HTRA1 cd trimeric fraction remained unsuccessful. Nevertheless the finding that no McoTI-II 
variants were obtained that bound the native protease domain is not as surprising as for VHH library 
which was immunized with HTRA1 cd. Despite the fact that the difference of both targets is only 
comprised by three amino acid residues the chance for selection of molecules binding both should be 
equally high. 
A major problem of addressing HTRA1 is that a substrate, as well as various allosteric ligands could 
turn the trimeric oligomeric state into a higher oligomeric state, as discussed in section 6.1. Thus, a 
majority of epitopes that could be targeted by the library in the monomeric fraction of HTRA1 
cd-mono3 could be inaccessible in a higher oligomer of unknown composition. But even in a trimer 
epitopes are buried that were accessible in a monomer. Nevertheless, the major competence of a 
miniprotein binding molecule is the extremely small size which allows protruding into niches and 
small pores of proteins and therefore may be advanatageous over the VHH scaffold to access recessed 
epitopes. 
It will be worth repeating the screening of the library, because it is technically difficult to sample the 
complete set of variants of the library, due to its large size and the limitations of fluorescence activated 
cell sorting (FACS). Here switching the target from monomeric to trimeric fraction from round to 
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round could result in molecules binding both variants. Furthermore candidates could be isolated that 
have an influence on HTRA1 activity. 
6.4. Isolation and Characterization of HTRA1 Binding Molecules from vNAR Library and the 
Matured Sub-Libraries 
The library derived from a shark santibody domain named vNAR combined two features. It carries the 
naïve repertoire of a cohort of three bamboo sharks and a synthetically randomized CDR3. This has the 
benefit of different framework mutations residing in the scaffold that may contribute to scaffold 
stabilizing effects in combination with rational biased randomization of a special binding region 
(CDR3). Although the large library size covers not the whole theoretical sequence variety, multiple 
binding molecules against HTRA1 cd-mono3 were isolated. After four rounds of enrichment thirteen of 
fifteen clones showed HTRA1 cd-mono3 binding, while six individual clones were obtained. In contrast 
to the isolated clones of VHH and McoTI-II based library screening, five analyzed clones displayed 
binding of HTRA1 cd and HTRA1 cd+PDZ with native protease domain, as well as an additional PDZ 
domain. This result could raise the expectation that also native HTRA1 is addressed by these 
molecules. 
One clone was found five times, three clones twice and two clones only one times. Interestingly, K10 
that was found five times did not show the lowest KD but the second highest with 8 µM. The isolated 
clones in general have a KD value in the micromolar range, ranging from 1.25 µM for K03 up to 
24.4 µM for K07. The KD values determined by affinity titration in general suit well with the KD values 
determined for the identical soluble molecules as reported by Wittrup et al333, 334. Furthermore CDR3 
sequences of the analyzed molecules revealed no consensus sequence suggesting that they all address 
different epitopes. This fueled expectations that at least one candidate should have an effect on HTRA1 
activity. Moreover sequences of HV2 were identical in all clones and CDR1 only contains slight 
variations from third to fifth position. The isolated clones also revealed differences in the framework 
on eight positions. Combining the results of similar sequences of binding segments with the naïve 
framework variety it is conceivable that CDR1 and HV2 are only recruited by the affinity maturation 
domain antibodies seem to mediate binding only by CDR3. This observation matches with the 
sequence analyses of non-immunized bamboo shark which was done before library construction272, 311. 
The eight positions with observed framework variations reveal the desired variety of pooled starting 
material for construction of the library that reflects the naïve repertoire of framework variations of the 
bamboo shark. It is still uncertain whether these mutations are necessary for maintaining the vNAR-
fold in combination with different HV and CDR sequences or whether they just appeared in the 
directed evolution experiment by coincidence. 
The affinity maturation of isolated CDR3 clones by recruiting HV2 or CDR1, respectively, delivered five 
different HV2 as well as five different CDR1 clones of five analyzed clones each. Four clones of each 
matured sub-library showed HTRA1 cd-mono3 binding. Interestingly all clones of HV2 maturation and 
three clones of CDR1 maturation share CDR3 of K07 which showed the highest KD value with 24.5 µM 
in the initial enrichment approach. Under consideration that target concentration in the first round of 
maturation was 100 nM it is distinctly obvious that the additional binding region contributes to 
affinity. It is very unlikely that binding is only mediated by the newly recruited binding segment HV2 
or CDR1 because libraries were quite small, only two rounds for selection were performed and only 
five residues were involved in randomization. Further it is currently unclear why the other CDR3 
sequences mediating higher affinities to HTRA1 did not give rise to variants with enhanced affinity 
upon maturation. Several reasons such as biased amplification by PCR for sub-library construction, 
clone dependent differences in cell doubling times upon growth or instabilities in folding for example 
could account for this finding. The sequences of HV2 revealed no conserved positions in view of 
functionality of the amino acid side chains although they may face a related epitope due to the same 
CDR3 sequence. A similar observation is made for CDR1 sequences. Structure analysis revealed that 
CDR1 is facing in most vNAR isoforms in the same direction as CDR3, while HV2 is facing more in an 
angle of 90° to the side311. A vNAR with bi-functionality introduced through HV2 emphasizes this 
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feature311. Interestingly, KD values of affinity improved variants from the HV2 sublibrary are 
comparable with clones matured in CDR1. 
The KD values determined by affinity titration on the yeast surface ranged from 0.47 µM to 2.80 µM for 
HV2 matured clones and from 0.29 µM to 3.22 µM for CDR1 matured clones. Compared with parental 
K07 the affinity was increased about 10 to 100-fold. This result demonstrates the effect on affinity by 
recruiting an extra region that mediates interactions with the target. The KD determined for KC03 that 
has K14 as origin is in the triple-digit nanomolar range between that of KC02 and KC05. Unfortunately 
there was no KD determined for parental K14. Only one of the HV2 matured clones, but three of the 
CDR1 matured clones showed KD values in the nanomolar range, while the others showed KD values in 
the micromolar range. This result confirm the notion of the structure analysis described above, that 
CDR1 is facing more in direction of the target compared to HV2 and therefore may be better suited to 
support CD3-mediated target binding. Here again evaluation of more clones would lead to a 
statistically better understanding of this assumption. 
To bring matters to a head, clones that were previously matured in HV2 were followed by maturation 
of CDR1. Implementation of this was easy by using the same strategy as for CDR1 maturation of initial 
isolated CDR3 clones. The library constructed from mixture of clones enriched in the first round of 
HV2 maturation was used as starting point for receiving high diversity despite the small size of the 
HV2 sub-library. Size of generated vNAR CDR1-HV2-CDR3 library was 200-fold larger with 107 
independent clones compared with the HV2 sub-librariy of the first maturation step. Ten of twelve 
analyzed clones showed HTRA1 cd-mono3 binding and shared CDR3 sequence with K07. This is not 
surprising due to the fact that almost 90 % of clones from first maturation attempts contained this 
sequence. Only two clones appeared twice, namely KHC04 and KHC05, while the other eight clones 
were individual at least in CDR1. Different from the first maturation approach conserved positions in 
CDR1 emerged. A tyrosine on position five appeared in five clones and large aliphatic amino acids in 
two clones of the nine individual sequences. In position four also large aliphatic sidechains are 
prominent in five clones and aromatic side chains in three clones. For positions one to three no 
preference for side chains could be detected. 
In HV2 of isolated double matured clones no sequences of the initial affinity maturation attempt of 
HV2 were detected. HV2 sequence of clones KHC04, KHC06, and KHC07 were identical and contained 
a glutamine in position one and five, while CDR1 sequences of these clones were independent. 
Interestingly, also clone KH01 from the previous HV2 maturation carried a glutamine in position one 
and five in HV2. This clone showed the lowest KD value in HV2 maturation with 469 nM, while the 
other clones of this maturation attempt showed KD values in the micromolar range. According to this 
finding, these residues seem to be important in HTRA1 cd-mono3 binding in combination with CDR3 
of K07. Besides the HV2 sequences of KHC04, KHC06, and KHC07, the remaining isolated clones were 
individual. In the HV2 sequences of clones KHC01, KHC02, and KHC08 also a glutamine was present 
in position five, additionally emphasizing the importance of a glutamine in this position. In position 
four, a proline emerged in the four independent clones KHC01, KHC02, KHC03, and KHC11. Thus, 
positions one, four and five seem to be involved in target binding in combination with CDR3 of 
parental clone K07. The absence of HV2 sequences found upon HV2 affinity maturation in the clones 
obtained by the following maturation by CDR1 variation could have several reasons. An explanation 
could be cooperative effects of HV2 and CDR1 in the tertiary structure of the folded vNAR, whereby 
one segment is involved in binding while the other segment is responsible for the orientation of the 
residues of the first one. Thus, not all three designed regions have to be involved directly in increased 
affinity, but could also act indirectly by improving molecular interactions between epitope and 
paratope. 
It is important to note that the engineered regions of the isolated molecules share no motifs with the 
recognition sequences of known native or synthetic substrate335, 336. The presence of HTRA1 substrate 
recognition sequences in the isolated molecules would raise expectations for candidates that directly 
interact with the active site, like canonical inhibitors337. If these sequences were recognized, but not 
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proteolytically degraded, they could competitive block the active site as shown for cystine knot 
miniproteins for example338. 
The seven unique isolated clones of the second maturation attempt that were titrated revealed KD 
values in the double digit nanomolar range. Here again an additional increase in affinity of the factor 
10-100 was measured compared to the KD values of analyzed clones after initial maturation of HV2 or 
CDR1. In general molecules isolated from synthetic or naïve libraries are often in the micromolar 
range339, 340. The engineering of affinity by the applied method enables transformation of candidates 
fulfilling a biological task into molecules with affinities being in the low nanomolar range that would 
be required for therapeutic applications103. 
Interestingly, the high occurence of a tyrosine in position five found in the initial affinity maturation 
step of CDR1 was not confirmed upon CDR1 maturation of the CDR3-HV2 binders. Hence, it is not 
totally clear after the second maturation attempt, whether binding is mediated by an additional region 
resulting in interactions of all three recruited regions or just by CDR3 and CDR1. Even other 
combinations of segments involved in binding such as CDR3 and HV2, HV2 and CDR1 or only CDR1 
are theoretically possible that might have emerged upon screening for high affinity binders. To clarify 
this point grafting of nonbinding segments, an alanine scanning341, saturation transfer difference (STD) 
NMR342 or a co-crystal structure of an interesting candidate in combination with HTRA1 could be 
considered. The stepwise increase in affinity upon stepwise affinity maturation not necessarily 
indicates that an enhanced affinity is mediated by the interaction of a target epitope by three instead 
of two loops. For example, the increase in affinity could also be related to the larger library size used 
for the second maturation and additional rounds of enrichment compared to the first one. Likewise, 
the enhanced affinity could also be the result of avidity effects that may arise upon target interaction 
with two independent binding units addressing two distinct epitopes343. If one binding unit, for 
example that mediated by CDR3/CDR1 binding dissociates from the target the other one, e.g. 
mediated by HV2 might remain bound to another epitope prior to complete diffusion from the target. 
Nevertheless, it could be shown that each step of affinity maturation individually contributed to 
increased affinity. 
Zielonka et al. demonstrated that it is possible to generate bispecific vNAR molecules by screening a 
CDR1 matured single clone against EpCAM by an additional screening of randomized HV2 towards 
CD3ε and human Fcγ311, 312. Thus, HV2 could be used for different purposes such as increasing affinity 
as shown in this work, or for binding an additional target. 
Double determination of KD values as it was performed for the clones KHC04 and KHC05 which were 
identical clones reveals that affinity titration suits well for basic assertion of affinity, but not for a 
detailed ranking of isolated clones with similar affinities. For a more detailed comparison analysis of 
soluble molecules by surface plasmon resonance or bio-layer interferometry should provide more 
reliable data. 
Due to the high number of different sequences observed in CDR1 and HV2 after four screening rounds, 
an extra competitive koff screening was performed. By additional incubation with excess of unlabeled 
target after labeling with 10 nM fluorescently labeled HTRA1, clone KHC02 emerged as the only clone 
upon analysis of ten sequences. Unfortunately KHC02 showed low yeast surface presentation resulting 
in an unacceptable error in affinity titration. It should be emphasized that a low dissociation rate 
constant does not necessarily indicate a low KD since the association rate constant may also be 
compromised. Here again more detailed binding kinetics especially for kon and koff rates should be 
evaluated by surface plasmon resonance or bio-layer interferometry328. 
Comparison of clones isolated in this work with clones from the same library isolated against EpCAM 
or EphA2 showed that compared to the target HTRA1 initial CDR3 clones against EpCAM and EphA2 
revealed 10-fold lower KD values each
272. Nevertheless screening towards interleukin-8 delivered a 
vNAR in the same range as vNARs against HTRA1 cd-mono3. Additionally the affinity maturation of 
CDR1 delivered 100-fold lower KD values in only two rounds for EpCAM, but only less than 10-fold for 
interleukin-8. These results demonstrate the impact of different targets when isolating vNARs from a 
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master library. Nevertheless, the KD values of HTRA1 cd-mono3 binding vNARs decreased with the first 
step of affinity maturation affecting HV2 or CDR1 and the second step affecting CDR1 at least 10-fold 
for each approach. 
For HTRA1 the unpredictable oligomeric states were challenging and resulted in no enrichment of 
binding molecules over several initial attempts. Similar problems were reported by Ciferri et al. who 
tried isolation of HTRA1 inhibitors by phage display from a human Fab library against human full-
length HTRA1335. They overcame the problems by using a murine variant composed only of the 
catalytic domain comparable to HTRA1 cd used in this work. Unfortunately they did not specify 
whether they separated fractions of different oligomeric states and if yes, which one they used for 
screening. In this work the problem was overcome through engineering the target prior to screening 
binding molecules. By reviewing all selection experiments it becomes apparent that not the alternating 
change of labeling as it was performed for VHH library screening but the engineering of the target 
made the difference in successful isolation of binding molecules since screening for VHH or McoTI-II 
based binders against native protease was unsuccessful. Despite all these difficulties multiple binding 
molecules of different classes were isolated against monomeric variant of HTRA1. At least an effect on 
activity of native catalytic domain of HTRA1 was demonstrated for various vNAR molecules. Thus, 
engineering the oligomeric state of a target protein prior to screening for binding molecules could be a 
general strategy for difficult to address oligomeric targets. 
Although there was an anti HTRA1 antibody against the catalytic domain isolated by phage display335, 
the generation of HTRA1 monomer in our opinion was crucial for isolating binding molecules by yeast 
surface display. Using large oligomers as target protein bears a high risk of isolating low affinity 
binders due to avidity effects. Additionally in our first screening attempts HTRA1 oligomers were that 
large that they were detectable in FACS and it was nearly impossible to distinguish between yeast cells 
and protein particles by side-scatter analysis. Unfortunately it was technically impossible to involve the 
forward-scatter of the FACS in the sorting decision, which might help to detect and sort out only 
particles of the distinct characteristic of yeast cell. 
The most interesting question for binding molecules interacting with enzymes is whether they have an 
influence on enzyme activity. It was desirable in this project that the isolated molecules were not only 
able to bind native HTRA1, which was shown for multiple molecules, but also to affect the protease 
activity. To investigate, whether the isolated binders also act as modulators of enzyme activity several 
proteins were produced recombinantly. For vNAR molecules K07, K10, K13 and K14 sufficient proteins 
amounts were obtained after purification for further studies as for double matured clone KHC01. For 
the missing initial clones and the missing double matured clones expression conditions have to be 
optimized or they have to be formatted differently, for example as Fc-fusion proteins as previously 
described for VHH and McoTI-II derived molecules. The clones only matured in CDR1 or HV2, 
respectively, were not included in the functional examination because they share the CDR3 of initial 
clones or were less affine than double matured clones. 
Successfully expressed molecules showed thermal stability between 51°C and 75°C which is in the 
range of antibodies and adequate for application in mammals344. Clones K10 and K13 had no effect on 
HTRA1 activity, as well as the control vNAR that binds EpCAM. This led to the conclusion that both 
vNARs recognize epitopes not involved in substrate processing, substrate recognition or structural 
changes during switching from active to inactive conformation. Clone K14 had a slight activating effect 
on the trimeric protease by increasing activity by around 150 % compared to control vNAR. Moreover, 
activity was almost doubled in presence of clone K07, despite the fact that it showed the highest KD of 
all isolated molecules. The most prominent effect was observed in presence of KHC01 with around 
4-fold enhancement of activity compared with EpCAM binding vNAR serving as a control. This result 
was not unexpected, because K07 and KHC01 share the same CDR3 sequence so they most probably 
address the same epitope. Furthermore, the much higher affinity of KHC01 most likely leads to a 
higher activation due to its significantly enhanced affinity compared to K07. It will be interesting to 
investigate, whether the other single and double matured molecules containing CDR3 of K07 have a 
comparable effect on HTRA1. A more detailed evaluation of soluble expressed KC03, an affinity 
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matured derivative of the K14, a binder that was found to slightly enhance HTRA1 activity would also 
be of great interest. 
Currently, only a few molecules are reportedly HTRA1 activators. A number of protoporphyrins was 
shown to increase HTRA1 activity by triggering higher oligomerization324. The same mechanism for 
HTRA1 activation was reported for citrate synthase that additionally acted as a substrate31. 
Furthermore it was shown that activity of E. coli homologue DegP was enhanced in presence of 
different peptides26. Only for human HTRA1 family member HTRA3 a classical monoclonal antibody 
6G6 was published, that activated proteolytic activity336. It was shown that the antibody 
simultaneously binds to the PDZ domain and catalytic domain. The epitope recognized in the catalytic 
domain is supposedly located in the substrate sensor loop L3. Thus, a reorientation of PDZ domain was 
suggested to be the mechanism for activation. The PDZ domain is suggested to be bended to the 
opposite site of the catalytic domain of the disc shaped HTRA3 trimer. This observation is interesting 
because HTRA3 activity is independent of the PDZ domain, as it is for HTRA1336. The antibody 6G6 
increased relative activity of HTRA3 by about 130 % when 4 µg and by 140 % when 20 µg were 
applied. The isolated vNAR molecules in this work mediated an increase of relative activity of HTRA1 
in the range of 150 % to 400 % in a comparable concentration range. In this respect the isolated vNAR 
molecules K07, K14 and KHC01 are the first specifically isolated activators of HTRA1 activity that 
exclusively address the catalytic domain. Moreover, molecules K07 and KHC01 that most probably 
address the same epitope showed an affinity-dependent potency to act as activators. 
Activators of HTRA1 could be interesting candidates as therapeutics in cancers because it was shown 
that HTRA1 is downregulated in many different types of cancer18, 43, 46, 48, 49, 56, 59, 61, 62. Especially the 
combination of HTRA1 enhancers with chemotherapy could be attractive due to the fact that 
chemo-therapeutic success is highly reduced if HTRA1 is downregulated61. Such type of activators 
could become valuable tools to study the general involvement of the protease in formation and 
progression of cancers in cell culture or animal models. It will be interesting to investigate, whether 
the vNAR-derived activators generated in this work are active in a rat or mouse model since rodent 
HTRA1 catalytic domains are highly homolog to human HTRA1 with only a few amino acid exchanges. 
For therapeutic applications, the potential immunogenicity of the non-human vNAR domain would 
have to be taken into consideration. Nevertheless, methods for humanizing non-human derived 
candidates have been reported197. Moreover, computer-assisted prediction for vNAR molecules suggest 
low tendency for immunogenicity of vNARs in general266, 345. 
Another interesting field of application of HTRA1 activators would be in the context of treatment of 
Alzheimer  via enhancing the HTRA1-mediated cleavage of tau-protein77. Likewise, activation 
of HTRA1 could be used to study and better understand the influence and the involvement of HTRA1 
in other diseases like osteoarthritis (OA) or age-related macular degeneration (AMD) where it was 
shown that HTRA1 expression levels are elevated48, 56, 60. In animal disease models these activators 
could become useful compounds to elucidate, how the multimeric protease is involved in disease 
progression. This would also open new avenues for the investigation, whether HTRA1 contributes by 
its proteolytic activity or by other domains to the progression in these diseases, when a catalytic 
domain selective activator is used. In current animal models such as rat or dog, OA is often induced by 
surgical intervention, which is an unselective trigger346. Activation of HTRA1 that is suggested to be a 
potential elicitor of OA could provide a more native scenario for disease induction in an animal model. 
Interestingly only binders were found in this work that enhanced proteolytic activity, but unexpectedly 
no molecules that reduced HTRA1 activity were isolated. It is possible that such candidates exist in the 
vNAR library since only a relatively small subset of clones was evaluated for activity modulation. Their 
identification would require a high-throughput expression, purification and functional screening of 
hundreds of candidates, which was beyond the scope and possibilities of this project. An inhibitory Fab 
fragment (Fab94) was recently reported by Genentech335. For the isolation of Fab94 from a phage 
display library that was additionally formatted as IgG94 antibody, the murine catalytic domain was 
used as a target which shares 96 % homology with the catalytic domain of human HTRA1, because 
screening with human HTRA1 failed. This is in accordance with the problems in isolating molecules 
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against human HTRA1 cd in this work. The KD value of Fab94 was 48.1 nM against human HTRA1, 
while the IC50 value of Fab94 was 17.7 nM and of IgG94 1.58 nM for human HTRA1 catalytic domain. 
No significant difference in binding affinity and inhibition was observed between the catalytic domain 
and full-length HTRA1, indicating that molecules isolated towards the active site of HTRA1 maintain 
their effect also in the physiologically relevant oligomeric state. The authors proposed a competitive 
inhibition mechanism, where Fab94 blocks substrate entrance to the active site. Analysis of negative-
staining EM of IgG94 in complex with HTRA1 catalytic domain revealed an interesting mode of action. 
Three IgG molecules address two HTRA1 trimers which resulted in formation of a distinct 
macromolecular inhibition complex. One Fab of each IgG binds one active site of the same HTRA1 
trimer and the same is done for the other trimer by the remaining antigen binding fragments. The 
linkage of both trimers to a cage-like structure is mediated by the Fc-parts via the Fab arms. This 
mechanism solved the problem of steric hindrance due to the close proximity of the active sites in a 
trimer. Incubation of the catalytic domain of HTRA1 with IgG94 at different molar ratios always 
resulted in the same single complex with a 2:3 ratio of HTRA1 trimers to IgG molecules. Thus, no free 
Fab arms for building larger aggregates with additional HTRA1 trimers remained. This mechanism 
circumvents the problem for inhibition of all active sites of a trimer by large molecules, but it also 
demonstrates the need for smaller vNAR, VHH or McoTI-II derived binders that could address all active 
sites simultaneously without steric hindrance. 
In addition to the phage display derived HTRA1 inhibiting IgG94, the monoclonal antibody 10H10 was 
reported, that inhibited the human HTRA1 family member HTRA3336. As for IgG94, the inhibitory 
mechanism of 10H10 was suggested to be a competitive blocking of the active site by addressing the 
sensor loop L3. This was confirmed among other data by the observation that activity of HTRA3 was 
not recovered by allosteric activating antibody 6G6 when being previously incubated with 10H10. 
Beyond VHHs, vNARs or knottins, other scaffolds could be considered as starting point for engineering 
HTRA1 activators or inhibitors. For example alpha-1-antitrypsin could be an interesting basis for 
engineering highly potent inhibitors against HTRA1, because it is already reported that it inhibits the 
protease19, 30, 44, 56. Moreover it is a protein that consists of 400 amino acids which makes it accessible 
for rational or evolutionary design. Further, the mechanism of alpha-1-antitrypsin for inhibition in the 
active site is well described and structural data is available348. As reported for cystine-knot miniproteins 
selectivity and affinity could be enhanced towards HTRA1 by changing residues that interact with the 
active site129. However, it was published recently that alpha-1-antitrypsin is degraded by HTRA1 
resulting in loss of inhibitor function which is contradictory to previous reports349. 
Both up- and downregulation of HTRA1 is connected to different diseases, a finding that renders it 
questionable whether HTRA1 can be considered as a therapeutic target. Nevertheless different 
compartments of the human body are involved in the diseases mentioned above. Thus fusion of 
activators or inhibitors to binding molecules addressing unique structures for these compartments 
could lead to a specific localization thereby reducing unwanted side effects. For example activators 
could be fused to antibodies against tumor cell specific markers for localization in a tissue, where 
HTRA1 is downregulated, aimed at enhancing the anti-carcinogenic effect of HTRA1. 
As previously mentioned, the studies of Truebestein31 and Jo324, as well as our results, emphasize the 
correlation between HTRA1 higher oligomeric states and an increase in activity. Thus it would be 
interesting to investgate, whether our isolated activators have an impact on oligomerization. Size-
exclusion chromatography would reveal the influence of isolated molecules when being incubated with 
the different protease variants aimed at addressing the question whether activators act in a way that 
they shift the equilibrium to higher oligomers. 
Additionally it would be interesting to investigate, whether HTRA1 substrates induce higher oligomer 
formation in general and if this only enhances or initiates activity. In the E. coli homologue DegP for 
example it is suggested that the oligomer size depends on the substrate size. Moreover it was shown 
that hexameric DegP is proteolytic inactive, because two trimers are inhibiting each other by a special 
loop that is not present in human HTRA158, 314. If active protease does not result from higher 
oligomerization, but is enhanced by this process, the isolated molecules showing no effect on trimeric 
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activity could act as inhibitors of higher oligomer formation and thus reduce activity for substrates 
inducing higher oligomer formation. 
Deeper insight into the addressed epitopes of isolated vNAR molecules and the differences of VHH and 
McoTI-II derived molecules that bound HTRA1 cd-mono3 but not HTRA1 cd could be obtained by 
structural analysis. Accordingly, the assumption that isolated VHH and McoTI-II derived molecules 
bound epitopes that are buried in trimeric HTRA1 could be confirmed and epitopes responsible for the 
increase in activity by isolated vNAR molecules could be identified. There are already structural 
elements that were described to be involved in HTRA1 activation such as the sensor loop L331. In the 
diploma theses of Bert Luck polyclonal antibodies against a hapten with chemically synthesized loop 
L3 were developed by immunization of a rabbit. However, corresponding antibodies purified by 
affinity chromatography of L3 showed specific binding towards HTRA1, but had no effect on activity, a 
finding that once more underlines the highly complicated mode of action of this enzyme347. 
  
   86 
7. References 
1. Kassell, B. & Kay, J. Zymogens of proteolytic enzymes. Science 180(4090), 1022-7 (1973). 
2. Neurath, H. Mechanisms of Zymogen Activation. Fed Proc. 23, 1-7 (1964). 
3. Kitano, H. Systems biology: a brief overview. Science 295, 1662-4 (2002). 
4. Khorana, H. G. et al. Polynucleotide synthesis and the genetic code. Cold Spring Harb. Symp. 
Quant Biol. 31, 39-49 (1966). 
5. Martin, R. B. Free energies and equilibria of peptide bond hydrolysis and formation. 
Biopolymers 45, 351-35 (1998). 
6. Rawlings, N. D. & Barrett, A. J. Evolutionary families of peptidases. Biochem J 290, 205-218 
(1993). 
7. Rawlings, N. D., Barrett, A. J. & Bateman, A. MEROPS: the peptidase database. Nucleic Acids 
Res. 38, 227-233 (2010). 
8. Rawlings, N. D., O'Brien, E. & Barrett, A. J. MEROPS: the protease database. Nucleic Acids Res 
30, 343-6 (2002). 
9. Rawlings, N. D., Tolle, D. P. & Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids 
Res 32, D160-4 (2004). 
10. Rawlings, N. D., Barrett, A. J. & Bateman, A. Asparagine Peptide Lyases: A Seventh Catalytic 
Type of Proteolytic Enzymes. J Biol Chem 286(44), 38321-8 (2011). 
11. Rawlings, N. D. & Barrett, A. J. Families of serine peptidases. Methods Enzymol 244, 19-61 
(1994). 
12. Bode, W. & Huber, R. Structural basis of the endoproteinase-protein inhibitor interaction. 
Biochim Biophys Acta 1477, 241-52 (2000). 
13. Ye, S. & Goldsmith, E. J. Serpins and other covalent protease inhibitors. Curr Opin Struct Biol 
11, 740-5 (2001). 
14. Huang, X. et al. Modulation of recombinant human prostate-specific antigen: activation by 
Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the 
activation by concentrated salts. Biochemistry 40, 11734-41 (2001). 
15. Spiess, C., Beil, A. & Ehrmann, M. A temperature-dependent switch from chaperone to protease 
in a widely conserved heat shock protein. Cell 97, 339-47 (1999). 
16. Chien, J., Campioni, M., Shridhar, V. & Baldi, A. HtrA serine proteases as potential therapeutic 
targets in cancer. Curr Cancer Drug Targets 9, 451-68 (2009). 
17. Coleman, H. R., Chan, C. C., Ferris, F. L., 3rd & Chew, E. Y. Age-related macular degeneration. 
Lancet 372, 1835-45 (2008). 
18. Grau, S. et al. Implications of the serine protease HtrA1 in amyloid precursor protein 
processing. Proc Natl Acad Sci U S A 102, 6021-6 (2005). 
19. Hara, K. et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel 
disease. N Engl J Med 360, 1729-39 (2009). 
20. Milner, J. M., Patel, A. & Rowan, A. D. Emerging roles of serine proteinases in tissue turnover 
in arthritis. Arthritis Rheum 58, 3644-56 (2008). 
21. Avrutina, O. et al. Trypsin inhibition by macrocyclic and open-chain variants of the squash 
inhibitor MCoTI-II. Biol Chem 386, 1301-6 (2005). 
22. Heitz, A. et al. Knottin cyclization: impact on structure and dynamics. BMC Struct Biol 8, 54 
(2008). 
23. Weber, N. & Kolmar, H. in Handbook of Proteolytic Enzymes (ed. Barrett, R., Woessner) 2567-
2571 (Elsevier, 2013). 
24. Lipinska, B., Sharma, S. & Georgopoulos, C. Sequence analysis and regulation of the htrA gene 
of Escherichia coli: a sigma 32-independent mechanism of heat-inducible transcription. Nucleic 
Acids Res 16, 10053-67 (1988). 
25. Danese, P. N., Snyder, W. B., Cosma, C. L., Davis, L. J. & Silhavy, T. J. The Cpx two-component 
signal transduction pathway of Escherichia coli regulates transcription of the gene specifying 
the stress-inducible periplasmic protease, DegP. Genes Dev 9, 387-98 (1995). 
   87 
26. Meltzer, M. et al. Allosteric activation of HtrA protease DegP by stress signals during bacterial 
protein quality control. Angew Chem Int Ed Engl 47(7), 1332-4 (2008). 
27. Meltzer, M. et al. Structure, function and regulation of the conserved serine proteases DegP 
and DegS of Escherichia coli. Res Microbiol 160, 660-6 (2009). 
28. Supanji, Shimomachi, M., Hasan, M. Z., Kawaichi, M. & Oka, C. HtrA1 is induced by oxidative 
stress and enhances cell senescence through p38 MAPK pathway. Exp Eye Res 112, 79-92 
(2013). 
29. Clausen, T., Southan, C. & Ehrmann, M. The HtrA Family of Proteases: Implication for Protein 
Composition and Cell Fate. Molecular Cell 10, 443-455 (2002). 
30. Eigenbrot, C. et al. Structural and functional analysis of HtrA1 and its subdomains. Structure 
20, 1040-50 (2012). 
31. Truebestein, L. et al. Substrate-induced remodeling of the active site regulates human HTRA1 
activity. Nat Struct Mol Biol 18, 386-8 (2011). 
32. Risor, M. W. et al. The autolysis of human HtrA1 is governed by the redox state of its N-
terminal domain. Biochemistry 53, 3851-7 (2014). 
33. Khan, A. R. & James, M. N. Molecular mechanisms for the conversion of zymogens to active 
proteolytic enzymes. Protein Sci 7, 815-36 (1998). 
34. Boehr, D. D., Nussinov, R. & Wright, P. E. The role of dynamic conformational ensembles in 
biomolecular recognition. Nat Chem Biol 5, 789-96 (2009). 
35. Subrini, O. & Betton, J. M. Assemblies of DegP underlie its dual chaperone and protease 
function. FEMS Microbiol Lett 296, 143-148 (2009). 
36. Maurizi, M. R. Love it or cleave it: Tough choices in protein quality control. nat Struct Biol 9, 
410-412 (2002). 
37. Chien, J., He, X. & Shridhar, V. Identification of tubulins as substrates of serine protease HtrA1 
by mixture-based oriented peptide library screening. J Cell Biochem 107, 253-63 (2009). 
38. Mauney, J., Olsen, B. R. & Volloch, V. Matrix remodeling stem cell recruitment: A novel in vitro 
model for homing of human bone marrow stromla cells to the site of injury shows crucial role 
of extracellular collagen matrix. Matrix Biology 29, 657-663 (2010). 
39. Lorenzi, T. et al. Expreesion Patterns of Two Serine Protease HTRA1 Forms in Human Placentas 
Complicated by Preeclampsia with and without Intrauterine Growth Restriction. Placenta 30, 
35-40 (2009). 
40. Zurawa-Janicka, D., Skorko-Glonek, J. & Lipinska, B. HtrA proteins as targets in therapy of 
cancer and other diseases. Expert Opin Ther Targets 14(7), 665-679 (2010). 
41. Chien, J. et al. Serine protease HtrA1 associates with microtubules and inhibits cell migration. 
Mol Cell Biol 29, 4177-87 (2009). 
42. Altobelli, E., Marzioni, D., Lattanzi, A. & Angeletti, P. M. HtrA1: Its future potential as a novel 
biomarker for cancer. Oncology Reports 34, 555-566 (2015). 
43. Baldi, A. et al. The HtrA1 serine protease is down-regulated during human melanoma 
progression and represses growth of metastatic melanoma cells. Oncogene 21, 6684-8 (2002). 
44. Hou, J., Clemmons, D. R. & Smeekens, S. Expression and characterization of a serine protease 
that preferentially cleaves insulin-like growth factor binding protein-5. J Cell Biochem 94, 470-
84 (2005). 
45. Launay, S. et al. HtrA1-dependent proteolysis of TGF-beta controls both neuronal maturation 
and developmental survival. Cell Death Differ 15, 1408-16 (2008). 
46. Oka, C. et al. HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. 
Development 131, 1041-53 (2004). 
47. Campioni, M. et al. The serine protease HtrA1 specifically interacts and degrades the tuberous 
sclerosis complex 2 protein. Mol Cancer Res 8, 1248-60 (2010). 
48. Grau, S. et al. The role of human HtrA1 in arthritic disease. J Biol Chem 281, 6124-9 (2006). 
49. Tsuchiya, A. et al. Expression of mouse HtrA1 serine protease in normal bone and cartilage and 
its upregulation in joint cartilage damaged by experimental arthritis. Bone 37, 323-36 (2005). 
   88 
50. An, E., Sen, S., Park, S. K., Gordish-Dressman, H. & Hathout, Y. Identification of novel 
substrates for the serine protease HTRA1 in the human RPE secretome. Invest Ophthalmol Vis 
Sci 51, 3379-86 (2010). 
51. Lipinska, B., Zylicz, M. & Georgopoulos, C. The HtrA (DegP) protein, essential for Escherichia 
coli survival at high temperatures, is an endopeptidase. J Bacteriol 172, 1791-7 (1990). 
52. Swamy, K. H., Chung, C. H. & Goldberg, A. L. Isolation and characterization of protease do 
from Escherichia coli, a large serine protease containing multiple subunits. Arch Biochem 
Biophys 224, 543-54 (1983). 
53. Martins, L. M. et al. Binding specificity and regulation of the serine protease and PDZ domains 
of HtrA2/Omi. J Biol Chem 278, 49417-27 (2003). 
54. Skorko-Glonek, J., Wawrzynow, A., Krzewski, K., Kurpierz, K. & Lipinska, B. Site-directed 
mutagenesis of the HtrA (DegP) serine protease, whose proteolytic activity is indispensable for 
Escherichia coli survival at elevated temperatures. Gene 163, 47-52 (1995). 
55. Clausen, T., Kaiser, M., Huber, R. & Ehrmann, M. HTRA proteases: regulated proteolysis in 
protein quality control. Nat Rev Mol Cell Biol 12, 152-62 (2011). 
56. Hu, S. I. et al. Human HtrA, an evolutionarily conserved serine protease identified as a 
differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 273, 34406-12 
(1998). 
57. Krojer, T. et al. Interplay of PDZ and protease domain of DegP ensures efficient elimination of 
misfolded proteins. Proc Natl Acad Sci U S A 105, 7702-7 (2008). 
58. Krojer, T. et al. Structural basis for the regulated protease and chaperone function of DegP. 
Nature 453, 885-90 (2008). 
59. Ajayi, F. et al. Elevated expression of serine protease HtrA1 in preeclampsia and its role in 
trophoblast cell migration and invasion. Am J Obstet Gynecol 199, 557 e1-10 (2008). 
60. Dewan, A. et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. 
Science 314, 989-92 (2006). 
61. Chien, J. et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin 
Invest 116, 1994-2004 (2006). 
62. Chien, J. et al. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. 
Oncogene 23, 1636-44 (2004). 
63. Mullany, S. A. et al. Expression and functional significance of HtrA1 loss in endometrial cancer. 
Clin Cancer Res 17, 427-36 (2011). 
64. Bowden, M. A., Di Nezza-Cossens, L. A., Jobling, T., Salamonsen, L. A. & Nie, G. Serine 
proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human 
endometrial cancer. Gynecol Oncol 103, 253-60 (2006). 
65. Wang, N. et al. Down-regulation of HtrA1 activates the epithelial-mesenchymal transition and 
ATM DNA damage response pathways. PLoS One 7, e39446 (2012). 
66. Baldi, A. et al. The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. 
Pharmacogenomics 9, 1069-77 (2008). 
67. Zhu, F. et al. Serine protease HtrA1 expression in human hepatocellular carcinoma. 
Hepatobiliary Pancreat Dis Int 9, 508-12 (2010). 
68. Catalano, V. et al. HtrA1, a potential predictor of response to cisplatin-based combination 
chemotherapy in gastric cancer. Histopathology 58, 669-78 (2011). 
69. He, X. et al. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal 
dissemination of ovarian cancer cells. Cancer Res 70, 3109-18 (2010). 
70. Rosenthal, A., Gohr, C. M., Ninomiya, J. & Wakim, B. T. Proteomic Analysis of Articular 
Cartilage Vesicles From Normal and Osteoarthritic Cartilage. Arthritis Rheum 63, 401-411 
(2011). 
71. Chamberland, A. et al. Identification of a Novel HtrA1-susceptible Cleavage Site in Human 
Aggrecan. J Biol Chem 284, 27352 27359 (2009). 
72. Poole, C. A., Ayad, S. & Schofield, J. R. Chondrons from articular cartilage: I. 
Immunolocalization of type VI collagen in the pericellular capsule of isolated canine tibial 
chondrons. J Cell Sci 90 ( Pt 4), 635-43 (1988). 
   89 
73. Poole, C. A. Articular cartilage chondrons: form, function and failure. J Anat 191 ( Pt 1), 1-13 
(1997). 
74. Wu, J. et al. Comparative proteomic characterization of articular cartilage tissue from normal 
donors and patients with osteoarthritis. Arthritis Rheum 56, 3675-84 (2007). 
75. Polur, I., Lee, P. L., Servais, J. M., Xu, L. & Li, Y. Role of HTRA1, a serine protease, in the 
progression of articular cartilage degeneration. Histol Histopathol 25, 599-608 (2010). 
76. Skorko-Glonek, J. et al. HtrA protease family as therapeutic targets. Curr Pharm Des 19, 977-
1009 (2013). 
77. Tennstaedt, A. et al. Human high temperature requirement serine protease A1 (HTRA1) 
degrades tau protein aggregates. J Biol Chem 287, 20931-41 (2012). 
78. Human insulin receives FDA approval. FDA Drug Bull 12, 18-9 (1982). 
79. Goeddel, D. V. et al. Expression in Escherichia coli of chemically synthesized genes for human 
insulin. Proc Natl Acad Sci U S A 76, 106-10 (1979). 
80. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined 
specificity. Nature 256, 495-7 (1975). 
81. Beck, A., Wurch, T., Bailly, C. & Corvaia, N. Strategies and challenges for the next generation of 
therapeutic antibodies. Nat Rev Immunol 10, 345-52 (2010). 
82. Kellner, C., Derer, S., Valerius, T. & Peipp, M. Boosting ADCC and CDC activity by Fc 
engineering and evaluation of antibody effector functions. Methods 65, 105-13 (2014). 
83. Scott, A. M., Wolchok, J. D. & Old, L. J. Antibody therapy of cancer. Nat Rev Cancer 12, 278-
287 (2012). 
84. Bradbury, A. R. M., Sidhu, S., Dübel, S. & McCafferty, J. Beyond natural antibodies: the power 
of in vitro display technologies Nat Biotechnol 29, 245-254 (2011). 
85. Presta, L. G. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin 
Immunol 116, 731-6 (2005). 
86. Carter, P. J., Hazuda, D. & Wells, J. A. Next generation therapeutics. Curr Opin Chem Biol 17, 
317-9 (2013). 
87. Chan, A. C. & Carter, P. J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev 
Immunol 10, 301-16 (2010). 
88. Kolmar, H. Natural and engineered cystine knot miniproteins for diagnostic and therapeutic 
applications. Curr Pharm Des 17, 4329-36 (2011). 
89. Pillay, V., Gan, H. K. & Scott, A. M. Antibodies in oncology. Nat Biotechnol 28, 518-29 (2011). 
90. Wurch, T., Pierré, A. & Depil, S. Novel protein scaffolds as emerging therapeutic proteins from 
discovery to clinical proof-of-concept. Trends Biotechnol 30, 575-82 (2012). 
91. Saerens, D., Ghassabeh, G. H. & Muyldermans, S. Single-domain antibodies as building blocks 
for novel therapeutics. Curr Opin Pharmacol 8, 600-8 (2008). 
92. Grandjenette, C., Dicato, M. & Diederich, M. Bispecific antibodies: an innovative arsenal to 
hunt, grab and destroy cancer cells. Curr Pharm Biotechnol 16, 670-83 (2015). 
93. Skerra, A. Engineered protein scaffolds for molecular recognition. J Mol Recognit 13, 167-87 
(2000). 
94. Schroeder, H. W., Jr. & Cavacini, L. Structure and function of immunoglobulins. J Allergy Clin 
Immunol 125, S41-52 (2010). 
95. Gilbreth, R. N. & Koide, S. Structural insights for engineering binding proteins based on non-
antibody scaffolds. Curr Opin Struct Biol 22, 413-20 (2012). 
96. Löfblom, J., Frejd, F. Y. & Stahl, S. Non-immunoglobulin based protein scaffolds. Curr Opin 
Biotechnol 22, 843-8 (2011). 
97. Richter, A., Eggenstein, E. & Skerra, A. Anticalins: exploiting a non-Ig scaffold with 
hypervariable loops for the engineering of binding proteins. FEBS Lett 588, 213-8 (2014). 
98. Hey, T., Fiedler, E., Rudolph, R. & Fiedler, M. Artificial, non-antibody binding proteins for 
pharmaceutical and industrial applications. Trends Biotechnol 23, 514-22 (2005). 
99. Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on 
the virion surface. Science 228, 1315-7 (1985). 
   90 
100. Sanger, F. et al. Nucleotide sequence of bacteriophage phi X174 DNA. Nature 265, 687-95 
(1977). 
101. Pande, J., Szewczyk, M. M. & Grover, A. K. Phage display: Concept, innovations, applications 
and future. Biotechnol Adv 28, 849-58 (2010). 
102. Lipovsek, D. & Pluckthun, A. In-vitro protein evolution by ribosome display and mRNA display. 
J Immunol Methods 290, 51-67 (2004). 
103. Boder, E. T., Raeeszadeh-Sarmazdeh, M. & Price, J. V. Engineering antibodies by yeast display. 
Arch Biochem Biophys 526, 99-106 (2012). 
104. Getz, J. A., Schoep, T. D. & Daugherty, P. S. Peptide Discovery Using Bacterial Display and 
Flow Cytometry. Methods Enzymol 503, 75-97 (2012). 
105. Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide 
libraries. Nat Biotechnol 15, 553-7 (1997). 
106. Traxlmayr, M. W. & Obinger, C. Directed evolution of proteins for increased stability and 
expression using yeast display. Arch Biochem Biophys 526, 174-80 (2012). 
107. Richman, S. A., Kranz, D. M. & Stone, J. D. Biosensor detection systems: engineering stable, 
high-affinity bioreceptors by yeast surface display. Methods Mol Biol 504, 323-50 (2009). 
108. Raymond, C. K., Pownder, T. A. & Sexson, S. L. General method for plasmid construction using 
homologous recombination. Biotechniques 26, 134-8, 140-1 (1999). 
109. Rakestraw, J. A., Aird, D., Aha, P. M., Baynes, B. M. & Lipovsek, D. Secretion-and-capture cell-
surface display for selection of target-binding proteins. Protein Eng Des Sel 24, 525-30 (2011). 
110. Benatuil, L., Perez, J. M., Belk, J. & Hsieh, C. M. An improved yeast transformation method for 
the generation of very large human antibody libraries. Protein Eng Des Sel 23, 155-9 (2010). 
111. VanAntwerp, J. J. & Wittrup, K. D. Fine affinity discrimination by yeast surface display and flow 
cytometry. Biotechnol Prog 16, 31-7 (2000). 
112. Boder, E. T., Midelfort, K. S. & Wittrup, K. D. Directed evolution of antibody fragments with 
monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A 97, 10701-5 (2000). 
113. Kieke, M. C., Cho, B. K., Boder, E. T., Kranz, D. M. & Wittrup, K. D. Isolation of anti-T cell 
receptor scFv mutants by yeast surface display. Protein Eng 10, 1303-10 (1997). 
114. Meusser, B., Hirsch, C., Jarosch, E. & Sommer, T. ERAD: the long road to destruction. Nat Cell 
Biol 7, 766-72 (2005). 
115. Bowley, D. R., Labrijn, A. F., Zwick, M. B. & Burton, D. R. Antigen selection from an HIV-1 
immune antibody library displayed on yeast yields many novel antibodies compared to 
selection from the same library displayed on phage. Protein Eng Des Sel 20, 81-90 (2007). 
116. Blaise, L. et al. Construction and diversification of yeast cell surface displayed libraries by yeast 
mating: application to the affinity maturation of Fab antibody fragments. Gene 342, 211-8 
(2004). 
117. Weaver-Feldhaus, J. M. et al. Yeast mating for combinatorial Fab library generation and surface 
display. FEBS Lett 564, 24-34 (2004). 
118. Walker, L. M., Bowley, D. R. & Burton, D. R. Efficient recovery of high-affinity antibodies from 
a single-chain Fab yeast display library. J Mol Biol 389, 365-75 (2009). 
119. Wozniak-Knopp, G. et al. Introducing antigen-binding sites in structural loops of 
immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and 
antibody properties. Protein Eng Des Sel 23, 289-97 (2010). 
120. Dong, J. et al. A single-domain llama antibody potently inhibits the enzymatic activity of 
botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol 
397, 1106-18 (2010). 
121. Ryckaert, S., Pardon, E., Steyaert, J. & Callewaert, N. Isolation of antigen-binding camelid 
heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface 
of Pichia pastoris. J Biotechnol 145, 93-8 (2010). 
122. Graff, C. P., Chester, K., Begent, R. & Wittrup, K. D. Directed evolution of an anti-
carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. 
Protein Eng Des Sel 17, 293-304 (2004). 
   91 
123. Orcutt, K. D. et al. Engineering an antibody with picomolar affinity to DOTA chelates of 
multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol 38, 
223-33 (2011). 
124. Hu, X., Kang, S., Lefort, C., Kim, M. & Jin, M. M. Combinatorial libraries against libraries for 
selecting neoepitope activation-specific antibodies. Proc Natl Acad Sci U S A 107, 6252-7 
(2010). 
125. Papo, N., Silverman, A. P., Lahti, J. L. & Cochran, J. R. Antagonistic VEGF variants engineered 
to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin. Proc Natl Acad Sci U S 
A 108, 14067-72 (2011). 
126. Jones, D. S., 2nd, Tsai, P. C. & Cochran, J. R. Engineering hepatocyte growth factor fragments 
with high stability and activity as Met receptor agonists and antagonists. Proc Natl Acad Sci U S 
A 108, 13035-40 (2011). 
127. Lahti, J. L. et al. Engineered epidermal growth factor mutants with faster binding on-rates 
correlate with enhanced receptor activation. FEBS Lett 585, 1135-9 (2011). 
128. Shpilman, M. et al. Development and characterization of high affinity leptins and leptin 
antagonists. J Biol Chem 286, 4429-42 (2011). 
129. Glotzbach, B. et al. Combinatorial optimization of cystine-knot peptides towards high-affinity 
inhibitors of human matriptase-1. PLoS One 8, e76956 (2013). 
130. Moore, S. J. & Cochran, J. R. Engineering knottins as novel binding agents. Methods Enzymol 
503, 223-51 (2012). 
131. Silverman, A. P., Levin, A. M., Lahti, J. L. & Cochran, J. R. Engineered cystine-knot peptides 
that bind alpha(v)beta(3) integrin with antibody-like affinities. J Mol Biol 385, 1064-75 
(2009). 
132. Kimura, R. H. et al. Functional mutation of multiple solvent-exposed loops in the Ecballium 
elaterium trypsin inhibitor-II cystine knot miniprotein. PLoS One 6, e16112 (2011). 
133. Koide, S., Koide, A. & Lipovsek, D. Target-binding proteins based on the 10th human 
fibronectin type III domain ((1)(0)Fn3). Methods Enzymol 503, 135-56 (2012). 
134. Hackel, B. J., Kapila, A. & Wittrup, K. D. Picomolar affinity fibronectin domains engineered 
utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 381, 1238-
52 (2008). 
135. Gera, N., Hussain, M., Wright, R. C. & Rao, B. M. Highly stable binding proteins derived from 
the hyperthermophilic Sso7d scaffold. J Mol Biol 409, 601-16 (2011). 
136. Chen, I., Dorr, B. M. & Liu, D. R. A general strategy for the evolution of bond-forming enzymes 
using yeast display. Proc Natl Acad Sci U S A 108, 11399-404 (2011). 
137. Han, S. Y., Zhang, J. H., Han, Z. L., Zheng, S. P. & Lin, Y. Combination of site-directed 
mutagenesis and yeast surface display enhances Rhizomucor miehei lipase esterification 
activity in organic solvent. Biotechnol Lett 33, 2431-8 (2011). 
138. Lee, G. Y. et al. Isomaltulose production via yeast surface display of sucrose isomerase from 
Enterobacter sp. FMB-1 on Saccharomyces cerevisiae. Bioresour Technol 102, 9179-84 (2011). 
139. Parthasarathy, R., Bajaj, J. & Boder, E. T. An immobilized biotin ligase: surface display of 
Escherichia coli BirA on Saccharomyces cerevisiae. Biotechnol Prog 21, 1627-31 (2005). 
140. Wen, F., Sun, J. & Zhao, H. Yeast surface display of trifunctional minicellulosomes for 
simultaneous saccharification and fermentation of cellulose to ethanol. Appl Environ Microbiol 
76, 1251-60 (2010). 
141. Colby, D. W. et al. Engineering antibody affinity by yeast surface display. Methods Enzymol 
388, 348-58 (2004). 
142. Wang, X. X. et al. Affinity maturation of human CD4 by yeast surface display and crystal 
structure of a CD4-HLA-DR1 complex. Proc Natl Acad Sci U S A 108, 15960-5 (2011). 
143. Wen, F., Sethi, D. K., Wucherpfennig, K. W. & Zhao, H. Cell surface display of functional 
human MHC class II proteins: yeast display versus insect cell display. Protein Eng Des Sel 24, 
701-9 (2011). 
   92 
144. Boersma, Y. L., Chao, G., Steiner, D., Wittrup, K. D. & Pluckthun, A. Bispecific designed ankyrin 
repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell 
proliferation and receptor recycling. J Biol Chem 286, 41273-85 (2011). 
145. Bidlingmaier, S. & Liu, B. Construction of yeast surface-displayed cDNA libraries. Methods Mol 
Biol 729, 199-210 (2011). 
146. Schuijt, T. J. et al. Identification and characterization of Ixodes scapularis antigens that elicit 
tick immunity using yeast surface display. PLoS One 6, e15926 (2011). 
147. Kantha, S. S. A centennial review; the 1890 tetanus antitoxin paper of von Behring and 
Kitasato and the related developments. Keio J Med 40, 35-9 (1991). 
148. Tiselius, A. & Kabat, E. A. An Electrophoretic Study of Immune Sera and Purified Antibody 
Preparations. J Exp Med 69, 119-31 (1939). 
149. Chaplin, D. D. Overview of the immune response. J Allergy Clin Immunol 125, 3-23 (2010). 
150. Thomas, L. R., Cobb, R. M. & Oltz, E. M. Dynamic regulation of antigen receptor gene 
assembly. Adv Exp Med Biol 650, 103-15 (2009). 
151. Huston, D. P. The biology of the immune system. Jama 278, 1804-14 (1997). 
152. Bonilla, F. A. & Oettgen, H. C. Adaptive immunity. J Allergy Clin Immunol 125, S33-40 (2010). 
153. Williams, A. F. & Barclay, A. N. The immunoglobulin superfamily--domains for cell surface 
recognition. Annu Rev Immunol 6, 381-405 (1988). 
154. Terry, W. D. & Fahey, J. L. Subclasses of Human Gamma-2-Globulin Based on Differences in 
the Heavy Polypeptide Chains. Science 146, 400-1 (1964). 
155. Smith, K. A. et al. Demystified...recombinant antibodies. J Clin Pathol 57, 912-7 (2004). 
156. Leder, P. The genetics of antibody diversity. Sci Am 246, 102-15 (1982). 
157. Tonegawa, S. Somatic generation of antibody diversity. Nature 302, 575-81 (1983). 
158. Normansell, D. E. Human immunoglobulin subclasses. Diagn Clin Immunol 5, 115-28 (1987). 
159. Torres, M. & Casadevall, A. The immunoglobulin constant region contributes to affinity and 
specificity. Trends Immunol 29, 91-7 (2008). 
160. Nimmerjahn, F. & Ravetch, J. V. Antibodies, Fc receptors and cancer. Curr Opin Immunol 19, 
239-45 (2007). 
161. Ravetch, J. V. & Bolland, S. IgG Fc receptors. Annu Rev Immunol 19, 275-90 (2001). 
162. Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of 
glycosylation on the biological function and structure of human immunoglobulins. Annu Rev 
Immunol 25, 21-50 (2007). 
163. Liu, H., Bulseco, G. G. & Sun, J. Effect of posttranslational modifications on the thermal 
stability of a recombinant monoclonal antibody. Immunol Lett 106, 144-53 (2006). 
164. Siberil, S. et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: 
impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol 
118, 170-9 (2006). 
165. Kanda, Y. et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 
antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and 
complex types. Glycobiology 17, 104-18 (2007). 
166. Natsume, A. et al. Fucose removal from complex-type oligosaccharide enhances the antibody-
dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain 
antibody linked the antibody constant region. J Immunol Methods 306, 93-103 (2005). 
167. Raju, T. S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr 
Opin Immunol 20, 471-8 (2008). 
168. Khan, W. N. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J 
Immunol 183, 3561-7 (2009). 
169. Kurosaki, T. & Hikida, M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 
228, 132-48 (2009). 
170. Malisan, F. et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in 
human CD40-activated naive B lymphocytes. J Exp Med 183, 937-47 (1996). 
171. Chaudhuri, J. et al. Evolution of the immunoglobulin heavy chain class switch recombination 
mechanism. Adv Immunol 94, 157-214 (2007). 
   93 
172. Schmidlin, H., Diehl, S. A. & Blom, B. New insights into the regulation of human B-cell 
differentiation. Trends Immunol 30, 277-85 (2009). 
173. Burnet, F. M. The immunological significance of the thymus: an extension of the clonal 
selection theory of immunity. Australas Ann Med 11, 79-91 (1962). 
174. Dorner, T., Foster, S. J., Farner, N. L. & Lipsky, P. E. Somatic hypermutation of human 
immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. Eur J 
Immunol 28, 3384-96 (1998). 
175. Rada, C., Ehrenstein, M. R., Neuberger, M. S. & Milstein, C. Hot spot focusing of somatic 
hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. Immunity 
9, 135-41 (1998). 
176. Tangye, S. G. & Tarlinton, D. M. Memory B cells: effectors of long-lived immune responses. Eur 
J Immunol 39, 2065-75 (2009). 
177. Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 
446-8 (1993). 
178. Blanc, M. R. et al. A one-step exclusion-binding procedure for the purification of functional 
heavy-chain and mammalian-type gamma-globulins from camelid sera. Biotechnol Appl 
Biochem 54, 207-12 (2009). 
179. Alexander, A. et al. gamma Heavy chain disease in man: cDNA sequence supports partial gene 
deletion model. Proc Natl Acad Sci U S A 79, 3260-4 (1982). 
180. Cogne, M., Preud'homme, J. L. & Guglielmi, P. Immunoglobulin gene alterations in human 
heavy chain diseases. Res Immunol 140, 487-502 (1989). 
181. Decanniere, K., Muyldermans, S. & Wyns, L. Canonical antigen-binding loop structures in 
immunoglobulins: more structures, more canonical classes? J Mol Biol 300, 83-91 (2000). 
182. Nguyen, V. K., Hamers, R., Wyns, L. & Muyldermans, S. Camel heavy-chain antibodies: diverse 
germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. Embo J 19, 
921-30 (2000). 
183. Harmsen, M. M. et al. Llama heavy-chain V regions consist of at least four distinct subfamilies 
revealing novel sequence features. Mol Immunol 37, 579-90 (2000). 
184. Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. & Hamers, R. Sequence and 
structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking 
light chains. Protein Eng 7, 1129-35 (1994). 
185. Vu, K. B., Ghahroudi, M. A., Wyns, L. & Muyldermans, S. Comparison of llama VH sequences 
from conventional and heavy chain antibodies. Mol Immunol 34, 1121-31 (1997). 
186. Chothia, C., Novotny, J., Bruccoleri, R. & Karplus, M. Domain association in immunoglobulin 
molecules. The packing of variable domains. J Mol Biol 186, 651-63 (1985). 
187. Muyldermans, S., Cambillau, C. & Wyns, L. Recognition of antigens by single-domain antibody 
fragments: the superfluous luxury of paired domains. Trends Biochem Sci 26, 230-5 (2001). 
188. Nguyen, V. K., Hamers, R., Wyns, L. & Muyldermans, S. Loss of splice consensus signal is 
responsible for the removal of the entire C(H)1 domain of the functional camel IGG2A heavy-
chain antibodies. Mol Immunol 36, 515-24 (1999). 
189. Woolven, B. P., Frenken, L. G., van der Logt, P. & Nicholls, P. J. The structure of the llama 
heavy chain constant genes reveals a mechanism for heavy-chain antibody formation. 
Immunogenetics 50, 98-101 (1999). 
190. Maass, D. R., Sepulveda, J., Pernthaner, A. & Shoemaker, C. B. Alpaca (Lama pacos) as a 
convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods 
324, 13-25 (2007). 
191. van der Linden, R. H. et al. Comparison of physical chemical properties of llama VHH antibody 
fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1431, 37-46 (1999). 
192. Dumoulin, M. et al. Single-domain antibody fragments with high conformational stability. 
Protein Sci 11, 500-15 (2002). 
193. Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R. & Muyldermans, S. Selection and 
identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS 
Lett 414, 521-6 (1997). 
   94 
194. Saerens, D. et al. Single domain antibodies derived from dromedary lymph node and peripheral 
blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem 
279, 51965-72 (2004). 
195. Coppieters, K. et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from 
camelids show superior potency and targeting to inflamed joints in a murine model of collagen-
induced arthritis. Arthritis Rheum 54, 1856-66 (2006). 
196. Baral, T. N. et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated 
human trypanolytic factor. Nat Med 12, 580-4 (2006). 
197. Vincke, C. et al. General strategy to humanize a camelid single-domain antibody and 
identification of a universal humanized nanobody scaffold. J Biol Chem 284, 3273-84 (2009). 
198. Barlow, J. N., Conrath, K. & Steyaert, J. Substrate-dependent modulation of enzyme activity by 
allosteric effector antibodies. Biochim Biophys Acta 1794, 1259-68 (2009). 
199. Oyen, D., Srinivasan, V., Steyaert, J. & Barlow, J. N. Constraining enzyme conformational 
change by an antibody leads to hyperbolic inhibition. J Mol Biol 407, 138-48 (2011). 
200. Conrath, K. E. et al. Beta-lactamase inhibitors derived from single-domain antibody fragments 
elicited in the camelidae. Antimicrob Agents Chemother 45, 2807-12 (2001). 
201. Hendrickx, M. L. et al. TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a 
new TAFIa conformation. J Thromb Haemost 9, 2268-77 (2011). 
202. Transue, T. R., De Genst, E., Ghahroudi, M. A., Wyns, L. & Muyldermans, S. Camel single-
domain antibody inhibits enzyme by mimicking carbohydrate substrate. Proteins 32, 515-22 
(1998). 
203. Lauwereys, M. et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. 
Embo J 17, 3512-20 (1998). 
204. Ledeboer, A. M. et al. Preventing phage lysis of Lactococcus lactis in cheese production using a 
neutralizing heavy-chain antibody fragment from llama. J Dairy Sci 85, 1376-82 (2002). 
205. Stijlemans, B. et al. Efficient targeting of conserved cryptic epitopes of infectious agents by 
single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279, 1256-61 
(2004). 
206. Cortez-Retamozo, V. et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer 
Res 64, 2853-7 (2004). 
207. Ismaili, A. et al. Production and characterization of anti-(mucin MUC1) single-domain antibody 
in tobacco (Nicotiana tabacum cultivar Xanthi). Biotechnol Appl Biochem 47, 11-9 (2007). 
208. Frenken, L. G., Hessing, J. G., Van den Hondel, C. A. & Verrips, C. T. Recent advances in the 
large-scale production of antibody fragments using lower eukaryotic microorganisms. Res 
Immunol 149, 589-99 (1998). 
209. Frenken, L. G. et al. Isolation of antigen specific llama VHH antibody fragments and their high 
level secretion by Saccharomyces cerevisiae. J Biotechnol 78, 11-21 (2000). 
210. Arbabi-Ghahroudi, M., Tanha, J. & MacKenzie, R. Prokaryotic expression of antibodies. Cancer 
Metastasis Rev 24, 501-19 (2005). 
211. van der Linden, R. et al. Induction of immune responses and molecular cloning of the heavy 
chain antibody repertoire of Lama glama. J Immunol Methods 240, 185-95 (2000). 
212. Davies, J. & Riechmann, L. Antibody VH domains as small recognition units. Biotechnology (N 
Y) 13, 475-9 (1995). 
213. Tanha, J. et al. Optimal design features of camelized human single-domain antibody libraries. J 
Biol Chem 276, 24774-80 (2001). 
214. Chames, P. & Baty, D. Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 
12, 276-83 (2009). 
215. Emmerson, C. D. et al. Enhancement of polymeric immunoglobulin receptor transcytosis by 
biparatopic VHH. PLoS One 6, e26299 (2011). 
216. Hmila, I. et al. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high 
neutralizing efficacy for scorpion toxin AahI'. Mol Immunol 45, 3847-56 (2008). 
217. Bell, A. et al. Differential tumor-targeting abilities of three single-domain antibody formats. 
Cancer Lett 289, 81-90 (2010). 
   95 
218. de Marco, A. Biotechnological applications of recombinant single-domain antibody fragments. 
Microb Cell Fact 10, 44 (2011). 
219. Wesolowski, J. et al. Single domain antibodies: promising experimental and therapeutic tools in 
infection and immunity. Med Microbiol Immunol 198, 157-74 (2009). 
220. Harmsen, M. M. & De Haard, H. J. Properties, production, and applications of camelid single-
domain antibody fragments. Appl Microbiol Biotechnol 77, 13-22 (2007). 
221. Perez-Martinez, D., Tanaka, T. & Rabbitts, T. H. Intracellular antibodies and cancer: new 
technologies offer therapeutic opportunities. Bioessays 32, 589-98 (2010). 
222. Tanaka, T., Sewell, H., Waters, S., Phillips, S. E. & Rabbitts, T. H. Single domain intracellular 
antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions 
using a single VH domain. J Biol Chem 286, 3707-16 (2011). 
223. Rothbauer, U. et al. A versatile nanotrap for biochemical and functional studies with 
fluorescent fusion proteins. Mol Cell Proteomics 7, 282-9 (2008). 
224. Schmidthals, K., Helma, J., Zolghadr, K., Rothbauer, U. & Leonhardt, H. Novel antibody 
derivatives for proteome and high-content analysis. Anal Bioanal Chem 397, 3203-8 (2010). 
225. Romer, T., Leonhardt, H. & Rothbauer, U. Engineering antibodies and proteins for molecular in 
vivo imaging. Curr Opin Biotechnol 22, 882-7 (2011). 
226. Koide, S. Engineering of recombinant crystallization chaperones. Curr Opin Struct Biol 19, 449-
57 (2009). 
227. Kirchhofer, A. et al. Modulation of protein properties in living cells using nanobodies. Nat 
Struct Mol Biol 17, 133-8 (2010). 
228. Broisat, A. et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of 
atherosclerotic lesions. Circ Res 110, 927-37 (2012). 
229. Vaneycken, I. et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of 
breast cancer. Faseb J 25, 2433-46 (2011). 
230. Vosjan, M. J. et al. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 
68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging 
38, 753-63 (2011). 
231. Vaneycken, I. et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol 22, 877-81 
(2011). 
232. Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Curr Opin 
Biotechnol 22, 868-76 (2011). 
233. Iqbal, U. et al. Kinetic analysis of novel mono- and multivalent VHH-fragments and their 
application for molecular imaging of brain tumours. Br J Pharmacol 160, 1016-28 (2010). 
234. Perruchini, C. et al. Llama VHH antibody fragments against GFAP: better diffusion in fixed 
tissues than classical monoclonal antibodies. Acta Neuropathol 118, 685-95 (2009). 
235. Li, T. et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-
GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: 
application to brain imaging. Faseb J 26, 3969-79 (2012). 
236. Holz, J. B. The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor 
Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci 
46, 343-6 (2012). 
237. Flajnik, M. F. & Rumfelt, L. L. The immune system of cartilaginous fish. Curr Top Microbiol 
Immunol 248, 249-70 (2000). 
238. Dooley, H. & Flajnik, M. F. Antibody repertoire development in cartilaginous fish. Dev Comp 
Immunol 30, 43-56 (2006). 
239. Clem, I. W., De Boutaud, F. & Sigel, M. M. Phylogeny of immunoglobulin structure and 
function. II. Immunoglobulins of the nurse shark. J Immunol 99, 1226-35 (1967). 
240. Greenberg, A. S. et al. A new antigen receptor gene family that undergoes rearrangement and 
extensive somatic diversification in sharks. Nature 374, 168-73 (1995). 
241. Barelle, C., Gill, D. S. & Charlton, K. Shark novel antigen receptors--the next generation of 
biologic therapeutics? Adv Exp Med Biol 655, 49-62 (2009). 
   96 
242. Rumfelt, L. L., Diaz, M., Lohr, R. L., Mochon, E. & Flajnik, M. F. Unprecedented multiplicity of 
Ig transmembrane and secretory mRNA forms in the cartilaginous fish. J Immunol 173, 1129-
39 (2004). 
243. Diaz, M., Greenberg, A. S. & Flajnik, M. F. Somatic hypermutation of the new antigen receptor 
gene (NAR) in the nurse shark does not generate the repertoire: possible role in antigen-driven 
reactions in the absence of germinal centers. Proc Natl Acad Sci U S A 95, 14343-8 (1998). 
244. Streltsov, V. A. et al. Structural evidence for evolution of shark Ig new antigen receptor variable 
domain antibodies from a cell-surface receptor. Proc Natl Acad Sci U S A 101, 12444-9 (2004). 
245. Diaz, M., Velez, J., Singh, M., Cerny, J. & Flajnik, M. F. Mutational pattern of the nurse shark 
antigen receptor gene (NAR) is similar to that of mammalian Ig genes and to spontaneous 
mutations in evolution: the translesion synthesis model of somatic hypermutation. Int Immunol 
11, 825-33 (1999). 
246. Du Pasquier, L., Wilson, M., Greenberg, A. S. & Flajnik, M. F. Somatic mutation in ectothermic 
vertebrates: musings on selection and origins. Curr Top Microbiol Immunol 229, 199-216 
(1998). 
247. Roux, K. H. et al. Structural analysis of the nurse shark (new) antigen receptor (NAR): 
molecular convergence of NAR and unusual mammalian immunoglobulins. Proc Natl Acad Sci 
U S A 95, 11804-9 (1998). 
248. Stanfield, R. L., Dooley, H., Flajnik, M. F. & Wilson, I. A. Crystal structure of a shark single-
domain antibody V region in complex with lysozyme. Science 305, 1770-3 (2004). 
249. Diaz, M., Stanfield, R. L., Greenberg, A. S. & Flajnik, M. F. Structural analysis, selection, and 
ontogeny of the shark new antigen receptor (IgNAR): identification of a new locus 
preferentially expressed in early development. Immunogenetics 54, 501-12 (2002). 
250. Criscitiello, M. F. & Flajnik, M. F. Four primordial immunoglobulin light chain isotypes, 
including lambda and kappa, identified in the most primitive living jawed vertebrates. Eur J 
Immunol 37, 2683-94 (2007). 
251. Hinds, K. R. & Litman, G. W. Major reorganization of immunoglobulin VH segmental elements 
during vertebrate evolution. Nature 320, 546-9 (1986). 
252. Lee, V. et al. The evolution of multiple isotypic IgM heavy chain genes in the shark. J Immunol 
180, 7461-70 (2008). 
253. Kokubu, F., Litman, R., Shamblott, M. J., Hinds, K. & Litman, G. W. Diverse organization of 
immunoglobulin VH gene loci in a primitive vertebrate. Embo J 7, 3413-22 (1988). 
254. Lee, S. S., Fitch, D., Flajnik, M. F. & Hsu, E. Rearrangement of immunoglobulin genes in shark 
germ cells. J Exp Med 191, 1637-48 (2000). 
255. Lee, S. S., Greenberg, A. & Hsu, E. Evolution and somatic diversification of immunoglobulin 
light chains. Curr Top Microbiol Immunol 248, 285-300 (2000). 
256. Rumfelt, L. L. et al. A shark antibody heavy chain encoded by a nonsomatically rearranged VDJ 
is preferentially expressed in early development and is convergent with mammalian IgG. Proc 
Natl Acad Sci U S A 98, 1775-80 (2001). 
257. Malecek, K. et al. Somatic hypermutation and junctional diversification at Ig heavy chain loci in 
the nurse shark. J Immunol 175, 8105-15 (2005). 
258. Bartl, S. et al. Terminal deoxynucleotidyl transferases from elasmobranchs reveal structural 
conservation within vertebrates. Immunogenetics 55, 594-604 (2003). 
259. Marchalonis, J. & Edelman, G. M. Phylogenetic origins of antibody structure. I. Multichain 
structure of immunoglobulins in the smooth dogfish (Mustelus canis). J Exp Med 122, 601-18 
(1965). 
260. Marchalonis, J. & Edelman, G. M. Polypeptide chains of immunoglobulins from the smooth 
dogfish (Mustelus canis). Science 154, 1567-8 (1966). 
261. Clem, L. W. & Small, P. A., Jr. Phylogeny of immunoglobulin structure and function. I. 
Immunoglobulins of the lemon shark. J Exp Med 125, 893-920 (1967). 
262. Dooley, H. & Flajnik, M. F. Shark immunity bites back: affinity maturation and memory 
response in the nurse shark, Ginglymostoma cirratum. Eur J Immunol 35, 936-45 (2005). 
   97 
263. Fange, R. & Pulsford, A. Structural studies on lymphomyeloid tissues of the dogfish, 
Scyliorhinus canicula L. Cell Tissue Res 230, 337-51 (1983). 
264. Rumfelt, L. L., McKinney, E. C., Taylor, E. & Flajnik, M. F. The development of primary and 
secondary lymphoid tissues in the nurse shark Ginglymostoma cirratum: B-cell zones precede 
dendritic cell immigration and T-cell zone formation during ontogeny of the spleen. Scand J 
Immunol 56, 130-48 (2002). 
265. Liu, J. L. et al. Selection of cholera toxin specific IgNAR single-domain antibodies from a naive 
shark library. Mol Immunol 44, 1775-83 (2007). 
266. Dooley, H., Flajnik, M. F. & Porter, A. J. Selection and characterization of naturally occurring 
single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol 
Immunol 40, 25-33 (2003). 
267. Shao, C. Y., Secombes, C. J. & Porter, A. J. Rapid isolation of IgNAR variable single-domain 
antibody fragments from a shark synthetic library. Mol Immunol 44, 656-65 (2007). 
268. Malecek, K. et al. Immunoglobulin heavy chain exclusion in the shark. PLoS Biol 6, e157 
(2008). 
269. Nuttall, S. D. et al. A naturally occurring NAR variable domain binds the Kgp protease from 
Porphyromonas gingivalis. FEBS Lett 516, 80-6 (2002). 
270. Nuttall, S. D. et al. Isolation and characterization of an IgNAR variable domain specific for the 
human mitochondrial translocase receptor Tom70. Eur J Biochem 270, 3543-54 (2003). 
271. Nuttall, S. D. et al. Selection and affinity maturation of IgNAR variable domains targeting 
Plasmodium falciparum AMA1. Proteins 55, 187-97 (2004). 
272. Zielonka, S. et al. Shark Attack: high affinity binding proteins derived from shark vNAR 
domains by stepwise in vitro affinity maturation. J Biotechnol 191, 236-45 (2014). 
273. Nuttall, S. D. et al. Isolation of the new antigen receptor from wobbegong sharks, and use as a 
scaffold for the display of protein loop libraries. Mol Immunol 38, 313-26 (2001). 
274. Simmons, D. P. et al. Dimerisation strategies for shark IgNAR single domain antibody 
fragments. J Immunol Methods 315, 171-84 (2006). 
275. Chiche, L. et al. Squash inhibitors: from structural motifs to macrocyclic knottins. Curr Protein 
Pept Sci 5, 341-349 (2004). 
276. Gracy, J. et al. KNOTTIN: the knottin or inhibitor cystine knot scaffold in 2007. Nucleic Acids 
Res 36, D314-9 (2008). 
277. Reinwarth, M., Nasu, D., Kolmar, H. & Avrutina, O. Chemical synthesis, backbone cyclization 
and oxidative folding of cystine-knot peptides: promising scaffolds for applications in drug 
design. Molecules 17, 12533-52 (2012). 
278. Gelly, J. C. et al. The KNOTTIN website and database: a new information system dedicated to 
the knottin scaffold. Nucleic Acids Res 32, D156-9 (2004). 
279. Werle, M., Kafedjiiski, K., Kolmar, H. & Bernkop-Schnurch, A. Evaluation and improvement of 
the properties of the novel cystine-knot microprotein McoEeTI for oral administration. Int J 
Pharm 332, 72-9 (2007). 
280. Werle, M., Kolmar, H., Albrecht, R. & Bernkop-Schnurch, A. Characterisation of the barrier 
caused by luminally secreted gastro-intestinal proteolytic enzymes for two novel cystine-knot 
microproteins. Amino Acids 35, 195-200 (2008). 
281. Werle, M. et al. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds 
in oral peptide drug delivery. J Drug Target 14, 137-46 (2006). 
282. Puttamadappa, S. S., Jagadish, K., Shekhtman, A. & Camarero, J. A. Backbone dynamics of 
cyclotide MCoTI-I free and complexed with trypsin. Angew Chem Int Ed Engl 49, 7030-4 
(2010). 
283. Craik, D. J. Discovery and applications of the plant cyclotides. Toxicon 56, 1092-102 (2010). 
284. Craik, D. J., Cemazar, M. & Daly, N. L. The cyclotides and related macrocyclic peptides as 
scaffolds in drug design. Curr Opin Drug Discov Devel 9, 251-60 (2006). 
285. Craik, D. J., Cemazar, M. & Daly, N. L. The chemistry and biology of cyclotides. Curr Opin Drug 
Discov Devel 10, 176-84 (2007). 
   98 
286. Daly, N. L. & Craik, D. J. Bioactive cystine knot proteins. Curr Opin Chem Biol 15, 362-8 
(2011). 
287. Hernandez, J. F. et al. Squash trypsin inhibitors from Momordica cochinchinensis exhibit an 
atypical macrocyclic structure. Biochemistry 39, 5722-30 (2000). 
288. Daly, N. L., Love, S., Alewood, P. F. & Craik, D. J. Chemical synthesis and folding pathways of 
large cyclic polypeptides: studies of the cystine knot polypeptide kalata B1. Biochemistry 38, 
10606-14 (1999). 
289. Tam, J. P., Lu, Y. A., Yang, J. L. & Chiu, K. W. An unusual structural motif of antimicrobial 
peptides containing end-to-end macrocycle and cystine-knot disulfides. Proc Natl Acad Sci U S 
A 96, 8913-8 (1999). 
290. Jennings, C., West, J., Waine, C., Craik, D. & Anderson, M. Biosynthesis and insecticidal 
properties of plant cyclotides: the cyclic knotted proteins from Oldenlandia affinis. Proc Natl 
Acad Sci U S A 98, 10614-9 (2001). 
291. Favel, A. et al. Protease inhibitors from Ecballium elaterium seeds. Int J Pept Protein Res 33, 
202-8 (1989). 
292. Felizmenio-Quimio, M. E., Daly, N. L. & Craik, D. J. Circular proteins in plants: solution 
structure of a novel macrocyclic trypsin inhibitor from Momordica cochinchinensis. J Biol Chem 
276, 22875-82 (2001). 
293. Bode, W., Greyling, H. J., Huber, R., Otlewski, J. & Wilusz, T. The refined 2.0 A X-ray crystal 
structure of the complex formed between bovine beta-trypsin and CMTI-I, a trypsin inhibitor 
from squash seeds (Cucurbita maxima). Topological similarity of the squash seed inhibitors 
with the carboxypeptidase A inhibitor from potatoes. FEBS Lett 242, 285-92 (1989). 
294. Kimura, R. H., Cheng, Z., Gambhir, S. S. & Cochran, J. R. Engineered knottin peptides: a new 
class of agents for imaging integrin expression in living subjects. Cancer Res 69, 2435-42 
(2009). 
295. Sommerhoff, C. P. et al. Engineered cystine knot miniproteins as potent inhibitors of human 
mast cell tryptase beta. J Mol Biol 395, 167-75 (2010). 
296. Christmann, A., Walter, K., Wentzel, A., Kratzner, R. & Kolmar, H. The cystine knot of a squash-
type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of 
conformationally constrained peptides. Protein Eng 12, 797-806 (1999). 
297. Avrutina, O. et al. Head-to-tail cyclized cystine-knot peptides by a combined recombinant and 
chemical route of synthesis. Chembiochem 9, 33-7 (2008). 
298. Stricher, F. et al. Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal 
structures with HIV-1 gp120 envelope glycoprotein. J Mol Biol 382, 510-24 (2008). 
299. Jiang, L. et al. 111In-labeled cystine-knot peptides based on the Agouti-related protein for 
targeting tumor angiogenesis. J Biomed Biotechnol 2012, 368075 (2012). 
300. Reinwarth, M. et al. Oxidative folding of peptides with cystine-knot architectures: kinetic 
studies and optimization of folding conditions. Chembiochem 14, 137-46 (2013). 
301. Sun, X., Goh, P. E., Wong, K. T., Mori, T. & Yap, M. G. Enhancement of transient gene 
expression by fed-batch culture of HEK 293 EBNA1 cells in suspension. Biotechnol Lett 28, 843-
8 (2006). 
302. Hermanson, G. T. Bioconjugate Techniques (Elsevier, 2008). 
303. Hermanson, G. T. Bioconjugate Techniques (Elsevier, 2008). 
304. Mojsov, S. & Merrifield, R. B. An improved synthesis of crystalline mammalian glucagon. Eur J 
Biochem 145, 601-5 (1984). 
305. Knight, C. G., Willenbrock, F. & Murphy, G. A novel coumarin-labelled peptide for sensitive 
continuous assays of the matrix metalloproteinases. FEBS Lett 296, 263-6 (1992). 
306. Chao, G. et al. Isolating and engineering human antibodies using yeast surface display. Nat 
Protoc 1, 755-68 (2006). 
307. Dickgießer, S. in Chemie (TU Darmstadt, Darmstadt, 2016). 
308. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G. & Gray, T. How to measure and predict the 
molecular absorption coefficient of a protein. Protein Sci 4, 4211-23 (1995). 
309. Steinmann, B. in Clemens-Schöpf-Institut (TU-Darmstadt, Darmstadt, 2015). 
   99 
310. Maass, F. et al. Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4). J Pept Sci 21, 651-60 (2015). 
311. Zielonka, S. in Chemistry (TU-Darmstadt, Darmstadt, 2015). 
312. Zielonka, S. et al. The Shark Strikes Twice: Hypervariable Loop 2 of Shark IgNAR Antibody 
Varaible Domains and Its Potential to Function as an Autonomous Paratope. Mar Biotechnol 17, 
386-92 (2015). 
313. Könning, D. et al. Camelid and shark single domain antibodies: structural feautures and 
therapeutic potetial. Curr Opin Struct Biol 45, 10-16 (2016). 
314. Sawa, J., Heuck, A., Ehrmann, M. & Clausen, T. Molecular transformers in the cell: lessons 
learned from the DegP protease-chaperone. Curr Opin Struct Biol 20, 253-8 (2010). 
315. Krojer, T., Garrido-Franco, M., Huber, R., Ehrmann, M. & Clausen, T. Crystal structure of DegP 
(HtrA) reveals a new protease-chaperone machine. Nature 416, 455-9 (2002). 
316. Jiang, J. et al. Activation of DegP chaperone-protease via formation of large cage-like oligomers 
upon binding to substrate proteins. Proc Natl Acad Sci U S A 105, 11939-44 (2008). 
317. Tocharus, J. et al. Developmentally regulated expression of mouse HtrA3 and its role as an 
inhibitor of TGF-beta signaling. Dev Growth Differ 46, 257-74 (2004). 
318. Hauske, P. et al. Selectivity profiling of DegP substrates and inhibitors. Bioorg & Med Chem 17, 
2920-24 (2009). 
319. Nam, M. K. et al. The homotrimeric structure of HtrA2 is indispensable for executing its serine 
protease activity. Exp Mol Med 38, 36-43 (2006). 
320. Boehr, D. D. & Wright, P. E. How Do Proteins Interact? Science 320, 1429-30 (2008). 
321. Changeux, J. P. & Edelstein, S. Conformational selection or induced fit? 50 years of debate 
resolved. F1000 Biol Rep 3, 19 (2011). 
322. Hasselblatt, H. et al. Regulation of the sigmaE stress response by DegS: how the PDZ domain 
keeps the protease inactive in the resting state and allows integration of different OMP-derived 
stress signals upon folding stress. Genes Dev 21, 2659-70 (2007). 
323. Wilken, C., Kitzing, K., Kurzbauer, R., Ehrmann, M. & Clausen, T. Crystal structure of the DegS 
stress sensor: How a PDZ domain recognizes misfolded protein and activates a protease. Cell 
117, 483-94 (2004). 
324. Jo, H., Patterson, V., Stoessel, S., Kuan, C. Y. & Hoh, J. Protoporphyrins enhance 
oligomerization and enzymatic activity of HtrA1 serine protease. PLoS One 9, e115362 (2014). 
325. Krojer, T., Sawa, J., Huber, R. & Clausen, T. HtrA proteases have a conserved activation 
mechanism that can be triggered by distinct molecular cues. Nat Struct Mol Biol 7, 844-52 
(2010). 
326. Merdanovic, M. et al. Determinants of structural and functional plasticity of a widely conserved 
protease chaperone complex. Nat Struct Mol Biol 7, 837-43 (2010). 
327. Sommerhoff, C. P. et al. Engineered cystine knot miniproteins as potent inhibitors of human 
mast cell tryptase beta. J Mol Biol 395, 167-75 (2009). 
328. Ernst, R. E., High, K. N., Glass, T. R. & Zhao, Q. in Therapeutic Monoclonal Antibodies: From 
Bench to Clinic (ed. An, Z.) (John Wiley & Sons Inc., Hoboken, New Jersey, 2009). 
329. Gibson, C. R., andhu, P. & Hanley, W. D. in Therapeutic Monoclonal Antibodies: From Bench to 
Clinic (ed. An, Z.) (John Wiley & Sons Inc., Hoboken, New Jersey, 2009). 
330. Puorger, C. et al. Infinite kinetic stability against dissociation of supramolecular protein 
complexes through donor strand complementation. Structure 16, 631-42 (2008). 
331. Lorey, S. et al. Novel ubiquitin-derived high affinity binding proteins with tumor targeting 
properties. J Biol Chem 289, 8493-507 (2014). 
332. Mahon, C. M. et al. Comprehensive interrogation of a minimalist synthetic CDR-H3 library and 
its ability to generate antibodies with therapeutic potential. J Mol Biol 425, 1712-30 (2013). 
333. Gai, S. A. & Wittrup, K. D. Yeast surface display for protein engineering and characterization. 
Curr Opin Struct Biol 17, 467-73 (2007). 
334. Lipovsek, D. et al. Evolution of an interloop disulfide bond in high-affinity antibody mimics 
based on fibronectin type III domain and selected by yeast surface display: molecular 
   100 
convergence with single-domain camelid and shark antibodies. J Mol Biol 368, 1024-41 
(2007). 
335. Ciferri, C. et al. The trimeric serine protease HtrA1 forms a cage-like inhibition complex with an 
anti-HtrA1 antibody. Biochem J 472, 169-81 (2015). 
336. Singh, H., Nero, T. L., Wang, Y., Parker, M. W. & Nie, G. Activity-modulating monoclonal 
antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA 
proteolytic activities. PLoS One 9, e108235 (2014). 
337. Krowarsch, D., Cierpicki, T., Jelen, F. & Otlewski, J. Canonical protein inhibitors of serine 
proteases. Cell Mol Life Sci 60, 2427-44 (2003). 
338. Daly, N. L. et al. Structural insights into the role of the cyclic backbone in a squash trypsin 
inhibitor. J Biol Chem 288, 36141-8 (2013). 
339. Boder, E. T. & Jiang, W. Engineering antibodies for cancer therapy. Annu Rev Chem Biomol 
Eng 2, 53-75 (2011). 
340. Wark, K. L. & Hudson, P. J. Latest technologies for the enhancement of antibody affinity. Adv 
Drug Deliv Rev 58, 657-70 (2006). 
341. Morrison, K. L. & Weiss, G. A. Combinatorial alanine-scanning. Curr Opin Chem Biol 5, 302-7 
(2001). 
342. Mayer, M. & Meyer, B. Group epitope mapping by saturation transfer difference NMR to 
identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 135, 
6108-17 (2001). 
343. Wolff, E. A., Schreiber, G. J., Cosand, W. L. & Raff, H. V. Monoclonal antibody homodimers: 
enhanced antitumor activity in nude mice. Cancer Res 53, 2560-5 (1993). 
344. Rahbarizadeh, F., Ahmadvand, D. & Sharifzadeh, Z. Nanobody; an old concept and new vehicle 
for immunotargeting. Immunol Invest 40, 299-338 (2011). 
345. Muller, M. R. et al. Improving the pharmacokinetic properties of biologics by fusion to an anti-
HSA shark VNAR domain. MAbs 4, 673-85 (2012). 
346. Bendele, A. M. Animal models of osteoarthritis. J Musculoskelet Neuronal Interact 1, 363-76 
(2001). 
347. Luck, B. in Clemens-Schöpf-Institut (TU Darmstadt, Darmstadt, 2013). 
348. Dementiev, A., Dobo, J. & Gettins, P. G. Active site distortion is sufficient for proteinase 
inhibition by serpins: structure of the covalent complex of alpha1-proteinase inhibitor with 
porcine pancreatic elastase. J Biol Chem 281, 3452-7 (2006). 
349. Frochaux, V., Hildebrand, D., Talke, A., Linscheid, M. W. & Schluter, H. Alpha-1-antitrypsin: a 
novel human high temperature requirement protease A1 (HTRA1) substrate in human 
placental tissue. PLoS One 9, e109483 (2014). 
   101 
8. Appendix 
8.1. Appendix A: Fitted data of KD values of single clones determined by yeast surface display 
 
   102 
   103 
 
  
   104 
8.2. Appendix B: Abbreviations 
A Adenine 
aa Amino acid(s) 
ADCC Antibody-dependent cellular cytotoxicity  
Aga1p a-agglutinin anchoring subunit 1 
Aga2p a-agglutinin anchoring subunit 2 
amp Ampicillin 
APC Allophycocyanin 
APS Ammonium persulfate 
bp basepairs 
BSA Bovine serum albumin 
C Cytosine 
CDC Complement-dependent cytotoxicity 
CDR Complementarity determining region 
CH Constant domain of the heavy chain 
CL Constant domain of the light chain 
Cm Chloramphenicol 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleoside triphosphate 
DTT Dithiothreitol 
dYT Double concentrated yeast extract tryptone 
E. coli Escherichia coli 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EpCAM Epithelial cell adhesion molecule 
EphA2 Receptor tyrosine kinase EphA2 
Fab Fragment antigen binding 
FACS Fluorescence-activated cell sorting 
Fc Fragment crytalizable 
Fcγ Fc-part of IgG1 
FcRn Neonatal Fc receptor 
FDA US Food and Drug Administration 
FITC Fluorescein isothiocyanate 
FPLC Fast Protein Liquid Chromatography 
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Fv fragment variable 
G Guanine 
GFC Gel filtration chromatography 
h hour 
HA Hemagglutinin 
HCAb Heavy-chain only antibody 
HEK Human embryonic kidney 
HPLC High-performance liquid chromatography 
HTRA1 High temperature requirement A1 
HV Hypervariable loop 
IGFBP Insulin-like growth factor binding protein 
IgG  Immunoglobulin G 
IgNAR Immunoglobulin New Antigen Receptor 
IgNAR V domain IgNAR variable domain 
IMAC Immobilized Metal Ion Affinity Chromatography 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
KD Equilibrium dissociation constant 
kDa Kilo Dalton 
KI Kazal-like inhibitor domain 
koff Dissociation rate 
l Liter 
LB Low broth 
LCMS liquid chromatography mass spectroscopy 
mAbs Monoclonal antibodies 
MalE Maltose binding protein 
MBP Maltose binding protein 
McoTI-II Momordica cochinchinensis trypsininhibitor II 
MHC Major Histocompatibility Complex 
min Minute 
mM Milimolar 
µM Micromolar 
ml Mililiter 
µl Microliter 
MS Mass spectrometry 
MW Molecular weight 
MWCO Molecular weight cut off 
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nM Nanomolar 
nm Nanometer 
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 
PDZ post synaptic density, discs large, zonula occludentes-1 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
rel Relative 
rpm Revolutions per minute 
s Second 
S. cerevisiae Saccharomyces cerevisiae 
scFv Single-chain variable fragment 
SDS Sodium dodecyl sulfate 
SEC Size exclusion chromatography 
SOE Splicing by overlap extension 
T Thymine 
TCR T-cell receptor 
Temed Tetramethylethylenediamine 
TEV Tabacco etch virus 
TM Transmembrane domain 
Tm Melting temperature 
TNF Tumor necrosis factor 
VDJ Variable, diversifying, joining 
VH Variable domain of the heavy chain 
VHH Variable domain of a camelid heavy-chain only antibody 
VL Variable domain of the light chain 
vNAR IgNAR variable domain 
v/v Volume per volume 
Vol Volume 
wt Wild type 
w/v Weight per volume 
YPD Yeast extract peptone dextrose 
YSD Yeast surface display 
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8.3. Appendix C: List of Figures 
Figure 1 Basic reaction mechanism catalyzed by serine protease chymotrypsin. Amino acid residues of 
chymotrypsin involved in catalysis are shown in red. Asp102, His57 and Ser195 build up the 
catalytic triad. The phenylalanine is in P1 position of the substrate. P2 
substrate are indicated by R (amino- -terminus). ................................... 4 
Figure 2 HTRA domain organization of different organisms (modified from Clausen et al.29). 
Transmembrane domain (TM) in dark blue; insulin-like growth factor binding protein (IGFBP) in 
green; Kazal-like inhibitor domain (KI) in light blue; catalytic domain (protease) in blue and post 
synaptic density, discs large, zonula occludentes-1 domain (PDZ) in red. ...................................... 6 
Figure 3 a) X-ray crystal ribbon structure (PDB entry 3CS0) of DegP monomer protease domain 
(green) with its two carboxyl terminal PDZ domains (blue, purple) is shown at the top. Side 
chains of catalytic triad are shown in grey. DegP 24-mer is shown at the bottom. b) X-ray crystal 
ribbon structure (PDB entry 3NUM) of trimeric human HTRA1 protease domains (each in green, 
blue, and red) in side view at the top and in top view at the bottom. ............................................. 7 
Figure 4 a) X-ray crystal ribbon structures of human HTRA1 protease domain in active (dim grey) and 
inactive state (grey) superimposed. The loops LD, L1, L2 and L3 involved in reversible activation 
mechanism are indicated in green, red, gold and blue. Active side residues are shown in detail at 
the bottom. b) X-ray ribbon structure of human HTRA1 trimer. Aromatic residues mediating 
trimerization by hydrophobic interactions are shown in detail at the bottom. ................................ 8 
Figure 5 X-ray crystal surface structure of DegP 24-mer (gold). Each monomer consists of 1 protease 
and 2 PDZ domains. DegP is surrounded by ribbon structures of different molecules used as 
scaffold for introducing new functionalities. Molecules in clockwise: IgG antibody (green), FAB 
fragment (yellow), SFTI (blue), ocMcoTI-II (orange), vNAR (silver), VHH (bronze) and scFv 
(magenta). All molecules are shown in identical scale (PDB entries 3CS0, 1IGT, 3WIF, 1JBL, 
1HA9, 1VES, 1I3V, 1X9Q). .......................................................................................................... 11 
Figure 6 Scheme of the workflow of a typical directed evolution experiment (a). Schematic construct 
presented on the yeast surface in yeast surface display (b). Aga1p is anchored in the yeast cell wall 
and is covalently linked to Aga2p by cystines. The displayed scaffold library is flanked by a HA and 
a myc tag for evaluation of surface presentation via labeling with antibodies. Target molecules and 
antibodies are typically fluorescently labeled for isolation of molecules by fluorescent-activated 
cell sorting (FACS). ..................................................................................................................... 13 
Figure 7 X-ray crystal ribbon structure of murine IgG (PDB entry 1IGT). The heavy chains are shown in 
blue and red, the light chains are shown in green. Bars indicate the IgG derived scaffolds Fc, Fab 
and scFv. ..................................................................................................................................... 15 
Figure 8 X-ray crystal structure (PDB entry 1HA9) of open chain variant of McoTI-II (top). Amino acid 
side chains of the inhibitor loop are shown in red. Disulfide bridges are shown in light grey. Color 
code belongs to amino acid sequence (bottom) that reflects the degree of randomization in the 
sloning library according to its position. Cystines are indicated by black bars. Yellow letters 50 %, 
green letters 10 % and red letters 100 % randomization of all 19 amino acids (without cysteine).
 ................................................................................................................................................... 20 
Figure 9 Vector map for bacterial expression plasmid based on pET21d-HTRA1-cd. Arrows indicate 
orientations of genetic elements encoding for: Bacterial origin of replication (F1 ori), ampicillin 
resistance (AmpR), lac operator of lac operon (LacO), human Htra1 catalytic domain (hHTRA1 
cd), histidine tag (His(6)) and stop codon (Stop). NcoI and XhoI recognition sequences for 
restriction enzymes. .................................................................................................................... 23 
Figure 10 Vector map for yeast surface display plasmid based on pCT-HTRA1-VHH-KV07. Arrows 
indicate orientations of genetic elements encoding for: Yeast origin of replication (CEN6/ARS4), 
ampicillin resistance (AmpR), Galactose1 Promoter for protein expression in yeast (Gal1 
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Promoter), A-agglutinin-binding subunit 2 for presentation of fused protein by attachment to A-
agglutinin-binding subunit 1 in the cell wall (Aga2p), Linker (Linker), recognition site for cleavage 
by Factor Xa (Factor Xa), hemagglutinin epitope (HA-tag), 3 repeats of 4 glycine 1 serine linker 
((Gly4Ser)3 Linker), isolated HTRA1 binding VHH clone 7 (HTRA1-VHH KV07), myc epitope 
(myc-tag), stop codon (Stop), S. cerevisiae terminator of transcription (terminator), bacterial 
origin of replication (F1 ori) and auxotrophic selection marker (Trp1). NheI and BamHI 
recognition sequences for restriction enzymes. ............................................................................ 24 
Figure 11 Vector map for Maltose-binding Protein-encoding plasmid based on pMX-HTRA1-vNAR-K07. 
Arrows indicate orientations of genetic elements encoding for: Chloramphenicol resistance (CmR), 
Maltose-binding Protein (Maltose-binding Protein), recognition site for tobacco etch virus protease 
(TEV Site), isolated HTRA1 binding vNAR clone 7 (HTRA1-vNAR-K07), spacer of three alanines 
(Ala-Linker), histidine tag (His(6)), stop codon (stop) and a bacterial origin of replication (F1 
ori). Acc65I and XbaI recognition sequences for restriction enzymes. .......................................... 25 
Figure 12 Vector map for Fc-encoding plasmid based on pEXPR-H12-HTRA1-VHH-KV07. Arrows 
indicate orientations of genetic elements encoding for: Ampicillin resistance (AmpR), 
cytomegalovirus promoter (CMV promoter), signal sequence for protein secretion (BM40), 
isolated HTRA1 binding VHH clone 7 (HTRA1-VHH-KV07), IgG1 hinge region (H12 Linker), CH2 
and CH3 domains of human IgG1 (Fc), sortase A recognition sequence  (Sortase Site), stop codon 
(Stop), resistance against neomycin (Kan/neoR)  and a bacterial origin of replication (pUC 
origin). NheI and ApaI recognition sequences for restriction enzymes.......................................... 26 
Figure 13 Schematic domain arrangement of human full-length HTRA1 and its recombinant derived 
variants. Insulin-like Growth-Factor Binding Protein (green), Kazal-like Inhibitor Domain (light 
blue), Trypsin-like Protease Domain (blue), Post Synaptic Density, Discs Large and Zonula 
Occludentes-1 domain (red) and 6 Histidine-Tag (grey). Amino acid exchanges are indicated by 
black bars in the protease domain with position and residue above. ............................................ 45 
Figure 14 Size-exclusion chromatography (SEC) of his-tagged HTRA1 variants after immobilized metal 
ion affinity chromatography (IMAC). Chromatograms of calibrator proteins, HTRA1 cd, HTRA1 
cd-mono2, HTRA1 cd-mono3, HTRA1 cd+PDZ (from top to bottom). Different HTRA1 fractions 
that were confirmed by SDS-PAGE are indicated by their oligomeric states. Detection was at 
220 nm wavelength. .................................................................................................................... 47 
Figure 15 Plots of size-exclusion chromatography (SEC) of previously separated HTRA1 variant 
fractions of different oligomeric states. Chromatograms of HTRA1 cd (top-left), HTRA1 cd-mono2 
(bottom-left), HTRA1 cd-mono3 (top-right), HTRA1 cd+PDZ (bottom-right). Specific oligomeric 
states are indicated. Detection was at 220 nm wavelength........................................................... 48 
Figure 16 Melting curve analysis of HTRA1 variants using SYPRO-Orange. Melt points (Tm) were 
measured in duplicates and values are indicated in the plots. ...................................................... 49 
Figure 17 HTRA1 variants after separation by size-exclusion chromatography (SEC). Standardization 
of protease amount on optical density (OD280) (top) and BCA-Assay (bottom) (a). Verification of 
labeling with biotin by Western blot (middle) and labeling with fluorescein by PAGE under UV-
light (right) (b). .......................................................................................................................... 50 
Figure 18 Activity measurement of HTRA1 variants and their different oligomeric states. Higher 
oligomeric states (a), trimeric states (b), monomeric states (c) and HTRA1 cd-mono3 with its 3 
fractions with different protease and substrate concentrations (d). Activity was measured with 
H2Opt-K as fluorescence substrate over time in duplicates. Substrate concentration is increased for 
trimeric and monomeric fraction to 63.5 µM. Protease concentration of monomeric fraction is 
increased to 10 µM. For all plots only every second data point is shown. ..................................... 52 
Figure 19 Histograms of enrichment of HTRA1 cd-mono3 binding cells presenting VHH library. Sorting 
rounds 1-5 (top) and resorts of round 4 and 5 (bottom). FL1 channel for HTRA1 cd-mono3 (round 
1, 2 and 4) and myc-tag (round 3 and 5) on the x-axis. FL3 channel for myc-tag (round 1, 2 and 
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4) and HTRA1 cd-mono3 (round 3 and 5) on the y-axis. Gates for sorted cells are indicated by 
percentage of events that were isolated. ...................................................................................... 54 
Figure 20 Amino acid sequence alignment of HTRA1 cd-mono3 binding VHH molecules isolated by 
FACS. Clone name, selection round and occurrence are designated for each clone Positions that 
are unique in framework are indicated in red. CDR1 is shown in light grey, CDR2 in dim grey and 
CDR3 in black. ............................................................................................................................ 55 
Figure 21 Analysis of HTRA1 cd-mono3 binding VHH. Titer of Llama Serum against HTRA1 cd 
(Trimer) previous to building library (a), ELISA of Fc fusion KV07-Fc against HTRA1 cd (Trimer) 
and HTRA1 cd-mono3 (Monomer)(b), Activity measurement of HTRA1 cd (Trimer) with addition 
of KV07-Fc (c) and activity measurement of HTRA1 cd-mono3 (Monomer) with addition of 
KV07-Fc (d). Cleavage of fluorescence quenched substrate H2Opt-K was recorded over time in 
duplicates. Only every second data point is shown....................................................................... 56 
Figure 22 Histograms of enrichment of HTRA1 cd-mono3 binding cells presenting McoTI-II derived 
library. Sorting rounds 1-4 (top) and corresponding resorts (bottom). FL1 channel for HTRA1 
cd-mono3 on the x-axis and FL3 channel for myc-tag on the y-axis. Gates for sorted cells are 
indicated by percentage of events that were isolated. .................................................................. 57 
Figure 23 Amino acid sequence alignment of HTRA1 cd-mono3 binding McoTI-II derived molecule 
KS01 isolated by FACS. Loop 1 with 100 % randomization is highlighted in black, fourth loop and 
two positions in the second loop with 10 % randomization are highlighted in light grey. Flanking 
regions of loop 1 with 50 % randomization are highlighted in dim grey. ..................................... 58 
Figure 24 Analysis of HTRA1 cd-mono3 binding McoTI-II derived molecule KS01. ELISA of Fc fusion 
KV07-Fc against HTRA1 cd (Trimer) (a), Activity measurement of HTRA1 cd (Trimer) with 
addition of KS01-Fc (b) and activity measurement of HTRA1 cd-mono3 (Monomer) with addition 
of KS01-Fc (c). Cleavage of fluorescence quenched substrate H2Opt-K was recorded over time in 
duplicates. Only every second data point is shown. Histogram of presented KS01 on the yeast 
surface labeled with HTRA1 cd-mono3 (black), HTRA1 cd (red), HTRA1 cd+PDZ (blue) and 
unlabeled (green). Relative fluorescence intensity is on the x-axis and counts are on the y-axis (d).
 ................................................................................................................................................... 58 
Figure 25 Histograms of enrichment of HTRA1 cd-mono3 binding cells presenting CDR3 randomized 
library of vNAR scaffold. Sorting rounds 1-4 (top) and corresponding resorts (bottom). FL1 
channel for HTRA1 cd-mono3 (round 1, 3 and 4) and myc-tag (round 2) on the x-axis. FL3 
channel for myc-tag (round 1, 3 and 4) and HTRA1 cd-mono3 (round 2) on the y-axis. Gates for 
sorted cells are indicated by percentage of events that were isolated. .......................................... 60 
Figure 26 Alignment of unique amino acid sequences of HTRA1 cd-mono3 binding CDR3 randomized 
vNAR molecules isolated by FACS. Clone name, selection round, randomized region and 
occurrence are designated for each clone. Framework mutations are indicated in red, CDR1 is 
indicated in dim grey, HV2 in grey and CDR3 in black. ................................................................ 60 
Figure 27 Histograms of clone K03, K07, K09, K10 and K13 labeled with HTRA1 cd-mono3 (black), 
HTRA1 cd (red), HTRA1 cd+PDZ (blue) and unlabeled (green). Relative fluorescence intensity is 
on the x-axis and counts are on the y-axis. .................................................................................. 61 
Figure 28 Histograms of enrichment of HTRA1 cd-mono3 binding cells presenting matured CDR1 (a) 
and HV2 (b) vNAR scaffolds. Histograms for cells presenting CDR1 matured vNAR molecules 
binding HTRA1 cd-mono3 previously matured in HV2 (c). Sorting rounds 1 and 2 (top) and 
corresponding resorts (bottom). FL1 channel for HTRA1 cd-mono3 is shown on the x-axis. FL3 
channel for myc-tag is shown on the y-axis. Gates for sorted cells are indicated by percentage of 
events that were isolated. ............................................................................................................ 63 
Figure 29 Alignment of amino acid sequences of CDR1 (a), HV2 (b) and HV2-CDR1 (c) matured 
HTRA1 cd-mono3 binding vNAR molecules isolated by FACS. Clone name, selection round, 
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randomized region and occurrence are designated for each clone Framework mutations are 
indicated in red, CDR1 is indicated in dim grey, HV2 in grey and CDR3 in black. ........................ 64 
Figure 30 Plots of size-exclusion chromatography of successfully recombinant expressed vNAR-MBP 
fusion proteins after TEV cleavage on Superdex 75 16/60 column. First elution peak is MBP. 
Second elution peak is particular vNAR. Detection was at 220 nm wavelength. ........................... 68 
Figure 31 Plots of Protein A affinity chromatography of successfully recombinant expressed Fc and Fc 
fusion proteins of VHH and McoTI-II derived molecules. 0-40 ml is cell culture supernatant 
applied to column followed by elution with citric acid. Elution peak of KS01-Fc is additionally 
showed zoomed in (inside the plot). Detection was at 280 nm wavelength. ................................. 69 
Figure 32 Melting curve analysis of recombinant expressed vNAR molecules and KV07-Fc using 
SYPRO-Orange. Melting temperatures were measured in duplicates and Melting point values are 
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Figure 33 Activity measurement of HTRA1 cd (Trimer) in addition with HTRA1 cd-mono3 binding 
vNAR molecules. Concentration of vNAR molecules was adjusted to 14 µM. Cleavage of 
fluorescence quenched substrate H2Opt-K over time in duplicates. .............................................. 71 
Figure 34 Activity of HTRA1 cd (Trimer) in presence of recombinant vNAR and Fc Fusion proteins of 
isolated vNAR, VHH and ocMcoTI-II derived molecules. V0 was measured in double determination 
by cleavage of fluorescence quenched substrate H2Opt-K over time............................................. 72 
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